Gut Microbiota Modulate CD8 T Cell Responses to Influence Colitis-Associated Tumorigenesis by Yu, Amy
 
 
 
 
 
 
 
 
Gut Microbiota Modulate CD8 T Cell Responses to 
Influence Colitis-Associated Tumorigenesis  
 
by 
 
Amy I-Wen Yu 
 
 
A dissertation submitted in partial fulfillment  
of the requirements for the degree of  
Doctor of Philosophy  
(Immunology)  
in the University of Michigan 
2020 
 
 
 
 
Doctoral Committee: 
 
Associate Professor Grace Y. Chen, Co-Chair 
 Professor Gabriel Nuñez, Co-Chair 
Associate Professor Eric C. Martens 
 Professor Asma Nusrat 
Associate Professor Yatrik Shah 
 
 
  
 
 
 
 
Amy I-Wen Yu 
aiyu@umich.edu 
ORCID: 0000-0002-0219-7359 
 
© Amy I-Wen Yu 2020 
 
 
 
 
 
ii 
 
DEDICATION 
媽媽, 爸爸, 謝謝你們不斷的支持我. 
 
I would like to dedicate this dissertation to my family. Thank you for everything. 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
I want to thank my dissertation advisor Dr. Grace Chen for her guidance, support, and 
encouragement. She gave me room to explore and take my project in the directions I wanted, 
allowing me to grow into an independent scientist. I also want to thank my thesis committee 
members, Drs. Gabriel Nuñez, Eric Martens, Asma Nusrat, and Yatrik Shah, for their continual 
support, feedback, and scientific input. 
In addition, I would like to thank all the past and present members of the lab as they have 
provided levity and support whenever needed. I’ve also had the immense joy of mentoring four 
undergraduate students; it’s been so rewarding to see them grow as people and scientists. I would 
also like to specifically thank Dr. Sergey Seregin and Jiachen Chen for their guidance and advice 
in both science and life.  
As per usual for science, this project would not have been possible without the generous 
assistance of others. This project would not have been possible without the Gabriel Nuñez and Eric 
Martens labs. The Nobuhiko Kamada and Naohiro Inohara labs have also provided scientific 
support and discussion. Dr. Kathryn A. Eaton assisted with histological scoring, and Dr. Lili Zhao 
provided statistical support. Thank you to Dr. Hideaki Fujiwara, who helped with intravenous 
injections, and the rest of the Pavan Reddy lab who have been the best lab neighbor anyone could 
ask for. Thank you to all the University of Michigan science cores who have provided scientific 
support. The Immunology Program has also been incredibly wonderful and supportive. Spotify, 
Netflix, and Hulu have been essential during my time writing this dissertation, especially under 
shelter-in conditions. This work was supported by the following funding sources: University of 
Michigan Rackham Research Grants and NIH grant T32 AI007413 (A.I.Y.), and NIH grant R01 
CA166879, an American Cancer Society Research Scholar Grant, and the Tom Liu Memorial Golf 
Tournament Fund from the University of Michigan Rogel Cancer Center (G.Y.C.). 
Lastly, I would like to thank my friends and family. Thank you for your unwavering 
confidence in me. I could not have done this without all of you.
iv 
 
TABLE OF CONTENTS 
 
DEDICATION ................................................................................................................................ ii 
ACKNOWLEDGEMENTS ........................................................................................................... iii 
LIST OF FIGURES ...................................................................................................................... vii 
ABSTRACT .................................................................................................................................... x 
CHAPTER 1: Introduction ............................................................................................................. 1 
1.1 Colorectal cancer overview .................................................................................................. 1 
1.1.1 Colorectal cancer global patterns ................................................................................... 1 
1.1.2 The microbiome and colorectal cancer .......................................................................... 2 
1.2 Dysbiosis in colorectal cancer .............................................................................................. 3 
1.2.1 Background .................................................................................................................... 3 
1.2.2 Fusobacterium nucleatum .............................................................................................. 5 
1.2.3 Enterotoxigenic Bacteroides fragilis ............................................................................. 6 
1.2.4 Escherichia coli .............................................................................................................. 6 
1.3 Mechanisms by which gut microbiota contribute to CRC .................................................. 11 
1.3.1 Modulation of host immune responses ........................................................................ 12 
1.3.2 Stimulation of cellular proliferation ............................................................................. 14 
1.3.3 Promotion of DNA damage ......................................................................................... 15 
1.3.4 Production of metabolites ............................................................................................ 16 
1.4 Conclusion and Goals ......................................................................................................... 18 
CHAPTER 2: Microbiome Differences Between Two C57BL/6 Mouse Colonies Promote CRC 
Tumor Burden Differences ........................................................................................................... 20 
2.1 Introduction ......................................................................................................................... 20 
2.2 Materials and Methods ........................................................................................................ 21 
2.2.1 Mice ............................................................................................................................. 21 
2.2.2 Inflammation-induced colon tumorigenesis ................................................................. 21 
2.2.3 Bacteria preparation for oral gavage ............................................................................ 22 
2.2.4 MC38 subcutaneous tumor model ............................................................................... 22 
2.2.5 AOM-only model ......................................................................................................... 23 
2.2.6 ELISA .......................................................................................................................... 23 
2.2.7 Histological scoring ..................................................................................................... 23 
2.2.8 qPCR ............................................................................................................................ 23 
2.2.9 Isolation of bacterial DNA and 16S rRNA sequence analyses .................................... 23 
2.2.10 Statistical analyses ..................................................................................................... 24 
v 
 
2.3 Results ................................................................................................................................. 24 
2.3.1 Two WT mouse colonies develop different tumor burdens after AOM/DSS treatment
 ............................................................................................................................................... 24 
2.3.2 The two WT mouse colonies have different microbiome compositions and metabolic 
profiles .................................................................................................................................. 27 
2.3.3 Gut microbiome differences between WT1 and WT2 mice directly contribute to colon 
tumor burden differences ...................................................................................................... 30 
2.3.4 Gut microbiome differences promote tumor burden differences in an inflammation-
dependent way ....................................................................................................................... 35 
2.4 Discussion and Future Directions ....................................................................................... 36 
CHAPTER 3: Microbiome Transfer Experiments Reveal Novel Candidate Bacteria That May 
Promote or Prevent Colon Tumorigenesis .................................................................................... 39 
3.1 Introduction ......................................................................................................................... 39 
3.2 Materials and Methods ........................................................................................................ 40 
3.2.1 Mice ............................................................................................................................. 40 
3.2.2 Inflammation-induced colon tumorigenesis ................................................................. 40 
3.2.3 Microbiome transfer ..................................................................................................... 40 
3.2.4 Microbiome culturing .................................................................................................. 41 
3.2.5 Bacteria preparation for oral gavage ............................................................................ 41 
3.2.6 Isolation of bacterial DNA and 16S rRNA sequence analyses .................................... 41 
3.2.7 Statistical analyses ....................................................................................................... 42 
3.3 Results ................................................................................................................................. 43 
3.3.1 Cohousing and one-to-one cohousing did not transfer the tumor burden phenotype .. 43 
3.3.2 Cross-fostering resulted in an intermediate tumor burden phenotype ......................... 45 
3.3.3 Specific bacteria are associated with high or low tumor burdens ................................ 47 
3.3.4 Culturing candidate bacteria ........................................................................................ 49 
3.4 Discussion and Future Directions ....................................................................................... 51 
CHAPTER 4: Two WT Mouse Colonies with Microbiome Differences Have Host Immune 
Differences .................................................................................................................................... 55 
4.1 Introduction ......................................................................................................................... 55 
4.2 Materials and Methods ........................................................................................................ 55 
4.2.1 Mice ............................................................................................................................. 55 
4.2.2 Inflammation-induced colon tumorigenesis ................................................................. 56 
4.2.3 Microarray .................................................................................................................... 56 
4.2.4 Bacteria preparation for oral gavage ............................................................................ 56 
4.2.5 Microbiome depletion by antibiotic and antifungal water ........................................... 57 
4.2.6 Immune cell isolation ................................................................................................... 57 
4.2.7 Flow cytometry and staining ........................................................................................ 58 
4.2.8 RNA isolation and qPCR ............................................................................................. 59 
4.2.9 Preparation of heat-killed bacteria ............................................................................... 60 
4.2.10 Bone marrow-derived dendritic cell (BMDC) preparation and stimulation .............. 60 
4.2.11 ELISA ........................................................................................................................ 60 
4.2.12 CD8 depletion ............................................................................................................ 60 
4.2.13 CD8 T cell adoptive transfer ...................................................................................... 61 
vi 
 
4.2.14 MC38 subcutaneous tumor model ............................................................................. 61 
4.2.15 Isolation of bacterial DNA and 16S rRNA sequence analyses .................................. 61 
4.2.16 Statistical analyses ..................................................................................................... 62 
4.3 Results ................................................................................................................................. 62 
4.3.1 Host immune differences are measured between WT1 and WT2 mouse colons ......... 62 
4.3.2 Dysbiotic microbiome of WT2 mice promotes inflammation-associated tumorigenesis 
via adaptive immune cells ..................................................................................................... 64 
4.3.3 WT2 mice have increased colon LP CD8+ IFNg+ T cells ............................................ 66 
4.3.4 Colon LP CD8 T cells partly mediate increased tumor susceptibility in WT2 mice ... 70 
4.3.5 WT2 microbiota directly promote increased colon LP CD8+ IFNg+ T cells ................ 73 
4.3.6 WT2 microbiota may promote increased colon LP CD8+ IFNg+ T cells through IL-12 
production by DCs ................................................................................................................ 76 
4.3.7 CD8 T cell depletion does not promote increased tumorigenesis in WT1 mice .......... 77 
4.3.8 CD8 T cells may promote increased tumorigenesis in the context of the WT2 
microbiome ........................................................................................................................... 78 
4.3.9 Intratumoral T cells in WT2 mice exhibit an exhausted phenotype ............................ 80 
4.3.10 Increased intratumoral WT2 exhausted T cells are specific to AOM/DSS tumors ... 83 
4.3.11 Intratumoral tumor antigen-specific CD8 T cells are not associated with MC38 
subcutaneous tumors ............................................................................................................. 84 
4.4 Discussion and Future Directions ....................................................................................... 85 
CHAPTER 5: Conclusion ............................................................................................................. 89 
5.1 Summary ............................................................................................................................. 89 
5.2 Discussion and Future Directions ....................................................................................... 91 
APPENDIX ................................................................................................................................... 96 
REFERENCES ............................................................................................................................. 98 
vii 
 
LIST OF FIGURES 
Figure 1 Microbial mechanisms of CRC induction ...................................................................... 11 
Figure 2.1 Timeline of AOM/DSS-induced colon tumorigenesis ................................................ 20 
Figure 2.2 No significant tumor burden differences are measured between days 60-70 of 
AOM/DSS ..................................................................................................................................... 22 
Figure 2.3 Two colonies of C57BL/6 WT mice have different colon tumor burdens in the 
AOM/DSS model of inflammation-associated colon tumorigenesis ............................................ 25 
Figure 2.4 WT2 mice have similar microbiomes as Nod1-/- mice and are genetically similar to WT1 
mice ............................................................................................................................................... 27 
Figure 2.5 WT1 and WT2 mice have significantly different gut microbiome compositions ....... 28 
Figure 2.6 Predicted metagenomic differences between naïve WT1 and WT2 mouse microbiomes
 ....................................................................................................................................................... 30 
Figure 2.7 Colonized GF mice have comparable stool bacteria levels as SPF mice .................... 31 
Figure 2.8 GF WT mice colonized with SPF intestinal contents or cultivable SPF intestinal bacteria 
have microbiomes that resemble that of the donor microbiomes after four weeks of colonization
 ....................................................................................................................................................... 32 
Figure 2.9 Gut microbiome differences of WT1 and WT2 mice directly contribute to differences 
in tumor susceptibility ................................................................................................................... 34 
Figure 2.10 The tumorigenic effects of WT2 microbiota are inflammation-dependent ............... 36 
Figure 3.1 Cohousing did not promote microbiome or tumor phenotype transmission ............... 44 
Figure 3.2 One-to-one cohousing did not promote tumor phenotype transmission ..................... 45 
Figure 3.3 Cross-fostering promoted better microbiome transfer but cross-fostered mice developed 
intermediate tumor burdens between SPF WT1 and WT2 controls ............................................. 46 
Figure 3.4 Microbiome transfer experiments reveal bacteria that are associated with low of high 
tumor burdens ............................................................................................................................... 49 
Figure 3.5 Low abundance of candidate bacteria produces challenges in cultivation and isolation
 ....................................................................................................................................................... 50 
viii 
 
Figure 3.6 Gavaging SPF intestinal contents into a GF host promotes expansion of some candidate 
OTUs ............................................................................................................................................. 51 
Figure 4.1 Microarray of relative RNA expression from distal colon tissue of WT1 and WT2 mice 
on day 0 and 10 of AOM/DSS treatment ...................................................................................... 63 
Figure 4.2 WT2 mice have increased colon LP B and T cells ...................................................... 64 
Figure 4.3 The WT2 microbiome promotes increased AOM/DSS-induced colon tumor burdens via 
adaptive immune cells ................................................................................................................... 66 
Figure 4.4 Naive WT2 mice have increased IFNg-producing, activated, resident memory, and 
effector memory colon LP CD8 T cells ........................................................................................ 68 
Figure 4.5 No T cell differences are present in mesenteric lymph nodes ..................................... 69 
Figure 4.6 WT2 mice have increased colon inflammatory cell infiltration on day 12 of AOM/DSS
 ....................................................................................................................................................... 69 
Figure 4.7 WT2 mice have increased colon LP CD8+ IFNg+ T cells on day 12 of AOM/DSS .... 70 
Figure 4.8 Colon LP CD8 T cells partly mediate increased tumor susceptibility in WT2 mice .. 72 
Figure 4.9 SPF WT1 mice colonized with WT2 microbiota have increased colon LP CD8+ IFNg+ 
T cells ............................................................................................................................................ 74 
Figure 4.10 GF WT mice colonized with WT2 microbiota have increased colon LP CD8+ IFNg+ T 
cells ............................................................................................................................................... 75 
Figure 4.11 WT2 microbiota promotes increased IL-12 production by BMDCs ......................... 77 
Figure 4.12 Mice remain CD8-depleted five days after antibody-mediated depletion ................. 78 
Figure 4.13 Antibody-mediated CD8 depletion in WT1 mice can exacerbate DSS-induced colitis 
and may promote tumorigenesis ................................................................................................... 78 
Figure 4.14 Antibody-mediated CD8 depletion in WT2 mice can exacerbate DSS-induced colitis 
but may reduce tumorigenesis ...................................................................................................... 79 
Figure 4.15 CD8 T cells promote increased tumorigenesis in the context of a WT2 microbiome
 ....................................................................................................................................................... 80 
Figure 4.16 Intratumoral WT2 CD8 T cells display decreased IFNg activity and increased 
exhaustion ..................................................................................................................................... 82 
Figure 4.17 No differences in CD8 T cell exhaustion are measured in CDX2-Cre Apcfl/fl and MC38 
tumors ........................................................................................................................................... 83 
ix 
 
Figure 4.18 Increased intratumoral tumor antigen-specific CD8 T cells in subcutaneous MC38 
tumors are not associated with increased tumor size .................................................................... 84 
Figure 4.19 Naïve WT2 mice have decreased stool IgA levels and SPF WT2 microbiota do not 
directly promote colon LP B cell differences ............................................................................... 87 
Figure 5.1 Visualization of the microbiota and CD8 T cell activity in WT1 and WT2 mice during 
AOM/DSS tumorigenesis ............................................................................................................. 90 
x 
 
ABSTRACT 
The gut microbiome plays important physiological roles, including aiding in digestion of 
non-digestible starches and fibers, production of nutrients, protection against pathogens, as well 
as inducing mucosal immune system development. Disturbances to the composition of the gut 
microbiome are associated with intestinal disease including inflammatory bowel disease (IBD) 
and colorectal cancer (CRC), where CRC is the third most common cancer in both men and women 
in the United States. There is increasing evidence that CRC patients have altered microbiomes 
compared to healthy controls; specific bacteria known to be increased in CRC patients include E. 
coli with the pks pathogenicity island, enterotoxigenic B. fragilis and F. nucleatum. Additionally, 
specific microbiota have been shown to modulate host immunity, but the mechanisms by which 
the gut microbiota can contribute to colon carcinogenesis remain to be fully elucidated.  
Our lab is interested in studying the interplay between the gut microbiome and CRC 
development. Using the azoxymethane (AOM)/dextran sulfate sodium (DSS) mouse model of 
colitis-associated colorectal cancer (CAC), our lab discovered two colonies of specific pathogen 
free (SPF) C57BL/6J wild type (WT) mice housed in the same mouse room that develop 
differential tumor burdens. Mice from the “WT1” colony developed five tumors on average while 
mice from the “WT2” colony developed 15 tumors on average. The increased tumor susceptibility 
in WT2 mice can be directly attributed to the gut microbiome as germ-free (GF) WT mice, where 
GF mice are sterile and have no microbiota, colonized with WT2 bacteria developed more tumors 
compared to that of GF WT mice colonized with WT1 bacteria. Additionally, 16S rRNA gene 
sequencing of fecal bacteria from WT1 and WT2 mice revealed distinct microbiomes with certain 
bacteria consistently associated with high or low tumor numbers.  
As the microbiome can promote altered immunity, we further examined SPF WT1 and 
WT2 immune compositions. Immunologically, naïve and acutely-inflamed (day 12 of AOM/DSS) 
WT2 mice have increased colon lamina propria (LP) CD8+ IFNγ+ T cells compared to WT1 mice 
as measured by flow cytometry. Bone marrow-derived dendritic cells (BMDCs) stimulated with 
WT2 bacteria produced increased IL-12, a cytokine that induces increased IFNγ activity by CD8 
xi 
 
T cells, compared to BMDCs stimulated with WT1 bacteria. Additionally, introduction of WT2 
microbiota promoted an increase in colon LP CD8+ IFNγ+ T cells in GF WT and microbiome-
depleted SPF WT1 mice. However, in tumor-bearing WT2 mice, there was decreased tumor-
infiltrating CD8+ T cells with reduced IFNγ production, where these cells are increasingly 
exhausted. GF Rag1-/- mice as well as SPF CD8-/- mice inoculated with WT2 gut microbiota 
developed fewer tumors than SPF WT2 mice, suggesting that the gut microbiome of WT2 mice 
increases tumor susceptibility, in part, through an effect on CD8 T cells. Altogether, our data 
reveals a potential novel role of microbiota in altering colon CD8 T cell function that ultimately 
impacts colon cancer risk. 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1: Introduction 
1.1 Colorectal cancer overview 
1.1.1 Colorectal cancer global patterns 
Colorectal cancer (CRC) is the third most common cause of cancer and fourth leading 
cause of cancer-related deaths worldwide (1). While incidence and mortality rates are declining in 
the United States, Western Europe, and Australia, likely due to increased and improved screening 
and therapies, CRC incidence rates are rising in Asia, Eastern Europe and South America. This 
may be attributable to westernization and economic transitioning of countries as a higher incidence 
of CRC has typically been associated with economically developed countries (1, 2). In addition, 
there has been a disturbing increase in incidence of young onset colorectal cancer, and in particular, 
rectal cancer in individuals aged 50 years and younger. This rise in incidence cannot be entirely 
explained by genetic predispositions, and suggests lifestyle and environment factors potentially 
play a role (3). Besides genetic predisposition and inflammatory bowel disease (IBD), which 
account for a small percentage of CRC, risk factors related to dietary and lifestyle habits include 
smoking, obesity, increased alcoholic consumption, and a diet rich in red meat and reduced in 
whole grains and dairy (4, 5). Many of these factors can influence or be influenced by the 
composition of the microbiota (6-11).  
In addition, just as different parts of the colon are associated with specific subtypes of CRC, 
the composition of the gut microbiota also changes with anatomic location, further suggesting a 
potential link between the microbiota and CRC pathogenesis (2, 12-14). Thus, there is increasing 
interest in understanding the role of the gut microbiome in dictating CRC risk. Indeed, there is 
now significant evidence that the gut microbiome composition is altered in patients with CRC and 
that these perturbations from a healthy state, often referred to as dysbiosis, may contribute to the 
development and/or progression of CRC.  
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1.1.2 The microbiome and colorectal cancer 
The gut microbiome is comprised of commensal bacteria, Archaea, viruses, fungi, and 
more. In this thesis, we focus on the role of the bacteria component of the colon microbiome, which 
consists of trillions of bacteria of at least 1000 different species and plays an important role in the 
promoting health and intestinal homeostasis (15, 16). For example, gut microbiota are required for 
the digestion and provision of certain nutrients including resistant starches and vitamins, the 
development and education of the host immune system, and resistance against colonization by 
harmful pathogens (16-18).  
The gut microbiota is dominated by two phyla, Bacteroidetes and Firmicutes, but also 
includes Actinobacteria, Fusobacteria, Proteobacteria, and Verrucomicrobia (19, 20). Although 
there is significant inter-individual heterogeneity in the composition of the gut microbiota such 
that a “core” microbiome has not been identified, the human microbiome may be stratified into 
specific enterotypes defined by the relative abundance of certain phylotypes, such as Bacteroides, 
Prevotella, and Ruminococcus genera, as well as co-occurring bacterial species found in the 
healthy human gut (7, 19, 21, 22). On the other hand, there is much more similarity in the 
functional gene content of the gut microbiome and the metabolic pathways they represent between 
individuals (7). These observations suggest the possibility of using the composition of the 
microbiota and the metabolites they produce as potential biomarkers or therapeutic targets for 
disease. 
When the microbiome is perturbed, a dysbiotic or imbalanced microbiome can occur which 
can lead to colon inflammation and intestinal pathology including infectious colitis, IBD, and CRC 
(23). For instance, multiple studies have shown that IBD and CRC patients have a dysbiotic 
microbiome community represented by decreased Firmicutes and increased Bacteroidetes bacteria 
compared to healthy controls. In this chapter, we discuss mechanisms of how specific microbiota 
promote CRC. Consistently, studies of CRC patients have identified potential metabolic signatures 
(24, 25). 
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1.2 Dysbiosis in colorectal cancer  
1.2.1 Background 
There are a growing number of studies that show differences in the composition of the gut 
microbiome between individuals who are healthy or have CRC (Table 1). Identifying specific 
bacteria that are found in all cases of CRC, however, has been more of a challenge and may reflect 
pre-existing inter-individual heterogeneity, the relatively small numbers of patients examined to 
date, limitations in taxonomic resolution to the species level, differences in the source material 
used for sequencing analysis (e.g. tissue versus stool), and differences in sequencing method. Most 
studies evaluating the presence of dysbiosis in CRC patients have been small, case-control studies, 
typically less than 100 subjects per group, comparing either fecal or tissue samples from CRC 
patients and normal, healthy controls, some of which were performed with the goal of identifying 
potential microbial biomarkers of disease. These studies have not showed significant concordance 
on specific species that are predictive of or are associated with CRC; however, CRC patients 
generally have altered gut microbiomes, characterized by decreased Firmicutes and increased 
Bacteroidetes bacteria compared to healthy controls (26-29). 
Despite the lack of significant concordance between studies on microbiome differences 
between CRC and non-CRC control subjects to date, multiple studies have reported an enrichment 
of Fusobacterium nucleatum as well as oral commensal and pathogenic bacteria such as 
Porphyromonas spp., Prevotella spp., and Streptococcus spp. in CRC patients (30, 31). Although 
the reason behind this association is poorly understood, it has been posited that the ability of oral 
bacteria to produce and reside in biofilms enables them to colonize and adhere to the colon 
epithelium under predisposing conditions (e.g., during inflammation) that result in CRC 
development (16, 32). Consistently, the presence of biofilms is associated with the development 
of CRC, particularly in the proximal colon, and consistently, increased colonization of 
Fusobacterium has been observed in right-sided colon cancers (33).  
Despite the fact that Fusobacterium and other oral microbes are repeatedly identified in 
colon tumor tissue, one study suggests that the presence of these bacteria is still not predictive of 
CRC (34). Rather, the depletion of typically beneficial bacteria such as those capable of producing 
butyrate and other short chain fatty acids (e.g., Ruminococcoaceae, Lachnospiraceae and 
Eubacterium spp.) were more strongly predictive of CRC (34). A meta-analysis identified eight 
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taxa whose fecal abundance were significantly associated with carcinomas, namely, 
Fusobacterium, Parvimonas, Porphyromonas and Peptostreptococcus, which are commonly 
found in the oral cavity, and Clostridium, Enterobacteriaceae, Escherichia, and Ruminococcus, 
where decreases in Clostridium and Ruminococcus are associated with CRC (35). Interestingly, no 
individual taxa were sufficient to predict for the presence of cancer, suggesting that multiple 
bacterial populations contribute to cancer susceptibility (35).   
Whether the altered microbiomes observed in CRC patients cause the development of CRC 
or occur as a result of carcinogenesis and cancer progression remains unclear. In a longitudinal 
study of patients who developed CRC, the reversion of the gut microbiome to that associated with 
a normal colon in patients after treatment of their colorectal cancer suggests that a CRC-associated 
microbiome may in fact contribute to disease (36). In addition, studies using germfree (GF) mice 
strongly suggest that dysbiosis directly contributes to colon tumorigenesis (37). A commonly used 
mouse model to study the effects of the microbiota on colon carcinogenesis is the azoxymethane-
dextran sulfate sodium (AOM/DSS) model of inflammation-associated colon cancer in which mice 
are treated with the experimental carcinogen AOM followed by multiple rounds of water 
containing DSS, which causes bacteria-driven inflammation in the colon by disrupting the 
epithelial barrier (38). This results in the generation of adenomatous polyps, which although are 
premalignant, can eventually progress into adenocarcinomas, and therefore, have been used as a 
surrogate marker for cancer (38). AOM/DSS treatment also causes microbiome alterations similar 
to that of human CRC patients, including reduced species richness and alpha diversity and 
significant shifts in beta diversity (37). Using this model, it was shown that the colonization of GF 
C57BL/6 (B6) mice with the microbiome of tumor-bearing AOM/DSS-treated mice resulted in 
significantly more and larger tumors compared to GF mice colonized with the microbiota of 
healthy, untreated mice (37). Similarly, conventionalization of GF B6 mice with the fecal 
microbiome of five CRC patients also resulted in increased tumors, intestinal dysplasia, and 
inflammation after injection of a single dose of AOM compared to GF mice that were gavaged 
with stool from healthy controls (39). ApcMin/+ mice, which spontaneously develop intestinal 
tumors due to a mutation in the tumor suppressor gene Apc that occurs in the majority of human 
CRC, developed more tumors after gavage of fecal contents from CRC patients than from healthy 
controls (40). The potential carcinogenicity of biofilm-associated microbiota was demonstrated in 
a study in which GF Apc mutant mice developed significantly more tumors when gavaged with 
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the homogenates of biofilm-positive colon mucosa compared to biofilm-negative colon mucosa 
(41). However, in one study, GF B6 mice that were gavaged with the stool from either three CRC 
or three healthy individuals had different susceptibilities to colon tumorigenesis after AOM/DSS 
treatment that did not correlate with donor cancer status, which may in part be due to incomplete 
reconstitution of GF mice with human donor microbiota (28). As human-derived microbiota may 
not interact with the mouse immune system in the same way as an indigenous mouse microbiota, 
studies involving “humanized” GF mice should still be interpreted with caution although remain 
one of the few methods to evaluate causality between the microbiome and disease (42, 43).  
1.2.2 Fusobacterium nucleatum 
Fusobacterium spp. were first noted to be enriched in tumors compared to normal adjacent 
tissue in a small study of six CRC patients (44). This was further confirmed in a larger study of 95 
paired tumor and normal tissue from CRC patients in which there was over-representation of the 
Fusobacterium taxon, including Fusobacterium nucleatum (45). F. nucleatum is a Gram-negative, 
anaerobic bacterium typically found in the oral cavity and was initially recognized to promote 
gingivitis and periodontitis (46, 47). Transcriptomic analysis of tumor tissue from 11 matched 
pairs of CRC and adjacent normal tissue revealed that Fusobacterium nucleatum was 
disproportionately increased in most tumor tissue samples, although it was not more abundant in 
all cases (48). Increased Fusobacterum spp. were also found to be increased in premalignant 
adenomatous tissue compared to adjacent tissues, suggesting that Fusobacterium may be involved 
in tumor progression. Indeed, oral gavage of F. nucleatum into ApcMin/+ mice increased the growth 
and number of tumors that developed (49). Examination of over 1069 cases of CRC from two large 
U.S. prospective cohort studies, the Nurses’ Health Study and the Health Professionals Follow-up 
Study, revealed detectable F. nucleatum DNA in only 13% of cases, although tissue fixation may 
have affected the detection of F. nucleatum in this particular study (50). Interestingly, F. nucleatum 
DNA levels directly correlated with CRC-specific mortality, proximal tumor location, and poor 
tumor differentiation (33, 51). Furthermore, higher levels of F. nucleatum DNA correlated with 
microsatellite instability (MSI-high) and the CpG island methylator phenotype (CIMP-high), 
which was also observed in a second retrospective analysis of 246 Asian patients (50). F. 
nucleatum was also more abundant in the tumor tissue of patients who had recurrences, suggesting 
F. nucleatum can promote chemotherapy resistance (52). Altogether, these studies suggest that the 
presence of F. nucleatum in CRC tissue correlates with poorer prognosis. The link between F. 
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nucleatum with microsatellite instability is interesting given that F. nucleatum levels are otherwise 
associated with poor prognostic features since patients with MSI-high tumors tend to have better 
prognosis. This may reflect the fact that MSI-high tumors tend to be located in the proximal colon 
which coincides with the preferential location of F. nucleatum in biofilms that are dominant on the 
right side in both tumors and normal adjacent tissue and not on the left (53). Regardless, it remains 
unclear why Fusobacterium preferentially colonizes proximal tumors. How it affects tumor 
biology is also not fully understood; however, as it has been shown to preferentially bind to CRC 
cells rather than pre-cancerous adenoma cells and induces their cellular proliferation, it has been 
suggested that it acts as a cancer promoter rather than as an initiator (54). 
1.2.3 Enterotoxigenic Bacteroides fragilis 
Enterotoxigenic B. fragilis (ETBF) is a strain of B. fragilis characterized by the expression 
of the zinc-dependent metalloprotease toxin B. fragilis toxin (BFT). ETBF causes inflammatory 
diarrhea in children and asymptomatically colonizes 20-35% of adults (55). A potential link 
between ETBF and colon carcinogenesis was suggested by a study in which inoculation of ApcMin/+ 
mice with ETBF, but not non-toxigenic B. fragilis (NTBF), increased tumor numbers (56). 
Subsequently, at least two studies were able to identify enhanced levels of ETBF and the BFT gene 
(bft) in the stool of CRC patients by PCR although the numbers of patients evaluated were small 
(< 100) (57, 58). Interestingly, like F. nucleatum, B. fragilis and the bft gene can be found in 
biofilms that largely occur in the proximal colon and are also prevalent in patients with familial 
adenomatous polyposis (FAP), a hereditary condition in which the Apc gene is mutated and 
universally leads to the development of CRC, suggesting the interesting possibility that biofilm 
formation and aggregation of cancer-associated microbiota may be a precursor to and predictive 
of malignant transformation (53, 59). In addition, like F. nucleatum, B. fragilis was increased in 
biofilms associated with right-sided CRC (60). Also consistent with the enrichment of B. fragilis 
in right-sided colon tumors, B. fragilis is more abundant in MSI-high tumors; however, in a study 
of 83 individuals with CRC, there was no significant difference in the presence of the bft gene 
between MSI-high and microsatellite stable (MSS) CRC (61). 
1.2.4 Escherichia coli 
Several studies suggest a possible role for E. coli in promoting CRC. In one study, 90-92% 
of CRC patients had tumor-associated bacteria compared to 3% of healthy controls where E. coli 
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was enriched in 62-77% of CRC patients (62). Another study found 71% of CRC patients to have 
mucosa-associated bacteria where the majority of the gram-negative mucosa-associated bacteria 
were E. coli (63). Finally, in a third study, mucosa-associated E. coli were found in 50% of 
adenocarcinoma samples (64). E. coli in the B2 phylogenic group are enriched for the polyketide 
synthase (pks) genomic island which encodes the genotoxin called colibactin (65).  
A role for pks+ E. coli, specifically, in modulating susceptibility for colon tumorigenesis 
was discovered in a seminal study by Arthur et al., in which increased pks+ E. coli was observed 
in 21 CRC tissue specimens compared to 24 non-CRC controls (66.7% versus 20.8%) (66). The 
accumulation of this bacterium in tumors may, in part, be due to the presence of chronic 
inflammation as pks+ E. coli were also enriched in patients with IBD, a major risk factor for the 
development of colitis-associated CRC. In mice, Arthur et al. found increased colonization of E. 
coli in conventionalized GF Il10-/- mice, which developed spontaneous colitis in SPF conditions, 
compared to that of conventionalized GF WT mice that do not develop colitis (66). This is 
consistent with the association of Enterobacteriaceae and E. coli in IBD and suggests that 
inflammation promotes the bloom of E. coli that occurs prior to frank carcinogenesis (66, 67). 
More importantly, mono-association of GF Il10-/- mice treated with the carcinogen AOM, which 
results in the development of inflammation-associated colon tumors, with pks+ E. coli, but not 
pks-deficient E. coli, resulted in increased numbers of invasive adenocarcinomas. The ability of 
pks+ E. coli to promote colon tumorigenesis was not necessarily due to an effect on inflammation 
as GF Il10-/- mice mono-associated with pks-deficient E. coli or E. faecalis, both of which induced 
similar levels of colitis as pks+ E. coli, did not result in any tumors (66). However, in the context 
of IL-10 deficiency, inflammation is required for the tumor-promoting effects of pks+ E. coli, as 
Il10-/- mice that were also deficient in T cells (Il10-/-;Rag2-/-) are non-colitic and did not develop 
tumors after AOM treatment despite the presence of similar levels of pks+ E. coli (68). Subsequent 
studies using other mouse models, namely, the AOM/DSS, ApcMin/+, and human xenograft models 
of colon tumorigenesis also demonstrated a tumor-enhancing effect for E. coli in specific 
pathogen-free (SPF) mice (69, 70).  
 E. coli of the B2 phylotype is also capable of forming biofilms, which may contribute to 
their ability to adhere to intestinal epithelium and colonize the gut (71). Consistently, pks+ E. coli 
was identified in the biofilms of FAP patients in addition to B. fragilis (59). Regardless, it is 
important to note that pks+ E. coli has not been consistently observed to be significantly elevated 
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in all CRC patient cohorts compared to non-CRC controls, and therefore other bacteria likely 
contribute or are required for full malignant transformation (59, 71). Indeed, in GF genetically-
engineered mouse models of CRC, colonization of mice with both B. fragilis and pks+ E coli alone 
resulted in significantly greater tumor induction including adenocarcinoma formation compared 
to either alone (59).  
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Table 1 Microbiome studies involving stool samples of individuals with colorectal cancer 
Study Country Sample Sizes Sequencing Major Findings 
(72) France 6 CRC patients, 6 healthy controls 
V3/V4 region, 
pyrosequencing 
• Bacteroides/Prevotella group bacteria are increased in CRC patients 
compared to healthy controls 
(26) China 46 CRC patients, 56 healthy controls 
V3 region, 
pyrosequencing 
• Bacteroidetes phylum bacteria significantly increased in healthy controls and 
Proteobacteria phylum bacteria significantly increased in CRC patients 
• Bacteroides, Roseburia, Alistipes, Eubacterium and Parasutterella genera 
increased in healthy controls 
• Porphyromonas, Escherichia/Shigella, Enterococcus, Streptococcus and 
Peptostreptococcus genera increased in CRC patients 
• Healthy controls were enriched in OTUs of Alistipes, Phascolarctobacterium, 
Oscillibacter, unclassified genera of the order Clostridiales, as well as butyrate-
producing Roseburia and the Lachnospiraceae family. 
• CRC patients were enriched in OTUs from Escherichia/Shigella, Klebsiella, 
Streptococcus, Enterococcus, Peptostreptococcus, Eggerthella, 
Fusobacterium, and Gemella genera, as well as Citrobacter from the 
Enterobacteriaceae family 
(73) China 
Stool: 21 CRC 
patients, 22 healthy 
controls 
Lumen swabs: 32 
CRC patients, 34 
healthy controls 
V1-V3, 
pyrosequencing 
• Erysipelotrichaceae, Prevotellaceae, Coriobacteriaceae, and 
Peptostreptococcaceae family bacteria are enriched in CRC patient intestinal 
lumens compared to healthy controls 
• Peptostreptococcus, Porphyromonas, Mogibacterium, Anaerococcus, Slackia, 
Anaerotruncus, Collinsella, Desulfovibrio, Eubacterium and Paraprevotella 
genera bacteria are enriched in CRC patient stool compared to healthy controls 
(27) USA 47 CRC patients, 94 healthy controls 
V3-V4 region, 
pyrosequencing 
• CRC patients have decreased community diversity but no difference in 
community evenness compared to healthy controls 
• CRC patients have increased Bacteroidetes and decreased Firmicutes 
bacteria 
• In the Firmicutes, the Clostridia family, which include butyrate procuders, are 
particularly reduced in CRC patients 
• Fusobacterium, Atopobium and Porphyromonas genera are increased in CRC 
patients 
(74) China 
47 CRC (advanced 
colorectal adenoma) 
patients, 47 healthy 
controls 
V1-V3 region, 
pyrosequencing 
• Clostridium, Roseburia, and Eubacterium genera (butyrate producers) are 
reduced in CRC patients 
• Enterococcus, Streptococcus, and Bacteroidetes genera are enriched in CRC 
patients 
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(75) USA 11 CRC, 10 healthy controls 
V4 region, 
pyrosequencing 
• Several Bacteroides and Prevotella spp. as well as Dialister and Megamonas 
spp. enriched in healthy controls 
• Increased representation of Akkermansia in colorectal cancer patients 
(29) USA and Canada 
30 CRC (carcinoma) 
patients, 30 adenoma 
patients, 30 healthy 
controls 
V4 region, 
Illumina MiSeq 
(16S rRNA 
sequencing) 
• CRC patients are enriched for Fusobacterium, Porphyromonas, 
Lachnospiraceae, and Enterobacteriaceae bactiera and reduced Bacteroides, 
Lachnospiraceae, and Clostridiales bacteria 
(76) France 
53 CRC (carcinoma) 
patients, 42 adenoma 
patients, 61 healthy 
controls 
V4 region, 
Illumina MiSeq 
(16S rRNA 
sequencing); 
Illumina HiSeq 
(metagenome) 
• Bacteroidetes, Fusobacteria, and Proteobacteria are enriched in CRC 
patients; Firmicutes and Actinobacteria bacteria are reduced in CRC patients 
• Healthy control metagenomes are enriched for fiber-degrading enzymes and 
fiber-binding domains 
• CRC patient metagenomes suggest an increase in degradation of host 
glycans and amino acid uptake 
(77) Austria 
41 CRC patients, 42 
adenoma patients, 55 
healthy controls 
Illumina HiSeq 
(metagenome) 
•Bacteroides and Parabacteroides spp. as well as Alistipes putredinis, Bilophila 
wadsworthia, Lachnospiraceae bacterium and E. coli enriched in CRC 
compared with healthy and advanced adenomas. Fusobacterium, Pavimonas 
micra, Gemella morbillorum and Peptrostreptococcus stomatis elevated in 
carcinomas and adenomas compared with control 
•Bifidobactum animalis and Streptococcus thermophilus decreased in feces 
from adenoma or CRC patients 
(34) USA and Canada 
120 CRC patients, 
198 adenoma 
patients, 172 no 
colonic lesions 
V4 region, 
Illumina MiSeq 
(16S rRNA 
sequencing) 
• Depletion of Lachnospiraceae and Ruminococcoaceae families (butyrate-
producers) in CRC 
• Higher levels of Fusobacterium, Porphyromonas, Parvimonas, 
Peptostreptococcus and Prevotella in CRC 
(30) Ireland 
59 CRC patients, 21 
individuals with 
polyps, 56 healthy 
controls 
V3/V4 region, 
Illumina MiSeq 
(16S rRNA 
sequencing) 
• CRC patients are enriched for Bacteroides, Roseburia, Ruminococcus, 
Oscillibacter genera and certain genera containing known oral pathogens such 
as Fusobacterium and Porphyromonas 
• CRC patients enriched for bacteria in the Prevotella and Pathogen bacteria 
clusters and positively correlated with CXCL1, SERPINE1, and IL-17a and IL-
23 genes 
• Microbiota composition differed between proximal and distal colon tumors 
(78) China 74 CRC patients, 54 healthy controls 
Illumina HiSeq 
(metagenome) 
• Strong association between Parvimonas, Fusobacterium, Solobacterium, and 
Peptotreptococcus with CRC 
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1.3 Mechanisms by which gut microbiota contribute to CRC 
As discussed above, there are a number of well-studied bacteria that are linked to CRC. 
Although the mechanisms by which CRC-associated bacteria and dysbiosis in general promotes 
CRC development remains to be fully elucidated, studies, largely in mice, suggest a mechanism 
related to an effect on host immune responses, tumor suppressor activity, epithelial transformation 
and cellular proliferation via the production of bacterial immunostimulatory molecules, microbial 
metabolites, and genotoxins. These mechanisms are summarized below in Figure 1. 
 
Figure 1 Microbial mechanisms of CRC induction 
Specific microbiota can directly promote CRC through mechanisms such as activating Wnt cell cycle signaling 
(enterotoxigenic B. fragilis, S. bovis, Salmonella, and F. nucleatum), promoting inflammatory gene transcription (F. 
nucleatum) and epithelial cell proliferation (B. fragilis), and causing DNA damage that lead to mutations and 
chromosomal instability (E. coli with the polyketide synthase pathogenicity island). Furthermore, bacterial metabolites 
can promote anti- or pro-tumorigenic responses through inhibiting inflammation (SCFAs) or promoting DNA damage 
and activating cell cycle signaling pathways (secondary bile acids). The specifics of these mechanisms are discussed 
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in this chapter. CRC, colorectal cancer; LPS, lipopolysaccharide binding protein; SCFA, short chain fatty acid; TCF4, 
transcription factor 4; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; TLR4, Toll-like receptor 
4; STAT3, signal transducer and activator of transcription 3; MDSC, myeloid-derived suppressor cell; NKT, natural 
killer T cell. The figure image was made with BioRender.com. 
 
1.3.1 Modulation of host immune responses 
The gut microbiome is increasingly recognized as having a role in modulating both host 
immunity and susceptibility to colon tumorigenesis. For example, the gut microbiota can influence 
frequencies of intestinal lamina propria (LP) immune cells, notably regulatory T cells (Tregs) and 
T helper 17 (Th17) cells (79-81) which can affect inflammatory responses and tumor susceptibility 
(56, 82, 83). Recently, certain human gut bacteria have been associated with IFNg production by 
CD8 T cells and the promotion of antitumor immunity in mice (84). How these immunomodulatory 
activities ultimately contribute to colon cancer susceptibility remains to be fully elucidated. 
Chronic inflammation is a major risk factor for the development of CRC. An inflammatory 
response arises when tissue homeostasis is disrupted and is characterized by the recruitment of 
inflammatory cells to damaged tissue and production of soluble factors to promote tissue repair. 
These soluble factors promote cellular survival and proliferation, angiogenesis, and matrix 
remodeling that are required for effective tissue repair and regeneration (85). However, with 
chronic inflammation that is not self-limited, these same factors can result in the generation of 
DNA-damaging reactive oxygen species that can initiate tumorigenesis as well as promote a 
microenvironment that is conducive to tumor growth and survival (85). Thus, patients with IBD, 
for example, have a substantially increased risk for developing CRC. Inflammation also plays a 
role in the pathogenesis of sporadic CRCs as elevations in cytokines such as IL-8, IL-17, and IL-
23 have been observed in the serum and tissue of CRC patients (86-89). In the context of a 
breached epithelial barrier, the gut microbiome can further induce inflammation by stimulating 
innate immune receptors, such as the Toll-like receptors (TLRs) (89). In mice that harbor a 
mutation in the Apc tumor suppressor gene, colon tumors exhibit increased intestinal permeability 
indicative of a disrupted epithelial barrier, and the presence of intratumoral bacteria is associated 
with upregulation of IL-17 and IL-23 expression that is TLR-dependent (89). Deficiency in either 
IL-17 or IL-23 ameliorated tumorigenesis (89). Thus, shifts in the microbial community that result 
in the accumulation of bacteria that are highly immunostimulatory and pro-inflammatory would 
be a potential mechanism by which dysbiosis and CRC-associated microbiota can potentiate 
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tumorigenesis. Consistently, treatment of mice with antibiotics prior to the development of 
dysbiosis results in reduction in tumor numbers in the AOM/DSS model of colon tumorigenesis 
(37). 
F. nucleatum also interacts with the immune system and stimulates cytokine production 
through TLR4 and can be sensed by retinoic acid-inducible gene I (RIG-I) (90, 91). In periodontal 
disease, NK cells can recognize and bind to F. nucleatum via the NK killer receptor, NKp46 in 
humans, or NCR1 in mice, which promotes a TNF-α inflammatory response that promotes disease 
(92). Although F. nucleatum does not instigate or worsen intestinal inflammation in mice, daily 
gavage of F. nucleatum into ApcMin/+ mice resulted in expansion of tumor infiltrating myeloid cells, 
which are capable of promoting tumorigenesis, as well as upregulation of pro-inflammatory genes 
in tumor tissue similar to what is observed in human CRC tissue (49). 
The induction of chronic inflammation is also a potential mechanism by which ETBF 
promotes tumorigenesis as colonization of WT GF mice with ETBF results in colitis (93). ETBF-
colonized ApcMin/+ mice also developed inflammation in the colon, resulting in epithelial 
hyperplasia and neoplasia. Mechanistically, ETBF-colonized ApcMin/+ mice had increased colonic 
IL-17 expression, which, in turn, activates NF-κB signaling in colon epithelial cells to promote the 
production of the chemokines CXCL1, CXCL2, and CXCL5, which are neutrophil 
chemoattractants, in the distal colon (56, 94). Consistently, ETBF-colonized mice have increased 
colon and intratumoral neutrophils that is dependent on IL-17 and CXCL2 signaling (94, 95). Loss 
of IL-17 signaling either by antibody blockade or by genetic deletion in ApcMin/+ mice resulted in 
suppression of tumors after ETBF colonization (56, 94). In vitro studies using human intestinal 
epithelial cell lines further show that BFT treatment induces IL-8 chemokine expression, which is 
increased in IBD patient colons (96-99). Furthermore, IL-8 secretion by BFT-treated HT29/C1 
cells is NF-κB-dependent via activation of ERK and p38 MAPK pathways (99, 100). 
Although chronically dysregulated inflammation can lead to tumorigenesis, an effective 
immune response is also important for protecting against cancer development as exemplified by 
the increased incidence of cancer in immunocompromised patients. Immune responses can lead to 
the recruitment of immune cells, such as cytotoxic lymphocytes, that can eliminate nascent 
transformed cells in a process known as tumor immunoediting, or immune surveillance (101). 
Studies of biopsy samples from colon cancer patients suggest that a robust immune response as 
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measured by increased infiltration of activated T cells at the site of the cancer is associated with 
better prognosis and less aggressive behavior of the cancer (102, 103).  
Specifically, F. nucleatum has been shown to promote an immunosuppressive 
environment. When measured in colorectal carcinoma tissue, F. nucleatum was associated with a 
lower density of CD3+ T cells (104). Additionally, NK cells are less cytotoxic to F. nucleatum-
incubated tumor cells compared to tumor cells not incubated with F. nucleatum (105). The F. 
nucleatum protein Fap2 interacts with the receptor T cell immunoreceptor with Ig and ITIM 
domains (TIGIT) on intratumoral NK and T cells to inhibit tumor cell killing (105). Finally, F. 
nucleatum-colonized ApcMin/+ mice had increased intratumoral myeloid-derived suppressor cells 
(MDSCs), which are capable of suppressing CD4 T cells (49). In ETBF-colonized ApcMin/+ mice, 
tumor-infiltrating neutrophils have a transcriptional signature similar to MDSCs, including 
upregulation of iNOS, and were able suppress CD8 T cell proliferation in vitro, suggesting that B. 
fragilis may also affect anti-tumor immunity (95).  
Thus, CRC-associated microbiota such as F. nucleatum and ETBF may not only accelerate 
tumorigenesis via upregulating tumor-promoting pro-inflammatory mediators, but also promote a 
tumor environment that is deficient in anti-tumor activity.  
1.3.2 Stimulation of cellular proliferation 
In addition to altering inflammatory and immune responses, CRC-associated bacteria can 
also act directly on the intestinal epithelium to activate pathways involved in cellular proliferation. 
For example, F. nucleatum is known to have adherent and invasive properties via its FadA adhesin 
(106, 107), which is highly expressed in human adenoma and adenocarcinoma tissues compared 
to tissue from healthy patients (108). It was shown that FadA binds to E-cadherin (CDH1), which 
is expressed by epithelial cells, enabling F. nucleatum’s invasion into the host cell (108). 
Furthermore, binding of FadA to E-cadherin promotes E-cadherin’s phosphorylation and 
internalization into the host cell, resulting in increased β-catenin translocation into the nucleus and 
increased transcription of Wnt signaling genes, including the oncogenes c-myc and cyclin D1 
(108), which are directly involved in cellular proliferation and stem cell activity. Consistently, 
FadA increases the proliferative activity of multiple human CRC cells in vitro and in vivo in a 
FadA-dependent manner (108). FadA also upregulates the expression of the phospholipid-binding 
protein annexin A1 (ANXA1) in CRC cells via E-cadherin, and ANXA1 can engage β-catenin to 
activate cyclin D1 to promote cellular proliferation (54). 
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 Other CRC-associated microbiota such as B. fragilis and Salmonella can affect Wnt 
signaling to facilitate neoplastic transformation. In the case of B. fragilis, treatment of the CRC 
cell line HT29/C1 with BFT resulted in the cleavage of E-cadherin and activation of β-catenin, 
resulting in increased c-myc transcription and cellular proliferation (109, 110). Additionally, 
infection by Salmonella enterica serovar Typhimurium with the Salmonella effector protein AvrA 
is also associated with activated β-catenin signaling in colon epithelial cells (111). AvrA displays 
deubiquitinase activity and was able to block the degradation of IκBα and β-catenin, resulting in 
increased c-myc protein expression (112). Consistently, tumors from AOM/DSS-treated AvrA+ S. 
enterica ser. Typhimurium-infected mice displayed increased phosphorylated c-myc expression 
compared to AvrA- S. enterica ser. Typhimurium tumors (113).  
Bacteria can also stimulate cellular proliferation via mechanisms that do not necessarily 
involve Wnt signaling. For example, B. fragilis colonization of ApcMin/+ mice results in upregulated 
STAT3 signaling, which not only promotes Th17 differentiation, but can also drive epithelial 
proliferation, such that loss of STAT3 signaling in epithelial cells resulted in significantly fewer 
tumors (94, 114). Salmonella was capable of inducing cellular transformation of mouse embryonic 
fibroblasts (MEFs) harboring pre-transforming mutations that lead to the inactivation of the tumor 
suppressor protein p53 inactivation or overexpression of c-myc since infection resulted in 
anchorage-independent soft agar growth and permitted tumor growth in immunocompromised 
mice (115). This process was dependent on intact MAPK and Akt signaling (115).  
1.3.3 Promotion of DNA damage 
Another potential mechanism by which CRC-associated bacteria may facilitate the 
development of CRC is the promotion of DNA damage. In the case of pks+ E. coli, which produces 
the genotoxin colibactin, HeLa cells infected with pks+ E. coli exhibited signs of DNA double-
stranded breaks and cell cycle arrest (65, 66). This colibactin-associated DNA damage induced 
DNA repair responses, resulting in cells with chromosomal instability, including chromosomal 
alterations (e.g. translocations, ring chromosomes, etc.) and abnormal chromosome number (116). 
In vitro, pks+ E. coli were able to induce carcinogenic mutations in infected HCT116 (human 
colon carcinoma), IEC-6 (rat intestinal epithelial) and CHO (hamster ovarian epithelial) cells, 
revealing the mutagenic and pro-tumorigenic ability of pks+ E. coli (116). Rat epithelial cells 
infected with pks+ E. coli also exhibited increased DNA damage compared to cells infected with 
E. coli without the pks pathogenicity island (E. coli Δpks) (66). In vivo, AOM-treated GF Il10-/- 
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mice monocolonized with pks+ E. coli developed more tumors and had increased DNA damage 
and cell cycle arrest compared to E. coli Δpks-monocolonized mice despite no difference in 
inflammation, strongly suggesting that the tumor-promoting effects of E. coli were related to its 
genotoxic rather than inflammation-promoting effects (66).  
1.3.4 Production of metabolites 
 In addition to pro-tumorigenic activities of gut microbiota, there is growing recognition 
that microbial-derived metabolites can also affect both health and disease, including CRC. Specific 
metabolites, such as short chain fatty acids (SCFAs) and secondary bile acids, have received the 
most attention for their role in modulating immune responses, epithelial homeostasis, and cell 
signaling that can affect tumor susceptibility. 
1.3.4.1 Short chain fatty acids (SCFAs) 
Consistent with a potentially significant role for SCFAs in CRC pathogenesis, patients with 
CRC can have significant reduction in butyrate-producing bacteria (26, 34). Furthermore, risk for 
CRC is inversely associated with intake of dietary fiber, which is a source of SCFAs via microbial 
metabolism of resistant starches and other fiber polysaccharides (5). SCFAs, which include 
butyrate, propionate, and acetate, are generated from the digestion of dietary fibers, such as 
polysaccharides from plant cell wells, by the gut microbiota, and are then absorbed by host cells 
(117).  
In particular, butyrate is produced by Firmicutes bacteria and is an energy source of 
epithelial cells and helps maintain colon epithelial integrity (118). Notably, butyrate can inhibit 
histone deacetylaces (HDACs) in colon epithelial cells and immune cells, which can have anti-
tumorigenic effects, including the downregulation of pro-inflammatory cytokines such as IL-6 
(119-122). Increased histone acetylation at the Foxp3 locus results in the differentiation of 
regulatory T cells (Treg) (80). Consistent with members of Clostridia being relatively high 
producers of butyrate, Clostridia colonization of GF WT mice promoted colon Treg differentiation 
in GF WT mice (81). The impact of SCFAs on Treg differentiation may have implications on anti-
tumor immunity and response to therapy given its immunosuppressive effect although it remains 
to be determined whether regulatory T cells play a significant role in colon carcinogenesis. SCFAs, 
however, can promote intestinal homeostasis as the administration of SCFAs to GF mice made 
them more resistant to the epithelial damaging-effects of DSS (123). Similarly, butyrate- or 
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Clostridium-treated mice developed less severe colitis compared to their control counterparts (80, 
81). Deficiency in the receptor for butyrate that is expressed on epithelial cells, Gpr109a, resulted 
in reduced numbers of Tregs and the anti-inflammatory cytokine IL-10 as well as increased 
susceptibility to DSS-induced colitis (124-127). Furthermore, Gpr109a signaling was also required 
for butyrate-mediated epithelial expression of IL-18, which is important for promoting epithelial 
repair and resistance to epithelial-injury induced inflammation (124-127).  
Butyrate and SCFAs in general also have anti-tumor effects. Mice deficient in GPR109A, 
for example, have increased tumor development in both AOM/DSS and ApcMin/+ models (127). 
One mechanism, besides anti-inflammatory activity, is by sensitizing cancer cells to apoptosis. 
Cancer cells often express Fas, the receptor for Fas ligand (FasL), but are able to evade apoptotic 
cell death induced by Fas-FasL interactions by effector CD8 T cells and NK cells (128-130). 
Interestingly, in several human CRC cell lines, the addition of soluble FasL and sodium butyrate 
to the culture promoted increased CRC cell apoptosis compared to cells that were incubated with 
sodium butyrate alone (128). Similarly, many cancer cells, including CRC cells, are able to evade 
apoptotic death induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and 
its receptors, including the death receptors DR4 and DR5 (131-133). TRAIL-resistant human colon 
cancer cell lines KM12C, KML4A, and KM20 were incubated with TRAIL, and with or without 
sodium butyrate. Cells that received sodium butyrate displayed increased TRAIL-mediated cell 
death (134). Other mechanisms have been proposed including downregulation of pathways 
involved in cellular proliferation, induction of antioxidant pathways, and effects on microbiome 
composition (135, 136). However, microbial regulation of SCFA levels is unlikely to be the main 
contributor to colon cancer risk as fecal SCFA levels were not found to be predictive of either 
adenomas or carcinomas (137).  
1.3.4.2 Secondary bile acids 
On the other hand, secondary bile acids have been shown to have pro-tumorigenic effects. 
Primary bile acids are secreted by the liver into the gastrointestinal tract where they aid in lipid 
digestion (138). Bile acids have anti-microbial properties and can modify the gut microbiome 
composition (138, 139). Primary bile acids pass through and are mostly reabsorbed by the small 
intestine without microbial alterations (140). However, about 5% of total bile acids are not 
reabsorbed and enter the large intestine and undergo modification by the gut microbiome via bile 
acid hydrolases to generate secondary bile acids (138, 140). High fat diets, which lead to increased 
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bile acid levels, are a risk factor for CRC, and high levels of secondary bile acids have been 
measured in CRC patients (141-143). Interestingly, a meta-analysis of eight fecal metagenomic 
studies of CRC encompassing 386 cancer cases and 392 tumor-free controls demonstrated a 
significant enrichment of the bai operon, which encodes bile acid converting enzymes involved in 
secondary bile acid production, in the stool of CRC patients (25).  
Two well-studied secondary bile acids that have been linked to CRC are deoxycholic acid 
(DCA) and lithocholic acid (LCA). They can induce reactive oxygen and nitrogen species (ROS 
and RNS) production by human colon tissue and human adenocarcinoma cells (144-147). ROS 
and RNS induce DNA damage, and DCA and LCA have been shown to induce DNA breaks in 
human adenocarcinoma cell lines and human colon tissue (145, 147, 148). Bile acids can activate 
multiple pathways, including Wnt, EGFR, and NF-κB, which in turn, can stimulate the 
proliferation of CRC cells as well as induce tumor formation in mice (149-156). Administration 
of secondary bile acids has also been associated with changes in the gut microbiome, which may 
contribute to tumor promotion as gavage of feces from DCA-treated mice into ApcMin/+ mice 
resulted in increased tumorigenesis (151).  
 
1.4 Conclusion and Goals 
 Since the advent of 16S rRNA and metagenomic sequencing technologies and the 
establishment of germfree mouse models, significant advances have been made in our 
understanding of the role of the gut microbiome in the pathogenesis of colorectal cancer. It has 
now become apparent that the presence of CRC is associated with significant shifts in the microbial 
community compared to healthy individuals. The exact nature and timing of these changes and 
whether these changes directly cause colorectal cancer in humans remain active areas of intense 
research and would require a concerted effort by the scientific community to embark in large 
population studies that are prospective in nature and involved the longitudinal analysis of stool or 
mucosal tissue samples.  
It has become generally accepted that colon carcinogenesis is a multi-step process that 
requires the accumulation of genomic mutations that precipitate cellular transformation and that 
the gut microbiota, which can act either as tumor promoters or tumor suppressors by modulating 
inflammation. Inflammation, in turn, can also allow the bloom of harmful pathobionts that 
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outcompete and deplete potential beneficial bacteria to further facilitate tumor progression. Thus, 
it has become tantalizing to speculate that identification of specific bacteria associated with CRC 
and/or preneoplastic lesions (e.g., adenomas) would allow the establishment of microbial 
biomarkers to assess colorectal cancer risk or identify strategies to manipulate the microbiome or 
target specific microbes and their products for cancer chemoprevention.  
 While there are a growing number of studies investigating the interactions between specific 
microbiota, host immunity, and CRC, most studies have been done in genetically susceptible mice. 
Additionally, while some gut microbiota species have been shown to promote different immune 
cell subsets, namely T cells, in the context of CRC, further studies are needed to examine how the 
gut microbiota may alter other immune cell subsets. There also remains an overall gap in 
knowledge of how consortia of specific gut microbiota might alter host immune or carcinogenic 
responses, which is likely more physiologically analogous than studying the role of an individual 
bacterial species. Moreover, the role of microbial metabolites in host immune responses or CRC 
burdens needs to be further examined. 
 In this project, we remove host genetic differences to specifically study how microbiota 
alone can alter CRC susceptibility by utilizing two C57BL/6 wild-type (WT) mouse colonies 
which have significantly different microbiomes. Furthermore, these two WT colonies present with 
different tumor burdens in a chemically-induced model of colitis-associated colon cancer (CAC). 
Using this system, we seek to identify which gut bacteria contribute to tumor burden differences 
and how. Specifically, in Chapters 2 and 3, we identify microbiome differences that promote tumor 
burden differences and explore possible mechanisms. In Chapter 4, we investigate how these 
microbiome differences alter host immunity which ultimately leads to dissimilar CRC outcomes. 
Our findings propose several new avenues of study which are discussed in Chapter 5. Overall, this 
dissertation furthers our understanding of how the gut microbiome affects host immunity in the 
context of CAC, where the gut microbiome has preventative and therapeutic potential.  
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CHAPTER 2: Microbiome Differences Between Two 
C57BL/6 Mouse Colonies Promote CRC Tumor Burden 
Differences 
2.1 Introduction 
 We have previously demonstrated that alterations in the gut microbiome can directly 
contribute to tumorigenesis (37). In this study, we use the azoxymethane (AOM)/dextran sulfate 
sodium (DSS) model of inflammation-associated colon tumorigenesis (38, 157) in which mice are 
given an intraperitoneal injection of the carcinogen AOM followed by three rounds of chemical 
water containing 2% DSS. DSS compromises the intestinal barrier, resulting in increased epithelial 
permeabilization and inflammation (158). In this model, tumors develop by weeks 8-10 (37, 159) 
(Figure 2.1). Although this model is driven by epithelial injury and inflammation and has been 
used to understand the pathogenesis of IBD-associated colon cancer, there are features of this 
model that also recapitulate sporadic colorectal cancer including the predominance of tumor 
mutations that dysregulate Wnt signaling (160, 161), which occurs in the majority of human CRC, 
as well as the progression from adenomas to adenocarcinomas (162). AOM/DSS treatment also 
results in microbiome alterations similar to that observed in human CRC patients such as reduced 
species richness and alpha diversity as well as significant shifts in beta diversity (37).  
 
  
Figure 2.1 Timeline of AOM/DSS-induced colon tumorigenesis 
Age-matched C57BL/6 mice were treated with 10mg AOM/kg 
weight followed by three five-day rounds of 2% DSS. Mice were 
sacrificed at least one week after the last cycle of DSS, and tumors 
were counted. 
AOM
DSS
Tumor count
0 5 10 26 31 47 52 60+
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2.2 Materials and Methods 
2.2.1 Mice 
All SPF mice were housed in the University of Michigan Rogel Cancer Center Mouse 
Facility. SPF WT1 mice were originally purchased from Jackson Laboratory and bred in-house at 
the University of Michigan (UM). SPF WT2 mice were generated from WT littermates (Nod1+/+) 
of backcrosses between Jackson Laboratory B6 mice and transgenic Nod1-/- mice (>F8) and 
subsequently established as a separate wildtype colony on a different rack from WT1 mice to 
minimize cross-contamination of WT1 and WT2 microbiomes. Tails from WT1 and WT2 mice 
were sent to DartMouseTM for SNP genotyping using the Illumina Infinium Genotyping Assay. 
CDX2-Cre Apcfl/fl mice were bred in house, and 7-8 week-old CDX2-Cre Apcfl/fl mice were used. 
Germ-free (GF) WT and GF Swiss Webster mice were also used. GF WT mice originate from 
Jackson Laboratory B6 mice and were bred and housed at the University of Michigan Germ-free 
Mouse Facility. Animal studies were conducted under protocols approved by the University of 
Michigan Committee on the Use and Care of Animals. 
2.2.2 Inflammation-induced colon tumorigenesis 
6-10 week-old SPF WT1 and WT2 mice were injected intraperitoneally with 10mg 
azoxymethane (Sigma) per kg mouse weight. After five days, mice were treated with three cycles 
of 2% dextran sulfate sodium (MP Bio, m.w.=36,000-50,000) given for five days in the drinking 
water followed by 16 days of regular drinking water. Mice were sacrificed between days 60-70 
after AOM injection (Figure 2.1). This time range does not significantly affect tumor numbers 
between mice of the same group (Figure 2.2). For tumor counting, colons were flushed of stool 
with PBS, longitudinally cut open, and grossly counted using a magnifier and measured with 
calipers. For Figure 2.9 involving conventionalized GF mice, GF WT mice were 9-12 weeks old 
and GF SW mice were 5 weeks old when they were gavaged. Four weeks after colonization, all 
GF WT groups were treated with two rounds of 2% and a final round of 1.5% DSS water due to 
increased mortality of GF+WT2 microbiota after two DSS rounds; GF Swiss Webster mice 
received three rounds of 1.5% DSS water to ensure survival. 
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Figure 2.2 No significant tumor burden differences are measured between days 60-70 of AOM/DSS 
The tumor counts of WT1 and WT2 controls of seven different AOM/DSS experiment are shown. Mice sacrificed 
between days 60-70 of AOM/DSS. No differences in tumor burdens are measured between different days of sacrifice 
within this range. Data are mean ± SEM. 
 
2.2.3 Bacteria preparation for oral gavage 
Whole SPF stool and cecal contents were isolated from young adult SPF WT1 and WT2 
mice. Specifically, stool and cecal contents were collected under strictly anaerobic conditions 
(85% N2, 10% H2, 5% CO2) in a Coy anaerobic chamber immediately after euthanasia and 
homogenized in anaerobic PBS. Mice received 150µl of homogenate. Homogenates were 
aliquoted into Eppendorf tubes (one tube/donor) to ensure homogenates remained anaerobic before 
gavage. One tube was frozen for later 16S rRNA sequencing.  
Homogenates were also plated onto either brain-heart infusion (BHI, BD) agar 
supplemented with 10% horse blood (Quad Five), chopped-meat carbohydrate broth (CMCB) agar 
(163), or YCFA agar (164). Plates were cultured at 37°C anaerobically for 48 hours. Cultivable 
bacteria were resuspended from plates using anaerobic PBS and gavaged into GF WT mice. Mice 
received 150µl of homogenate. One tube was frozen for later 16S rRNA sequencing. 
2.2.4 MC38 subcutaneous tumor model 
 1x106 MC38 cells were injected into the flank of 7-8 week old SPF WT1 or WT2 mice. 
Tumors were measured over time with a caliper to determine growth speed. All mice were 
sacrificed on the same day once some tumors reached 20mm in diameter (approximately day 21). 
Endpoint subcutaneous tumors were cut out from the flank and weighed. 
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2.2.5 AOM-only model 
 10mg AOM/kg mouse weight was intraperitoneally injected weekly into 7-11 week old 
SPF WT1 or WT2 mice for six weeks. Six months after the first injection, mice were sacrificed 
for tumor counting; colons were flushed of stool with PBS, longitudinally cut open, and grossly 
counted using a magnifier and measured with calipers. 
2.2.6 ELISA  
Stool was collected on day 0, 12, 26 or 60 of AOM/DSS and homogenized in PBS at 100 
mg/ml. Homogenates were diluted to a range of 1:100 to 1:100000 and lcn-2 was measured using 
the Lcn-2/NGAL ELISA kit (R&D Systems) according to manufacturer’s instructions.  
2.2.7 Histological scoring 
Histological assessment of H&E sections was performed in a blinded fashion by board-
certified veterinary pathologist Kathryn A. Eaton using a previously described scoring system with 
some modifications (165). Briefly, a point scale was used to denote the severity of inflammation 
(0=none, 1=mild and mucosa only, 2=moderate infiltration of mucosa or extension to submucosa, 
3=severe in mucosa and submucosa, and 4=transmural), severity of epithelial loss (0=none, 1=mild 
or basal 1/3 of glands, 2=moderate or basal 2/3 crypts, 3=severe where only surface epithelium 
remains, 4=ulceration/erosion), and quantification of adenoma/carcinoma (0=none, 1=single 
focus, 2=multiple foci). Each parameter was then multiplied by a factor reflecting the percentage 
of the colon involved (none, 25% or less, 26-50%, 51-75%, and 76-100%), and then summed to 
obtain the overall score. 
2.2.8 qPCR 
 DNA was isolated from stool using the DNeasy PowerSoil Kit (Qiagen) and used for 
quantitative PCR using SYBR Green on the ABI 7900HT. Primer sequences used: 
qPCR primer: Eub F 5’-AGAGTTTGATCCTGGCTC-3’ 
qPCR primer: Eub R 5’-TGCTGCCTCCCGTAGGAGT-3’ 
2.2.9 Isolation of bacterial DNA and 16S rRNA sequence analyses 
16S rRNA analysis was performed with fecal samples that had been collected from 6-12 
week old mice on the day of AOM injection and were frozen at -20 or -80° C. Bacterial DNA was 
isolated using the PowerSoil-htp 96 Well Soil DNA isolation kit (Qiagen) with the epMotion 5075 
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manually with the DNeasy PowerSoil Kit (Qiagen). The V4 region of the 16S rRNA gene was 
amplified using custom barcoded primers, sequenced with the Illumina MiSeq Personal 
Sequencing platform, and processed using the mothur software package to reduce sequencing 
errors and remove chimeras as previously described (Kozich et al., 2013; Schloss et al., 2009). 
Sequences were aligned to the SILVA 16S rRNA sequence database (Pruesse et al., 2007). 
Sequences were grouped based on their taxonomic classification or clustered into operational 
taxonomic units (OTUs) using a 97% similarity cutoff. Parallel sequencing and processing of a 
mock community allowed us to determine a sequencing error rate of 1.38%. Dissimilarity in 
community structure between samples was calculated using the θYC (thetaYC) distance metric. 
ThetaYC distances between the samples were used for two-dimensional ordination analysis by 
non-metric dimensional scaling (NMDS). Microbial alpha diversity was calculated using the 
inverse Simpson index and the observed number of OTUs (richness) (37). Analysis of MOlecular 
VAriance (AMOVA) was used to determine significance between community structure 
differences of different groups of samples. LEfSe and Metatstats in mothur were used to determine 
statistically differential OTUs between group (166, 167). All FASTQ sequences can be obtained 
from the Sequence Read Archive at NCBI (BioProject number PRJNA557261).  
2.2.10 Statistical analyses 
Continuous data are shown as mean ± SEM. Sample sizes can be found in the Figure 
Legends. Statistical analyses were performed using GraphPad Prism7, R and mothur software. 
Statistically significant differences were determined by Mann-Whitney when only two groups are 
compared (e.g., tumor numbers, fecal Lcn-2 levels). Differences in bacterial community structure 
were analyzed using Analysis of MOlecular VAriance (AMOVA) in mothur (168). P-values below 
0.05 were considered statistically significant and are represented as follows: *p<0.05.  
 
2.3 Results  
2.3.1 Two WT mouse colonies develop different tumor burdens after AOM/DSS 
treatment 
In our previous study (37), we observed C57BL/6 (B6) wildtype (WT) mice with higher 
tumor numbers after AOM/DSS treatment than what we have typically observed (165, 169). 
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Specifically, when we compared the two mouse colonies, “WT1” mice (165, 169) developed five 
tumors on average, whereas “WT2” mice (37) developed 15 tumors on average (Figures 2.3A and 
2.3B). Not only do WT2 mice develop more tumors, they developed larger tumors, and also lost 
more weight after each round of DSS treatment compared to WT1 mice (Figures 2.3C and 2.3D). 
Additionally, on day 12 during the acute inflammatory response to the first round of DSS (day 12), 
WT2 mice developed significantly more colonic inflammation based on levels of stool lipocalin-
2, a surrogate marker for intestinal inflammation (170) and histologic scoring (Figures 2.3E and 
2.3F).  
 
Figure 2.3 Two colonies of C57BL/6 WT mice have different colon tumor burdens in the AOM/DSS model of 
inflammation-associated colon tumorigenesis 
A) Representative photo of WT1 and WT2 tumors at day 60 (tumor endpoint) of AOM/DSS treatment. Scale bar is 
1cm.  
B) Representative micrographs of H&E stains of WT1 and WT2 colon tissue at the tumor endpoint at 40x 
magnification. Tumors are denoted by black arrows. Scale bar is 100µm.  
C and D) Tumor numbers (C) and sizes (D) at the tumor endpoint are shown. WT1 n=42 and WT2 n=36.  
E) Representative graph of percent weight change during AOM/DSS treatment compared to day 0. n=5 mice/group. 
F) Stool lipocalin-2 levels were measured by ELISA on days 0, 12, 26, and 60 of AOM/DSS treatment. D0: WT1 
n=22 and WT2 n=13, D12: WT1 n=18 and WT2 n=17, D26: WT1 n=29 and WT2 n=23, D60: WT1 n=19 and WT2 
n=13. 
G) Severity and extent of inflammatory cell infiltration, epithelial loss and dysplasia of WT1 and WT2 mice on days 
0, 12, 26, and 60 of AOM/DSS treatment were assessed by histological scoring. D0: n=6/group, D12: n=11/group, 
D26: WT1 n=4 and WT2 n=5, D60: n=7/group. 
Data are mean ± SEM and are pooled from or representative of at least two experiments. *p<0.05 by Mann-Whitney 
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Both WT1 and WT2 mice are in the B6 background. WT1 mice include WT B6 mice 
bought directly from Jackson Laboratories or pups from in house breeding cages of Jackson WT 
B6 mice. The WT2 mouse colony was generated from breeding littermate WT (Nod1+/+) pups 
from backcrosses of Nod1-/- mice to WT1 mice (both on a B6 background) where Nod1-/- mice 
develop high tumor numbers similar to WT2 mice in a microbiome-dependent manner (165). We 
hypothesized that the potentially dysbiotic microbiome of Nod1-/- mice was transferred to 
Nod1+/+mice during backcrossing events. To confirm, we analyzed the microbiome composition 
of Nod1-/- and Nod1+/+ (aka WT2) mice through 16S rRNA sequencing of stool-extracted DNA. 
Community-level microbiome differences, or beta-diversity, was visualized by NMDS ordination 
in Figure 2.4A using thetaYC distances, which represents structure dissimilarities between two 
communities, as calculated by the Yue & Clayton dissimilarity index (171). Nod1-/- and Nod1+/+ 
mice have similar microbiomes, as the coordinates, each representing the overall microbiome 
composition of a single mouse, cluster together in overlap. Additionally, by Analysis of MOlecular 
Variance (AMOVA), which measures whether overall structural differences, or bacteria in this 
case, are statistically different between groups, these two mouse groups do not have significantly 
different microbiome compositions.  
To determine whether there are genetic differences between WT1 and WT2 mice, we sent 
tails to DartMouseTM. They performed preliminary SNP genotyping analysis and determined that 
both of our WT1 and WT2 colonies are ~98% homozygous B6 for all 5,307 SNP linkage markers 
compared to their Jackson C57BL/6J control, but that there are genetic differences even between 
mice within each colony (Figure 2.4B).  
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Figure 2.4 WT2 mice have similar microbiomes as Nod1-/- mice and are genetically similar to WT1 mice 
A) NMDS plot showing microbiome similarity of Nod1-/- mice and their Nod1+/+ littermates (aka WT2 mice). Data 
was generated by Joseph Zackular. 
B) SNP genotyping results of representative WT1 and WT2 mice compared to the B6 control. Data was generated by 
DartMouseTM. 
 
2.3.2 The two WT mouse colonies have different microbiome compositions and 
metabolic profiles 
To examine microbiome differences between the two colonies, we performed 16S rRNA 
sequencing on stool-extracted DNA from untreated WT1 and WT2 mice. Although no difference 
in species richness, or the observed number of species, was measured between the gut microbiomes 
of the two colonies, WT2 microbiomes have increased alpha diversity, which is comprised of 
species richness and species evenness, compared to WT1 microbiomes (Figures 2.5A and 2.5B). 
Beta diversity was visualized by NMDS ordination. Two separate clusters, representing the 
microbiomes of WT1 and WT2 mice, show that WT1 and WT2 colonies have distinct microbiome 
compositions (Figure 2.5C). Consistently, the gut microbial community structures of WT1 and 
WT2 mice were dissimilar as shown as thetaYC distances, where a distance of 1 means highly 
dissimilar and microbiome compositions compared within a group typically have a distance of 0.5; 
the thetaYC differences were significant as calculated by AMOVA (Figure 2.5D). 
Furthermore, when we examined specific bacterial differences between WT1 and WT2 
microbiomes, certain bacterial families are differentially abundant. Notably, WT1 mice have 
increased Anaeroplasmataceae, Erysipelotrichaceae, Clostridiales and Sutterellaceae bacteria 
while WT2 mice have increased Prevotellaceae and Helicobacteraceae bacteria (Figure 2.5E).  
In this study, operational taxonomic units (OTUs) are sequences of 97% similarity which 
classify to the genus level. To identify OTU differences that are significantly associated with WT1 
or WT2 microbiomes, we used linear discriminant analysis (LDA) effect size (LEfSe) analysis 
(166) (Figure 2.5F). Consistent with our relative abundance data in Figure 2.5E, as determined 
by an LDA score minimum cutoff of 4, WT1 mice are enriched in a member of the 
Erysipelotrichaceae family, and WT2 mice are enriched in a member of the Prevotellaceae family, 
where increased Prevotellaceae are also measured in human CRC patients (26, 72).  
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Figure 2.5 WT1 and WT2 mice have significantly different gut microbiome compositions 
A-C) 16S rRNA sequencing of naïve WT1 and WT2 fecal microbiota was performed, and richness (A) and alpha-
diversity (B) were measured. Beta-diversity (C) is shown as NMDS plot. *p<0.05 by Mann-Whitney 
D) Microbiome composition dissimilarity based on thetaYC distances. *p<0.05 by AMOVA 
E) Relative bacteria family abundances of naïve WT1 and WT2 mice. n=15/group. 
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F) The most differentially abundant OTUs between WT1 (blue) or WT2 (red) microbiomes were determined by LEfSe 
pairwise analysis. OTUs with LDA scores over 4 are shown.  
Data are pooled from at least five experiments; WT1 n=51 and WT2 n=45 unless otherwise noted. 
 
  
It is also known that different microbiota can produce different metabolites that can affect 
immunity and tumorigenesis. To determine if microbiome differences between our two B6 WT 
colonies may also alter metabolite production, we performed Phylogenetic Investigation of 
Communities by Reconstruction of Unobserved States (PICRUSt) analysis on stool-extracted 16S 
rRNA DNA sequences from naïve WT1 and WT2. PICRUSt is a bioinformatics software that can 
predict the functional content of the metagenome from 16S rRNA sequences (172). In other words, 
the bacteria present in sample, as determined by 16S rRNA sequencing, can be used to predict the 
functional genes that are differentially enriched between groups. The output from PICRUSt can 
be analyzed by the same statistical tests in mothur that are used for differential OTU analyses. By 
LEfSe, pathways that are predicted to be upregulated in WT1 mice include branched-chain amino 
acid (AA) degradation and butyrate metabolism; pathways that are predicted to be upregulated in 
WT2 mice include several AA metabolism and biosynthesis pathways as well as vitamin 
biosynthesis pathways (Figure 2.6).  
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Figure 2.6 Predicted metagenomic differences between naïve WT1 and WT2 mouse microbiomes 
Gene pathways that are predicted to be different between WT1 mice (blue) and WT2 mice (red) based on their 
microbiome compositions. Pathways with an LDA score over 2.3 and p-value<0.05 are shown. n=12 mice/group. 
 
2.3.3 Gut microbiome differences between WT1 and WT2 mice directly contribute 
to colon tumor burden differences 
We have previously shown that treating WT2 mice with an antibiotic cocktail starting two 
weeks before and throughout AOM/DSS treatment resulted in few to no tumors, further suggesting 
the microbiome plays a role in increased tumorigenesis in WT2 mice (37). To more rigorously 
determine whether the microbiome differences between WT1 and WT2 colonies are directly 
responsible for the differences in tumor phenotype, we gavaged anaerobically-prepared stool and 
cecal homogenates of SPF WT1 or WT2 mice into GF WT mice. After four weeks of colonization, 
GF WT mice had comparable stool bacteria levels compared to SPF control mice as measured by 
qPCR using universal bacteria primers (Figure 2.7). We further analyzed the microbiome 
compositions of the colonized GF WT mice. Relative abundances of bacterial families of mice 
colonized with SPF intestinal contents resembled that of the SPF intestinal content donors (Figure 
2.8A). For instance, GF WT mice colonized with SPF WT2 bacteria (WT2>GF WT) had increased 
Prevotellaceae bacteria compared to GF WT mice colonized with SPF WT1 bacteria (WT1>GF 
WT). Donor microbiome compositions were not significantly different from respective colonized 
GF WT mice as determined by thetaYC measurements and AMOVA (Figures 2.8B and 2.8C). 
Additionally, WT1>GF WT mice had significantly distinct microbiome compositions compared 
to WT2>GF WT (Figures 2.8B and 2.8C). Altogether, this suggests that successful microbiome 
transfer can be achieved with this method. 
Furthermore, to determine whether cultivable bacteria from SPF WT1 or WT2 
microbiomes also contribute to tumor susceptibility, stool and cecal homogenates were plated 
onto: 1) brain-heart infusion (BHI) agar supplemented with 10% horse blood, 2) chopped-meat 
carbohydrate broth (CM) agar (163), and 3) YCFA agar (164). These general purpose media were 
used to maximize the growth of a broad spectrum of bacteria including the Bacteroidetes, 
Firmicutes, and Proteobacteria phyla among others. After 48 hours at 37ºC under anaerobic 
conditions, bacterial colonies from all three media were resuspended and pooled in anaerobic PBS 
and gavaged into GF WT mice. Four weeks after colonization, microbiomes were analyzed for 
colonization transfer success. While the cultivable bacteria are similar in species with the SPF 
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inputs, expectedly, they differ in abundances (Figures 2.8A and 2.8D). However, GF WT mice 
colonized with cultivable SPF WT1 microbiota (cult WT1>GF WT) have bacteria similar to SPF 
WT1 mice (Figure 2.5E), with increased abundances of Lachnospiraceae and 
Anaeroplasmataceae compared to GF WT mice colonized with cultivable SPF WT2 microbiota 
(cult WT2>GF WT) (Figure 2.8D). Cult WT2>GF WT mice had increased Prevotellaceae and 
Helicobacteraceae bacteria compared to cult WT1>GF WT mice (Figure 2.8D), consistent with 
what we have observed in SPF WT2 mice (Figure 2.5E). Additionally, GF WT mice colonized by 
cultivable SPF bacteria had microbiomes similar to their respective cultivable bacteria inputs, and 
cult WT1>GF WT mice had significantly distinct microbiome compositions compared to cult 
WT2>GF WT mice as measured by thetaYC distances and AMOVA (Figures 2.8E and 2.8F). 
 
Figure 2.7 Colonized GF mice have comparable stool bacteria levels as SPF mice  
DNA was isolated from stool collected from colonized GF WT mice four weeks after gavage. qPCR using Eubacteria 
primers was used to measure total bacteria. Data are mean ± SEM. n=2/group. 
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Figure 2.8 GF WT mice colonized with SPF intestinal contents or cultivable SPF intestinal bacteria have 
microbiomes that resemble that of the donor microbiomes after four weeks of colonization 
A-C) GF WT mice were gavaged with whole anaerobically-prepared SPF stool and cecal contents. The microbiomes 
of colonized GF WT mice were analyzed four weeks after colonization. Relative abundances (A), thetaYC distances 
(B) and an NMDS plot (C) of microbiome similarity between donors and colonized GF WT are shown.  
D-F) Anaerobically-prepared SPF intestinal contents were also plated onto three different media plates. Cultivable 
bacteria that grew were gavaged into another group of GF WT mice. Their microbiomes were also analyzed four 
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weeks after colonization. Relative abundances (D), thetaYC distances (E) and an NMDS plot (F) of microbiome 
similarity between donors and colonized GF WT are shown.  
Data are mean ± SEM. n=4-5/group, *p<0.05 by AMOVA 
 
As determined in Figure 2.4B, WT1 and WT2 mice are not 100% genetically identical, 
and it is possible that genetic differences may contribute to the observed tumor susceptibilities. To 
determine if microbiome differences alone can contribute to tumor burden differences, four weeks 
after colonization, GF WT mice colonized with SPF intestinal contents or cultivable bacteria were 
treated with AOM/DSS to induce tumors. WT1>GF WT developed significantly fewer and smaller 
tumors compared to WT2>GF WT, suggesting that microbiome differences between SPF WT1 
and WT2 mice are sufficient to promote tumor burden differences regardless of any inherent 
genetic differences between the SPF WT colonies (Figures 2.9A-C). Interestingly, cult WT2>GF 
WT also developed more tumors compared to cult WT1>GF WT, but developed significantly 
fewer and smaller tumors compared to SPF WT2>GF, suggesting some bacteria that are promoting 
tumor differences are cultivable (Figures 2.9A-C).  
Furthermore, to determine if microbiome differences could promote tumor burden 
differences when host genetic differences are present, we gavaged anaerobically prepared SPF 
WT1 or WT2 stool and cecal contents into GF Swiss Webster (SW) mice, which are an outbred 
mouse strain where individuals are genetically dissimilar. After four weeks of microbiome 
colonization, colonized GF SW mice were treated with AOM/DSS to induce colon tumors. At the 
end of AOM/DSS, GF SW mice colonized with SPF WT2 microbiota developed significantly 
more tumors compared to GF SW mice colonized with SPF WT1 microbiota (Figure 2.9D). This 
suggests that even with host genetic differences, WT1 and WT2 microbiota are sufficient to induce 
tumor burden differences. 
Altogether, these data suggest that the different tumor susceptibilities of WT1 and WT2 
mice can be attributed to gut microbiome differences and that the absence or presence of specific 
bacterial populations, some of which may be cultivable, can determine tumor outcomes.  
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Figure 2.9 Gut microbiome differences of WT1 and WT2 mice directly contribute to differences in tumor 
susceptibility 
A and B) Tumor numbers (A) and sizes (B) of AOM/DSS-treated GF WT mice that were colonized with SPF WT1 
or WT2 whole stool and cecal homogenates or anaerobically cultivable WT1 or WT2 stool and cecal bacteria for 4 
weeks. Tumors were counted 10 days after the last DSS round. n=4-5/group.  
C) Representative micrographs of H&E stains of colonized GF WT colon tissue at the tumor endpoint at 40x 
magnification. Tumors are denoted by black arrows. Scale bar is 1mm.  
D) SPF intestinal contents were gavaged into 5 week-old GF Swiss Webster mice. Four weeks after colonization, mice 
were treated with AOM/DSS. Mice were sacrificed and tumors were counted on day 66. n=5/group. 
Data are mean ± SEM. *p<0.05 by Mann-Whitney  
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2.3.4 Gut microbiome differences promote tumor burden differences in an 
inflammation-dependent way 
 To determine if the tumor burden differences promoted by the two microbiome 
compositions were inflammation-dependent, we tested three additional mouse models of colon 
cancer that are not solely driven by inflammation: 1) AOM-only model, 2) subcutaneous MC38 
tumor model, and 3) CDX2-Cre Apcfl/fl genetic model. 
 The AOM-only model is driven by carcinogen-induced oncogenic mutations. Mice were 
intraperitoneally injected with the carcinogen AOM weekly for six weeks. Six months after the 
first injection, mice were sacrificed for tumor counting. No differences in colon tumor numbers 
between WT1 and WT2 mice were measured (Figure 2.10A).  
 In the MC38 model, MC38 colon adenocarcinoma cells, which are syngeneic to C57BL/6 
mice, are subcutaneously injected into the flank of experimental mice. Small tumors appear within 
a week, and growth can be measured over time. No differences in MC38 tumor growth (Figure 
2.10B) or endpoint tumor size (Figure 2.10C) were measured between SPF WT1 and WT2 mice. 
The tumor suppressor APC is mutated in the majority of colorectal cancers (173). CDX2-
Cre Apcfl/fl mice are a genetic model of colon cancer where APC is deleted in intestinal epithelial 
cells as a result of the CDX2 promoter. In our mouse rooms, these mice develop spontaneous colon 
tumors starting at two months old. To determine if WT2 microbiota can promote increased 
tumorigenesis compared to WT1 microbiota in this model, we treated CDX2-Cre Apcfl/fl mice with 
an antibiotic cocktail and antifungal water for one week before gavaging these mice with 
anaerobically-prepared SPF WT1 or WT2 stool and cecal homogenates for three consecutive days. 
Eleven weeks later, mice were sacrificed for colon tumor counting. No differences in overall tumor 
numbers were measured (Figure 2.10D), but tumors from CDX2-Cre Apcfl/fl mice with WT2 
microbiota were generally larger in size (Figure 2.10E). However, as these mice were already 7 
weeks old at the time of microbiome transfer, it is possible they had already developed small 
tumors. 
 Altogether, these three models show that the WT2 microbiome promotes increased colon 
tumorigenesis in an inflammation-dependent manner. However, in the genetic CDX2-Cre Apcfl/fl 
model, WT2 microbiota may promote increased tumor sizes after tumors have been established.  
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Figure 2.10 The tumorigenic effects of WT2 microbiota are inflammation-dependent 
A) WT1 and WT2 mice were injected once a week with AOM for six consecutive weeks. Colon tumors were counted 
six months after the first AOM injection. Data are mean ± SEM. n=5/group. 
B and C) 1x106 MC38 cells were subcutaneously injected in the flanks of SPF WT1 and WT2 mice. Tumor growths 
(B) were measured at intervals over 21 days; n=5/group. Mice were sacrificed on day 23 after cells were injected, and 
subcutaneous MC38 tumors were weighed (C); n=7-8/group. Data are mean ± SEM and representative of or pooled 
from at least two experiments.  
D and E) SPF WT1 and WT2 microbiomes were gavaged three times over consecutive days into microbiome-depleted 
CDX2-Cre Apcfl/fl mice. Eleven weeks after the last gavage, mice were sacrificed for colon tumor counting. Total 
tumor numbers (D) and tumor sizes of all tumors (E) are shown. Data are mean ± SEM. n=6-7/group, *p<0.05 by 
Mann-Whitney 
 
2.4 Discussion and Future Directions 
In Chapter 2, we described a unique model where two genetically WT mouse colonies 
develop significantly different inflammation-associated colon tumor burdens which can be directly 
attributed to microbiome differences between the two colonies. WT1 mice develop an average of 
5 tumors and WT2 mice develop an average of 15 tumors. Even before tumors are induced, 
microbiomes of WT2 mice resembled that of IBD patients and CRC patients. We also showed that 
gavage of anaerobically-prepared SPF intestinal contents was able to successfully colonize germ-
free mice where microbiomes of colonized mice resembled the donor microbiome composition. 
We also determined that some of the bacteria that promotes tumor burden differences are 
cultivable. Using three colon cancer models that are not driven by inflammation, we further 
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determined that the microbiome differences between WT1 and WT2 mice promoted tumor burden 
differences in an inflammation-dependent way.  
It is known that mice of the same genotype can have different phenotypes in different 
facilities or even in different mouse facilities at the same institution (174, 175). For instance, Il10-
/- mice develop spontaneous colitis in certain facilities but not in others, and have varying degrees 
of colitis severity, dependent on the microbiome composition (176, 177). Mice from different 
vendors are also known to have different microbiota (178-180). There has also been growing 
concern in recent years about reproducibility in research (181). Differences in microbiota between 
mouse rooms and facilities could confound phenotype results and may contribute to contradictory 
experimental results. While there is no way to resolve microbiome differences between facilities 
causing different experimental outcomes, for studies in fields where the microbiome contributes 
to disease, including microbiome composition sequences in research paper publications can help 
with experimental normalization and interpretation.  
 As described in Section 1.3.4, microbiome-produced metabolites can impact colorectal 
tumorigenesis. Here, we showed that not only do the two colonies have significantly different 
microbiomes, the metagenome of these mice are also different based on predictive PICRUSt 
analysis (Figure 2.6). A future direction of this finding would be metabolomics analyses on 
metabolites extracted from stool from the two colonies. We plan to determine which metabolites 
are significantly differentially abundant between the two colonies and if these metabolites can be 
commercially bought, we can directly test whether they play a role in protecting against or 
promoting colon tumors. To this end, we started a collaboration with Dr. Robert Quinn at Michigan 
State University to begin processing stool samples for metabolomics analyses.  
 In Figure 2.10, we show that the WT2 microbiome’s effects on increased tumorigenesis is 
dependent on inflammation; of note, CDX2-Cre Apcfl/fl mice were 7 weeks old when they received 
antibiotic and antifungal water. However, in our mouse facility, CDX2-Cre Apcfl/fl mice develop 
spontaneous tumors typically by week 8. Therefore, in this particular experiment, these mice likely 
already had tumors at the time of SPF WT1 or WT2 microbiome gavage, where the gavaged 
microbiome would be influencing tumor growth but not development. To better determine if WT1 
and WT2 microbiotas differentially affect tumor development in CDX2-Cre Apcfl/fl mice, we plan 
to repeat this experiment but begin antibiotics and antifungal treatment around four weeks old.  
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Here, our two WT colonies show that microbiome differences can significantly alter 
disease severity. These findings further show that microbiome-dependent phenotypes can occur 
independent of host genetics, emphasizing the importance of proper controls in animal 
experiments. As shown in Figure 2.4A, wildtype littermates do not have significantly different 
microbiomes compared to knockout littermates and are ideal controls for disease studies where the 
microbiome is known to play a role. With littermates, the microbiome is largely normalized across 
pups despite genetic differences and therefore different phenotypes can be directly attributed to 
host genetic differences. However, littermate controls are not always possible, but microbiome 
transfer methods can be used to help equilibrate microbiomes before experiments. In this chapter, 
we confirm that GF mice colonized with a gavage of bacteria had microbiome compositions highly 
similar to the composition of donor microbiome. In Chapter 3, we explore different microbiome 
transfer methods to determine which results in best microbiome, and therefore tumor burden 
phenotype, transfer. Determining the best microbiome transfer method could help normalize 
microbiomes of experimental and control mice when littermates aren’t possible. 
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CHAPTER 3: Microbiome Transfer Experiments Reveal 
Novel Candidate Bacteria That May Promote or Prevent 
Colon Tumorigenesis 
3.1 Introduction 
In Chapter 2, we showed that the different microbiomes of two WT colonies promote 
different tumor burdens after AOM/DSS treatment. In this chapter, we wanted to determine if the 
tumor burden phenotype difference between WT1 and WT2 mice could be transferred via 
microbiome transfer. As the gut microbiome is comprised mostly of obligate anaerobic microbes 
and are difficult to culture, the field has explored culture-independent methods of transfer to study 
the microbiome. Mice are coprophagic, and therefore eat stool, where microbiota may be 
transferred from one group to another through the ingestion of each other’s stool. Cohousing is a 
commonly used method to transmit microbiome-dependent phenotypes where mice of different 
microbiome compositions are placed in a cage for a certain amount of time (180, 182). In addition 
to cohousing, cross-fostering is another method to transfer the microbiome. With cross-fostering, 
pups are switched to another nursing mother within 48 hours of their birth. It has been shown that 
cross-fostered pups have microbiomes that more closely resemble the nursing mother than the birth 
mother (183-185).  
In this chapter, we determine whether cohousing or cross-fostering, or gavage into GF mice 
as described in Chapter 2, more successfully transfers the microbiome and therefore tumor burden 
phenotype. We also use the microbiome data generated from these microbiome transfer 
experiments to determine if specific bacteria are significantly associated with low or high tumor 
burdens. 
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3.2 Materials and Methods 
3.2.1 Mice 
SPF WT1 mice were originally purchased from Jackson Laboratory and bred in-house at 
the University of Michigan (UM). SPF WT2 mice were generated from WT littermates (Nod1+/+) 
of backcrosses between Jackson Laboratory B6 mice and transgenic Nod1-/- mice (>F8) and 
subsequently established as a separate wildtype colony on a different rack from WT1 mice to 
minimize cross-contamination of WT1 and WT2 microbiomes. Animal studies were conducted 
under protocols approved by the University of Michigan Committee on the Use and Care of 
Animals. 
3.2.2 Inflammation-induced colon tumorigenesis 
6-10 week-old mice were injected intraperitoneally with 10mg azoxymethane (Sigma) per 
kg mouse weight. After five days, mice were treated with three cycles of 2% dextran sulfate sodium 
(MP Bio, m.w.=36,000-50,000) given for five days in the drinking water followed by 16 days of 
regular drinking water. Mice were sacrificed between days 60-70 after AOM injection (Figure 
2.1). This time range does not significantly affect tumor numbers between mice of the same group 
(Figure 2.2). For tumor counting, colons were flushed of stool with PBS, longitudinally cut open 
and grossly counted using a magnifier and measured with calipers.  
3.2.3 Microbiome transfer  
3.2.3.1 Cohousing 
 6-10 week-old female WT1 and WT2 mice were cohoused for four or six weeks in mostly 
a 2:2: or 1:1 ratio, respectively. Mice were then treated with AOM and three rounds of 2% DSS. 
Stool was collected before and during cohousing and on the day of AOM injection for microbiome 
composition analysis. Tumor were counted between days 66-70 of the AOM/DSS model. 
3.2.3.2 Cross-fostering 
 Several new WT1 and WT2 breeding cages were set up at the same time. All WT1 or WT2 
dams were siblings from the same cage to minimize microbiome differences and cage effects. 
Within 48 hours of birth, pups were switched to a nursing mother of the opposite colony. Pups that 
were not born within 48 hours of the opposite colony were used as non-cross-fostered controls. 
Pups were weaned around three weeks of age. Once they reached six weeks of age, pups were 
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treated with AOM and three rounds of 2% DSS. Stool was collected on the day of AOM for 
microbiome composition analysis. Tumors were counted on days 60 or 61 of AOM/DSS treatment. 
3.2.4 Microbiome culturing 
Whole SPF stool and cecal contents were isolated from SPF WT1 and WT2 mice. Stool 
and cecal contents were collected under strictly anaerobic conditions (85% N2, 10% H2, 5% CO2) 
in a Coy anaerobic chamber immediately after euthanasia and homogenized in 9ml anaerobic PBS 
at roughly a 1:10 dilution. Homogenates were plated onto either brain-heart infusion (BHI, BD) 
agar supplemented with 10% horse blood (Quad Five), chopped-meat carbohydrate broth (CMCB) 
agar (163), or YCFA agar (164). Plates were cultured at 37°C anaerobically for 48 hours. 
Cultivable bacteria were resuspended from plates in anaerobic PBS and either frozen directly or 
mixed in a 1:1 ratio with 500µl of 25% glycerol in CMCB media. Frozen stocks were thawed and 
plated on the same media from which they were collected from. 48 hours later, bacteria were 
scraped off into anaerobic PBS and frozen directly. Stocks of both the initial cultivable bacteria 
and bacteria that grew after thawing were sequenced to determine the bacteria composition. 
3.2.5 Bacteria preparation for oral gavage 
Whole SPF stool and cecal contents were isolated from young adult SPF WT1 and WT2 
mice. Specifically, stool and cecal contents were collected under strictly anaerobic conditions 
(85% N2, 10% H2, 5% CO2) in a Coy anaerobic chamber immediately after euthanasia and 
homogenized in anaerobic PBS. Mice received 200µl of homogenate. Homogenates were 
aliquoted into Eppendorf tubes (one tube/recipient) to ensure homogenates remained anaerobic 
before gavage. One tube was frozen for later 16S rRNA sequencing.  
3.2.6 Isolation of bacterial DNA and 16S rRNA sequence analyses 
16S rRNA analysis was performed with fecal samples that had been collected from 6-14 
week old mice on the day of AOM injection and were frozen at -20 or -80° C. Bacterial DNA was 
isolated using the PowerSoil-htp 96 Well Soil DNA isolation kit (Qiagen) with the epMotion 5075 
manually with the DNeasy PowerSoil Kit (Qiagen). The V4 region of the 16S rRNA gene was 
amplified using custom barcoded primers, sequenced with the Illumina MiSeq Personal 
Sequencing platform, and processed using the mothur software package to reduce sequencing 
errors and remove chimeras as previously described (Kozich et al., 2013; Schloss et al., 2009). 
Sequences were aligned to the SILVA 16S rRNA sequence database (Pruesse et al., 2007). 
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Sequences were grouped based on their taxonomic classification or clustered into operational 
taxonomic units (OTUs) using a 97% similarity cutoff. Parallel sequencing and processing of a 
mock community allowed us to determine a sequencing error rate of 1.38%. Dissimilarity in 
community structure between samples was calculated using the θYC (thetaYC) distance metric. 
ThetaYC distances between the samples were used for two-dimensional ordination analysis by 
non-metric dimensional scaling (NMDS). Analysis of MOlecular VAriance (AMOVA) was used 
to determine significance between community structure differences of different groups of samples. 
LEfSe and Metastats in mothur were used to determine statistically differential OTUs between 
group (166, 167).  
In addition, a random forest regression model was used to identify OTUs that are associated 
with the number of tumors on the day of AOM injection (Zackular et al., 2016). Linear and Poisson 
regression analyses were used to correlate OTUs to tumor burdens. OTUs identified to be 
predictive of tumor outcomes based on random forest (see Statistical Analysis) and regression 
models were cross-referenced with LEfSe and Metastats methods, which were used to identify 
OTUs associated with low (0-5 tumors) or high tumor burdens (>15 tumors) based on abundance, 
using an LDA score cutoff of 3 and an abundance difference cutoff of 0.003, respectively. OTUs 
that were significant in all five statistical models were chosen as candidates. A phylogenetic tree 
of the candidates was generated based on the V4 region sequence of the 16S rRNA gene using the 
Clustal Omega program by the EMBL-EBI (Madeira et al., 2019). All FASTQ sequences can be 
obtained from the Sequence Read Archive at NCBI (BioProject number PRJNA557261). 
3.2.7 Statistical analyses 
Continuous data are shown as mean ± SEM. Sample sizes can be found in the Figure 
Legends. Statistical analyses were performed using GraphPad Prism7, R and mothur software. 
Statistically significant differences were determined by Mann-Whitney when only two groups are 
compared (e.g., tumor numbers, etc.). Differences in bacterial community structure were analyzed 
using AMOVA in mothur (168). P-values below 0.05 were considered statistically significant and 
are represented as follows: *p<0.05. A random forest (RF) regression model was used to identify 
OTUs that are associated with the number of tumors that developed. RF is a decision tree-based 
approach that allows for nonlinear relationship between the OTU and tumor count data and 
interactions between OTUs. The RF model included all 521 OTUs with a total normalized count 
over all mice > 0.005. It was fit using the randomForest package in R with default 
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parameters except that we increased the number of trees in RF to 1,000 trees (186). Finally, OTUs 
were ranked by importance in the RF model as determined by the percent reduction in the mean 
square error (MSE) when an OTU was removed from the model. As an alternative to the machine 
learning method, we also used parametric regression models to study the effect of each OTU on 
the tumor count data. Specifically, we considered the simple linear regression (lm function in R) 
and Poisson regression (glm function in R). The resulting p-values were adjusted to control the 
false discovery rate (187). 
 
3.3 Results 
3.3.1 Cohousing and one-to-one cohousing did not transfer the tumor burden 
phenotype 
We first began with the cohousing method of microbiome transfer. Age-matched female 
WT1 and WT2 mice were cohoused mostly in a 2:2 ratio for four weeks before AOM/DSS 
treatment (Figure 3.1A). Cohoused WT1 and cohoused WT2 mice exhibited significant tumor 
burden differences similar to non-cohoused control mice (Figure 3.1B).  
Although the microbiota of cohoused WT1 and cohoused WT2 mice were not significantly 
different from each other after four weeks of cohousing based on thetaYC distances, cohoused 
WT1 microbiome compositions remained significantly different from non-cohoused WT2 
microbiomes (Figure 3.1C). Cohoused WT2 microbiomes also remained distinct from control 
WT1 microbiomes based on thetaYC measurements, suggesting incomplete microbiome transfer 
(Figure 3.1C). Additionally, by NMDS ordination, cohoused WT1 and cohoused WT2 mice 
continued to cluster separately, similar to that of non-cohoused SPF WT1 and WT2 controls 
(Figure 3.1D). 
While cohousing did not result in complete transmission of tumor phenotype from either 
WT1 or WT2 mice to the other, there were two cohoused mice that developed tumors similar in 
number to mice from the other colony (Figure 3.1B, black boxes). These mice were cohoused in 
a 1:1 ratio (one WT1 and one WT2 mouse), which may have resulted in more efficient microbiome 
transfer by coprophagy.  
We therefore performed one-to-one (oto) cohousing experiments and also extended the 
cohousing time to six weeks to improve microbiome transfer and phenotype transmission (Figure 
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3.2A). However, significant tumor burden differences were observed between oto cohoused WT1 
and WT2 mice (Figure 3.2B). Furthermore, oto cohoused WT2 mice developed an intermediate 
tumor burden phenotype, and no differences in tumor numbers between oto cohoused WT1 and 
non-cohoused WT1 mice were measured (Figure 3.2B). Regarding microbiome composition, 
WT1 control mice were significantly different from oto cohoused WT2 mice, again suggesting 
incomplete microbiome transfer despite oto cohousing (Figure 3.2C). By NMDS ordination, 
microbiome compositions of oto cohoused WT1 and WT2 mice clustered between control WT1 
and WT2 mice, suggesting that cohoused mice have a hybrid microbiome, which may explain the 
intermediate tumor phenotype (Figure 3.2D). However, while no overall microbiome composition 
differences between cohoused WT1 and WT2 mice were measured by thetaYC distances, LEfSe 
analysis detected specific OTUs which were still significantly differentially abundant between the 
two groups (Figure 3.2E). 
 
Figure 3.1 Cohousing did not promote microbiome or tumor phenotype transmission 
A) WT1 and WT2 mice were cohoused in a 2:2 ratio (coh) for four week. Mice were treated with AOM/DSS and 
sacrificed for tumor counting on days 67 or 70.  
B) Number of tumors after cohousing and AOM/DSS treatment. Data are mean ± SEM. *p<0.05 by Mann-Whitney 
C and D) Stool was collected after four weeks of 2:2 cohousing for microbiome analysis. (C) Microbiome 
composition dissimilarity was analyzed by ThetaYC distance. (D) Beta diversity is shown as a non-metric dimensional 
scaling plot (NMDS). *p<0.05 by AMOVA  
Data are pooled from at least two independent experiments. Controls: WT1 n=9, WT2=2; coh: n=9/group. 
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Figure 3.2 One-to-one cohousing did not promote tumor phenotype transmission 
A) WT1 and WT2 mice were cohoused in a 1:1 ratio (oto) for six week. Mice were treated with AOM/DSS and 
sacrificed for tumor counting on days 66 or 67.  
B) Number of tumors after oto cohousing and AOM/DSS treatment. Data are mean ± SEM. *p<0.05 by Mann-Whitney 
C and D) Stool was collected after six weeks of 1:1 cohousing for microbiome analysis. Microbiome composition 
dissimilarity was analyzed by ThetaYC distance (C) and shown as an NMDS plot (D). *p<0.05 by AMOVA  
E) Microbiomes of cohoused WT1 (WT1 coh, blue) and WT2 (WT2 coh, red) were compared by LEfSe analysis and 
several OTUs were found to be associated with one group of mice. OTUs with LDA scores above 3.2 are shown. 
Data are pooled from at least two independent experiments. Controls: WT1 n=9, WT2=10; oto groups: n=10/group. 
 
3.3.2 Cross-fostering resulted in an intermediate tumor burden phenotype 
As the gut microbiome of an adult mouse is typically determined by maternal transmission, 
cross-fostering is another microbiome transfer method and may be more effective than cohousing 
(183, 188). We performed cross-fostering experiments where WT1 or WT2 pups were switched 
within 48 hours of birth to a WT2 or WT1 nursing mother, respectively. After reaching 6 weeks 
of age, cross-fostered mice were treated with AOM/DSS to induce tumors (Figure 3.3A). Unlike 
with cohousing, cross-fostered WT1 and WT2 mice no longer developed significantly different 
tumor burdens; however, average tumor numbers were again intermediate between control WT1 
and WT2 mice (Figure 3.3B).When we examined gut microbiome compositions of cross-fostered 
mice, we determined that the microbial community of WT1 mice cross-fostered by WT2 nursing 
mothers (WT1(WT2)) and WT2 mice cross-fostered by WT1 nursing mothers (WT2(WT1)) were 
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distinct (Figures 3.3C and 3.3D). Although microbiomes of WT2(WT1) and non-cross-fostered 
WT1 mice were overall similar, the microbiome compositions of WT1(WT2) and non-cross-
fostered WT2 mice were still significantly different despite improved microbiome transfer 
compared to cohousing based on thetaYC distances and NMDS ordination (Figure 3.3C). 
Significant differences in OTUs between WT1(WT2) or WT2(WT1) mice and control WT2 or 
WT1 mice, respectively, remained as determined by LEfSe, which may explain why the tumor 
phenotype was not completely transmissible (Figures 3.3E and 3.3F).  
 
Figure 3.3 Cross-fostering promoted better microbiome transfer but cross-fostered mice developed 
intermediate tumor burdens between SPF WT1 and WT2 controls 
A) WT1 and WT2 mice were cross-fostered (CF) and 6 week-old mice were treated with AOM/DSS and sacrificed 
for tumor counting on days 60 or 61. 
B) Number of tumors after AOM/DSS treatment. Data are mean ± SEM. *p<0.05 by Mann-Whitney  
C and D) Stool was collected on the day of AOM for microbiome analysis. Microbiome composition dissimilarity 
was analyzed by ThetaYC distance (C) and shown as an NMDS plot (D). *p<0.05 by AMOVA  
E and F) OTU differences between cross-fostered and non-cross-fostered control mice were measured by LEfSe 
analysis. OTUs with LDA scores above 3.5 are shown. 
Data are pooled from or representative of at least two independent experiments. Controls: WT1 n=18, WT2 n=13, CF: 
WT1(WT2) n=18, WT2(WT1) n=14. 
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3.3.3 Specific bacteria are associated with high or low tumor burdens 
As we observed multiple tumor phenotypes associated with various microbial communities 
that were generated from different microbiome transfer methods, we reasoned that certain bacterial 
populations may consistently be associated with either low or high tumor burdens regardless of 
the WT colony. We therefore examined 16S rRNA sequences from the stool of cohoused and 
cross-fostered WT1 and WT2, control WT1 and WT2 mice, and GF WT mice conventionalized 
with WT1 or WT2 microbiota that was collected right before AOM/DSS treatment to identify 
OTUs that directly correlated with tumor outcomes after AOM/DSS treatment. Based on relative 
abundances, we observed, for example, increased abundance of Prevotellaceae on the day of AOM 
injection in mice that eventually developed high tumor numbers after AOM/DSS treatment and 
increased abundance of Anaeroplasmataceae in mice that eventually developed low tumor burdens 
(Figure 3.4A). OTUs that were significantly associated with low or high tumor numbers were 
determined by the combination of the following analyses: Metastats (167), LEfSe (166), random 
forest (189), and linear and Poisson regression. In particular, we identified nine OTUs belonging 
to at least five different bacterial families that were significantly associated with either high or low 
tumors (Figure 3.4B). Many of these bacteria have not been previously classified, but 
phylogenetic tree analysis based on based on 16S sequence similarity suggests that some of the 
bacteria within a specific family may be closely related (Figure 3.4B) (190, 191).  
More specifically, two OTUs from the Lachnospiraceae family are significantly associated 
with and predictive of low tumor burdens. These OTUs are also more abundant in mice that 
eventually developed low tumor numbers (Figure 3.4C), and interestingly, Lachnospiraceae 
species have also been found to be decreased in CRC patients (26). On the other hand, seven OTUs, 
including bacteria from the Prevotellaceae family, which has been shown to be enriched in CRC 
patients (26, 72), are predictive of high tumor burdens (i.e., 15+ tumors) and are more abundant in 
mice that develop high tumor numbers (Figures 2.5E and 3.4D). Of note, although 
Helicobacteraceae appeared to be more abundant in WT2 mice (Figure 2.5E), it was not 
significantly associated with tumor numbers by linear regression or Metastats analyses. Altogether, 
these data reveal nine bacterial populations that may have tumor-suppressive or tumor-promoting 
activities. 
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Figure 3.4 Microbiome transfer experiments reveal bacteria that are associated with low of high tumor burdens 
A) Stool was collected on day 0 of AOM/DSS which is the day of AOM injection. Relative abundances of family-
level bacteria of naive mice that eventually developed low (0-5) or high (15+) tumors after AOM/DSS treatment are 
shown. Low tumor n=22, high tumor n=20, *p<0.05 by AMOVA  
B) A phylogenetic tree of nine bacterial candidates associated with low (blue) or high (red) tumor burdens was 
generated based on the sequence similarity of the V4 region of the 16S rRNA gene. 
C and D) Relative bacterial abundances in mice at the time of AOM injection that were associated with low (C) or 
high (D) tumor burdens. Black lines denote mean relative abundances. Poisson regression p-values are shown. LDA 
scores were determined by LEfSe analyses and scores above 3.5 are shown. Low n=85, high n=38. 
Data are pooled from at least six independent experiments.  
 
3.3.4 Culturing candidate bacteria 
We next wanted to determine if these candidate bacteria correlating with tumor burdens 
directly contribute to the observed tumor phenotypes in WT1 and WT2 mice. We did a BLAST 
search of the 16S rRNA gene V4 region sequence of these candidate bacteria, and none of the 
bacteria were a 100% match to a known bacteria, suggesting that our candidates have not been 
previously isolated. 
To determine which type of media the nine candidate bacteria grew best on, we plate 
anaerobically prepared stool and cecal contents from SPF WT1 and WT2 mice and plated 
homogenates onto horse blood (BL), chopped meat (CM), and yeast extract-casein hydrolysate-
fatty acids (YCFA) agar plates. The cultivable bacteria were frozen and thawed to see which 
candidates could survive the freezing and thawing process. After 16S rRNA sequencing, despite 
all nine candidates being detected in the input stool, only four high tumor-associated bacteria and 
one low tumor-associated bacteria were initially cultivable (Figure 3.5). After freeze/thaw, only 
one high tumor-associated bacteria was detected (Figure 3.5). Due to low abundances of these 
bacteria after plating and freezing/thawing, we would have to pick thousands of colonies to find 
the exact candidate. However, we were able to determine which type of media some of these 
candidate bacteria grow best on.  
 
BL CM YCFA BL CM YCFA BL CM YCFA BL CM YCFA
Otu00005_Prevotellaceae 0 0 0 0 0 0 0 3.30% 0.10% 0.05% 0 0 0 0
Otu00010_Porphyromonadaceae 0 0 0 0 0 0 0 6.35% 0 0 0 0 0 0
Otu00015_Porphyromonadaceae 0 0 0 0 0 0 0 3.70% 0 0.75% 0.50% 0 0 0.15%
Otu00022_Porphyromonadaceae 0 0 0 0 0 0 0 3% 0.10% 0 0.20% 0 0 0
Otu00036_Ruminococcaceae 1.20% 0.05% 0 0 0 0 0 0.45% 0 0 0 0 0 0
Otu00044_Rikenellaceae 0 0 0 0 0 0 0 1% 0 0 0.10% 0 0 0
Otu00082_Bacteria_uncflassified 0 0 0 0 0 0 0 0.10% 0 0 0 0 0 0
Otu00032_Lachnospiraceae 0.55% 0 0 0 0 0 0 0 0 0 0 0 0 0
Otu00085_Lachnospiraceae 0.25% 0 0 0.10% 0 0 0 0 0 0 0 0 0 0
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Figure 3.5 Low abundance of candidate bacteria produces challenges in cultivation and isolation 
Percentages indicate relative abundance of the nine candidate bacteria in stool, media plates at 1:10 dilution, and in 
freeze/thawed glycerol stocks of bacterial suspensions obtained from the indicated media plates. BL=horse’s blood 
agar, CM=chopped media broth agar, and YCFA= yeast extract-casein hydrolysate-fatty acids agar. 
 
As the relative abundances of these candidate bacteria are low, we wanted to determine if 
gavaging SPF intestinal contents into a GF mouse host could promote the expansion of these nine 
candidate OTUs from which we could get better cultivation success and freeze/thaw survival. For 
low tumor-associated bacteria, we gavaged SPF WT1 intestinal contents into GF WT mice, which 
is the genetic equivalent of SPF WT1 mice. We gavaged SPF WT2 intestinal contents into GF 
Nod1 KO mice as SPF WT2 microbiomes are similar to that of SPF Nod1 KO mice, where the 
absence of Nod1 may have altered the microbiome in SPF Nod1 KO mice. We collected stool on 
day 21 after colonization and compared the candidate bacteria abundances to the donor stool 
abundances.  
Of the two low tumor-associated candidates, OTU32 increased in abundance by day 21 of 
colonization in the GF WT host (Figure 3.6A). This OTU was previously undetected in our initial 
cultivation efforts (Figure 3.5). However, the other low tumor-associated OTU, OTU85 did not 
have increased abundance in the GF WT host (Figure 3.6A). For high tumor-associated 
candidates, OTU5, OTU36, OTU44, and OTU82 increased in abundance in the GF Nod1 KO host 
(Figure 3.6B) where both OTU36 and OTU82 were previously uncultivable (Figure 3.5). OTU10, 
OTU15, and OTU22 had decreased abundances (Figure 3.6B). Altogether, this suggests that this 
method of increasing candidate bacteria abundances could help us improve cultivation of some 
candidates but not all, and that we have to explore other methods of promoting candidate bacteria 
abundances before or during cultivation and isolation. 
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Figure 3.6 Gavaging SPF intestinal contents into a GF host promotes expansion of some candidate OTUs 
Percentages indicate relative abundance of the candidate bacteria in the colonized GF mouse stool at day 21 of 
colonization. Day 0 values represent the abundance of the candidate bacteria in the SPF donor mouse stool.  
 
3.4 Discussion and Future Directions 
 In this chapter, we performed microbiome transfer methods to determine if the tumor 
burden phenotype could be transmissible by the respective microbiomes associated with the two 
colonies. While neither cohousing nor cross-fostering methods promoted better microbiome 
transfer than direct gavage of intestinal contents into GF mice as described in Chapter 2, we were 
able to identify novel bacteria species statistically associated with low or high tumor burdens.  
There has been significant interest in optimizing microbiome transfer to control for or 
determine microbiome-specific effects on phenotype. The gold standard is fecal transplantation of 
donor microbiota into recipient GF mice. As we demonstrated in the previous chapter, the transfer 
of WT1 or WT2 microbiomes and their corresponding tumor phenotype was optimal using this 
system. Cohousing is a widely used method of microbiome transfer between mice of dissimilar 
microbiome compositions in host-microbiome association studies, but the optimal length of time 
of cohousing and ratio of mice harboring two different communities in a cage remain unclear. 
Here, we show that four weeks of 2:2 cohousing resulted in poor microbiome and phenotype 
transfer. Transfer was significantly improved with six weeks of 1:1 cohousing; however, 
microbiome analyses demonstrated that the transfer was still incomplete with significant 
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differences in OTU membership between cohoused mice by LEfSe analysis (Figure 3.2E), likely 
explaining the intermediate tumor phenotype. Generation of hybrid microbiomes and incomplete 
transfer by cohousing has also been observed by others (180, 192, 193).  
In this chapter, we show that cross-fostering provided better microbiome transfer from 
WT1 and WT2 mothers to WT2 and WT1 pups, respectively, than cohousing, demonstrating the 
strong influence of maternal transmission of the microbiome to offspring although as with 1:1 
cohousing, significant differences in microbiome composition remained (Figures 3.3E and 3.3F). 
Despite the improvement in microbiome transfer, the tumor phenotype of cross-fostered mice 
remained intermediate between that of control WT1 and WT2 mice. It is possible that the transfer 
of WT1 and WT2 microbiomes was incomplete with these methods given the difficulty of 
transferring mucosa-associated adherent bacteria (192). Alternatively, the lack of complete 
phenotype transmissibility with either cohousing or cross-fostering may also reflect the poor 
survivability of obligate anaerobes outside the colon 
Additionally, we identified several OTUs that were predictive of tumor susceptibility by 
analyzing the gut microbiomes of WT1 and WT2 mice as well as of mice from multiple fecal 
transfer experiments with hybrid microbiomes. We and others have used similar approaches and 
statistical tools to identify differential OTU(s) between groups that correlate with disease outcomes 
(180, 189, 193, 194). Here, the low or high tumor burdens of AOM/DSS-treated mice cannot be 
attributed to a single bacteria species or family. For example, the bacteria family Prevotellaceae 
is increased in naïve WT2 mice and strongly predictive of high tumor burdens, while 
Lachnospiraceae is significantly associated with decreased inflammation-associated 
tumorigenesis. Decreased Lachnospiraceae have been found in IBD and CRC patients (26, 195), 
where they may have anti-inflammatory function via butyrate production (26). In contrast, 
Prevotellaceae are enriched in IBD and CRC patients and are also associated with increased 
susceptibility to DSS-induced colitis in mice, suggesting they may be pro-inflammatory (26, 30, 
72, 126). Similarly, a member of the Ruminococcaceae was associated with high tumor burdens, 
where Ruminococcaceae have also been found to be enriched in IBD and CRC patients (26, 196). 
A phylogenetic tree based on 16S rRNA sequence similarity suggests that the OTU candidates 
associated with different tumor burdens but from the same family are evolutionarily distinct from 
each other (Figure 3.4B) (191, 197). Regardless, as we have only identified a correlation between 
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the identified OTUs and tumor outcomes, it still remains to be determined whether these bacteria 
regulate tumor susceptibility alone or via interactions with other bacterial populations.  
To determine if these specific bacteria have anti- or pro-tumorigenic effects, we started 
preliminary culturing efforts. Unfortunately, cultivating these bacteria from WT1 and WT2 mice 
has been a significant challenge given their generally low abundance. Based on relative bacteria 
abundances from 16S rRNA sequencing analyses in Figure 3.5, fewer than 1% of the colonies 
were the OTUs of interest on various select media plates, and the only OTU that survived 
freeze/thaw was 0.15% of total bacteria that survived freeze/thaw. Moving forward, we will try 
several methods to promote the expansion of certain bacterial populations including treating 
animals with antibiotics before harvesting intestinal contents or plating intestinal contents on 
different antibiotic-containing media to increase gram positive or negative bacteria numbers. 
Furthermore, we can try to bulk culture as many bacteria as possible in liquid media in plates; we 
can dilute homogenates so that only one bacterium is added per well. We can sequence each well 
and if candidate bacteria are detected, we can expand the liquid stock to test optimal freezing and 
thawing conditions including testing different freezing media at different concentrations. 
Similarly, we can try to directly culture single-species suspensions which would require more 
people and time. As our candidate bacteria may not immediately grow well in liquid cultures, we 
would pick colonies from the initial plate to re-streak and dilute on a second plate to ensure each 
colony is a single species. Afterward, single colonies are picked and grown in liquid media for 
expansion. Lastly, these liquid stocks are sequenced and frozen down. With this process, we are 
picking and expanding the abundance of bacteria into a single species stock before freezing, likely 
ensuring more successful survival after thawing. The downside to this process is the high number 
of initial colonies that have to be picked because the odds of picking one of the nine candidate 
bacteria is low.  
After cultivating and isolating as many candidates as possible, we plan to gavage low 
tumor-associated bacteria and high tumor-associated bacteria into two groups of GF WT mice. 
After colonization, these mice will undergo AOM/DSS to determine if these bacteria are not only 
associated with, but are sufficient in, mitigating or promoting colon tumorigenesis.  
These data show that success of cohousing or cross-fostering for microbiome transfer and 
normalization can depend on the microbiota involved. Despite not achieving complete microbiome 
transfer from one colony to the other, we were able to use these data to identify nine novel bacteria 
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species that are associated with low or high tumor burdens. Our next steps are to cultivate and 
isolate these nine candidate bacteria and determine if they are sufficient to promote tumor burden 
differences, and if they do, we plan to explore possible mechanisms of how these bacteria cause 
differential tumorigenesis. 
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CHAPTER 4: Two WT Mouse Colonies with Microbiome 
Differences Have Host Immune Differences  
4.1 Introduction 
 In Chapter 2, we revealed that the microbiome compositions of two WT colonies of mice 
were significantly different and contributed to tumor burden differences. It has been shown that 
the gut microbiota can modulate host immune responses (79, 198-200). For instance, GF mice 
have underdeveloped mucosal immunity and lymphoid organs, where immune development can 
be induced upon bacteria colonization (201). Furthermore, specific bacteria can modulate certain 
immune cell subsets. Clostridia-produced butyrate, a short chain fatty acid metabolite, promotes 
Treg cell differention and inhibits macrophage and neutrophil activation (80, 81, 123). Segmented 
filamentous bacteria attaches to small intestinal epithelial cells and induces Th17 cell 
differentiation (182, 202), and Bacteroides fragilis makes polysaccharide A which promotes 
inducible Treg cell differentiation in a TLR2-dependent manner (203, 204).  
 In this chapter, we explore whether host immune differences occur due to the different 
microbiomes and how host immune differences may contribute to the contrasting tumor burden 
phenotypes of the two WT mouse colonies.  
 
4.2 Materials and Methods  
4.2.1 Mice 
SPF WT1, Rag1-/- (Rag1tm1Mom) and Cd8-/- (B6.129S2-Cd8atm1Mak) mice (all in the C57BL/6 
background) were originally purchased from Jackson Laboratory (JL) and bred in-house at the 
University of Michigan (UM). WT2 mice were generated from WT littermates (Nod1+/+) of 
backcrosses between JL B6 mice with transgenic Nod1-/- mice (>F8) and subsequently established 
as a separate wildtype colony. WT1 and WT2 were kept on different racks to minimize cross-
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contamination of their microbiomes. Adult male or female 6-10 week-old mice were used except 
where noted. 7-8 week old CDX2-Cre Apcfl/fl mice were used and were bred in house. 
11-15 week old GF WT (Figure 4.10) and 7-8 week old GF Rag1−/− mice (Figures 4.3 
and 4.15), both in the C57BL/6 background, and derived from JL mice, were bred and housed at 
the UM Germ-free mouse facility. Sterility was regularly verified by aerobic and anaerobic 
cultures, Gram stains, and qPCR. GF mice were conventionalized via oral gavage of cecal and 
stool contents from young adult (6+ weeks) SPF WT1 or WT2 mice.  
Animal studies were conducted under protocols approved by the University of Michigan 
Committee on the Use and Care of Animals. 
4.2.2 Inflammation-induced colon tumorigenesis 
6-10 week-old mice were injected intraperitoneally with 10mg azoxymethane (Sigma) per 
kg mouse weight. After five days, mice were treated with three cycles of 2% dextran sulfate sodium 
(MP Bio, m.w.=36,000-50,000) given for five days in the drinking water followed by 16 days of 
regular drinking water. Depending on the particular experiment, mice were sacrificed between 
days 60-70 after AOM injection as specified in the Figure. For tumor counting, colons were flushed 
of stool with PBS, longitudinally cut open and grossly counted using a magnifier and measured 
with calipers. For experiments involving conventionalized GF mice, all groups received three 
rounds of 1.5% DSS water (Figure 4.3) or one round of 1.5% DSS followed by two rounds of 1% 
DSS to maximize survival (Figure 4.15). 
4.2.3 Microarray 
 RNA was extracted from distal colon tissue of SPF WT1 and WT2 mice on day 0 and 10 
of AOM/DSS treatment with the NucleoSpin RNA Kit (Macherey-Nagel). Equal amounts of RNA 
from several samples were pooled into for a single microarray sample per genotype and timepoint. 
RNA samples were submitted to the University of Michigan DNA Sequencing Core for 
transcriptome analysis using the Affymetrix GeneChip™ Mouse Gene 2.1 ST Array Strip. WT1 
and WT2 samples were compared within a timepoint. Probesets where expression values of one 
of the two samples was 24 or greater and with a 2 fold or greater in change are shown. 
4.2.4 Bacteria preparation for oral gavage 
Whole SPF stool and cecal contents were isolated from young adult SPF WT1 and WT2 
mice. Specifically, stool and cecal contents were collected under strictly anaerobic conditions 
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(85% N2, 10% H2, 5% CO2) in a Coy anaerobic chamber immediately after euthanasia and 
homogenized in anaerobic PBS. Mice received 200µl of homogenate. Homogenates were 
aliquoted into Eppendorf tubes (one tube/recipient) to ensure homogenates remained anaerobic 
before gavage.  
4.2.5 Microbiome depletion by antibiotic and antifungal water 
8 week-old CD8 KO (Figure 4.8), 4-5 week-old WT1 and WT2 mice (Figure 4.9), or 7-8 
week-old CDX2-Cre Apcfl/fl mice (Figure 4.17), were treated with antibiotic and antifungal water 
for one week to target Gram-positive, Gram-negative and anaerobic bacteria and to prevent fungal 
blooms (205). Mice were treated with an antibiotic cocktail consisting of 0.5g/L vancomycin 
(Pfizer), 2g/L streptomycin (Sigma), 0.75g/L metronidazole (Sigma), and 0.5g/L fluconazole 
(Sigma) that was sterile-filtered prior to administration. 2% sucralose (Apriva, Kroger®) was 
added to increase the antibiotic solution palatability (206). Mice then received regular water for 
24 hours, were gavaged with WT1 or WT2 stool and cecal homogenates from donor mice that 
were at least 6 weeks of age for three consecutive days, and then treated with AOM/DSS four 
weeks later.  
4.2.6 Immune cell isolation  
Spleens and mesenteric lymph nodes (MLNs) were isolated from naïve age-matched 6-12 
week old WT1 and WT2 mice or from mice on day 60 of AOM/DSS treatment and smashed 
through 70um cell strainers in complete RPMI (=RPMI (Gibco) + 10% FBS (Sigma Aldrich) + 
1% penicillin/streptomycin + 1% L-glutamine). MLN cells were washed once with PBS before 
downstream flow cytometry analysis. Splenocytes were treated with red blood cell lysis buffer for 
3-5 minutes and washed once with PBS before downstream flow cytometry analysis. 
Colon LP cells were isolated as previously described (165, 169). Whole colons were 
isolated from naïve 6-10 week old WT1 and WT2 mice and cut into small pieces and washed with 
HBSS+ (=HBSS (Gibco) supplemented + 2.5% heat-inactivated FBS (Sigma Aldrich) + 1% 
penicillin/streptomycin). After two washes with magnetic stirring, colon pieces were incubated in 
HBSS+ with 1mM DTT (Invitrogen) at 37°C. Colon pieces were washed once and incubated twice 
in HBSS+ with 1mM EDTA (Lonza) at 37°C with magnetic stirring for 30 minutes. After washing 
twice, colon tissue was digested in HBSS+ with 400 I.U./mL type III collagenase (Worthington) 
and 10 μg/mL DNase I (Worthington) at 37°C with magnetic stirring. The single cell suspension 
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was filtered through a 70-micron filter. Colon LP immune cells were collected at the interface of 
a 40%/75% Percoll gradient after centrifugation. For tumor endpoint analyses, tumor or adjacent 
tissue were cut from the colons and processed as described above but with a single EDTA step.  
For MC38 subcutaneous tumors, part of the tumor was minced into ~1mm pieces using a 
scalpel and digested with RPMI + 1% L-glutamine with 400 I.U./mL type III collagenase 
(Worthington) and 10 μg/mL DNase I (Worthington) at 37°C with magnetic stirring. The single 
cell suspension was filtered through a 70-micron filter and pelleted. Cells were resuspended in 
30ml RPMI + 1% L-glutamine, and 10ml of Ficoll-Paque PLUS (GE Healthcare) was layered 
underneath. Intratumoral immune cells were collected at the interface after centrifugation and 
washed once with complete RPMI before downstream flow cytometry analysis. 
4.2.7 Flow cytometry and staining 
MLN or colon LP immune cells were isolated from mice at day 0, day 12 of AOM/DSS or 
at the tumor endpoint (typically day 60) and surface stained. For intracellular staining, cells were 
incubated for 4 hours at 37°C with either 1) GolgiStop (monensin, BD) + 100 ng/ml PMA (Sigma) 
+ 1000 ng/ml ionomycin (“PMA/Iono”) or 2) with GolgiStop alone (“no stim”). Cells were surface 
stained, fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer Set 
(eBioscience), and then incubated with fluorochrome-conjugated antibodies against IFNγ, IL-17 
and Foxp3 (see below). For adgpk tetramer staining, intratumoral MC38 immune cells were 
incubated for 30 minutes with PE-Adpgk tetramer (NIH, gift from the James Moon lab) before 
surface staining. Samples were analyzed by a BD LSRFortessa, FACSCanto II, or FACSAria II 
flow cytometer. Flow cytometry staining antibodies used: 
Antibody and clone Source Catalog number 
CD3 APC-Cy7 clone 145-2C11 BioLegend Cat#100330 
CD3 PE-Cy7 clone 17A2 BioLegend Cat#100220 
CD3 FITC clone 145-2C11 BioLegend Cat#100204 
CD45.2 BV421 clone 104 BioLegend Cat#109832 
CD4 APC clone GK1.5 eBioscience Cat#17-004-82 
CD8 PerCP-Cy5.5 clone 53-6.7 BioLegend Cat#100732 
CD8 APC-Cy7 clone 53-6.7 BioLegend Cat#100714 
CD69 APC clone H1.2F3 BioLegend Cat#104514 
CD44 PE clone IM7 BioLegend Cat#103007 
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CD62L APC-Cy7 clone MEL-14 BioLegend Cat#104427 
Tim-3 PerCP-Cy5.5 clone B8.2C12 BioLegend Cat#134011 
PD-1 PE-Cy7 clone RMP1-30 BioLegend Cat#109109 
Lag-3 PE clone C9B7W BioLegend Cat#125207 
IFNg PE-Cy7 clone XMG1.2 BioLegend Cat#505826 
IL-17 FITC clone TC11-18H10.1 BioLegend Cat#506907 
Foxp3 PE clone FJK-16s eBioscience Cat#12-5773-80 
NK1.1 PerCP-Cy5.5 clone PK136 BD Pharmingen Cat#561111 
Ly6C FITC clone HK1.4 BioLegend Cat#128005 
Ly6G PE-Cy7 clone 1A8 BioLegend Cat#127617 
CD11b PE clone M1/70 BD Pharmingen Cat#561689 
CD11c APC clone N418 BioLegend Cat#117310 
B220 Pacific Blue clone RA3-6B2 BioLegend Cat#103227 
CD103 PE clone 2E7 BioLegend Cat#121405 
4.2.8 RNA isolation and qPCR 
Intraepithelial cells were isolated from naïve WT1 and WT2 mice from the EDTA steps of 
LP immune cell isolation. Total RNA was isolated using the Nucleospin RNA kit (Macherey-
Nagel). cDNA synthesis was performed using the iScript cDNA synthesis kit (BioRad) and used 
for quantitative PCR using SYBR Green on the ABI 7900HT. Gene transcript levels were 
normalized to actin. Primer sequences used: 
qPCR primer: IL-1β F 5’-GATCCACACTCTCCAGCTGCA-3’ 
qPCR primer: IL-1β R 5’-CAACCAACAAGTGATATTCTCCATG-3’ 
qPCR primer: CXCL9 F 5’-GGAACCCTAGTGATAAGGAATGCA-3’ 
qPCR primer: CXCL9 R 3’-TGAGGTCTTTGAGGGATTTGTAGTG-5’  
qPCR primer: CXCL10 F 5’-GACGGTCCGCTGCAACTG-3’ 
qPCR primer: CXCL10 R 3’-CTTCCCTATGGCCCTCATTCT-5’ 
qPCR primer: IL-6 F 5’-CACATGTTCTCTGGGAAATCG-3’ 
qPCR primer: IL-6 R 5’-TTTCTGCAAGTGCATCATCG-3’ 
qPCR primer: occludin F 5′-GGGAATGTCCAGAACGAGAAGA-3’ 
qPCR primer: occludin R 5’-CGTGGCAATGAACACCATGA-3’ 
qPCR primer: β-defensin2 F 5′-AAGTATTGGATACGAAGCAG-3′ 
qPCR primer: β-defensin2 R 5′-TGGCAGAAGGAGGACAAATG-3′ 
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qPCR primer: Reg3g F 5’-TCAGGTGCAAGGTGAAGTTG-3’ 
qPCR primer: Reg3g R 5’-GGCCACTGTTACCACTGCTT-3’ 
qPCR primer: actin F 5’-CAACTTGATGTATGAAGGCTTTGGT-3’ 
qPCR primer: actin R 5’-ACTTTTATTGGTCTCAAGTCAGTGTACAG-3’ 
4.2.9 Preparation of heat-killed bacteria 
Stool pellets from SPF WT1 and WT2 mice were homogenized in PBS, strained through a 
40um cell strainer, and centrifuged at 1000rpm for 10 seconds to pellet debris. The supernatant 
was centrifuged at 5000rpm for 10 minutes. The white bacteria layer of the pellet was diluted in 
PBS and incubated at 95°C for one hour. Heat-killed bacteria suspensions were stored at -20°C 
until use. 
4.2.10 Bone marrow-derived dendritic cell (BMDC) preparation and stimulation 
BMDCs were prepared from WT1 and WT2 mice as previously described (207). Briefly, 
bone marrow cells were cultured for seven days in BMDC-media (=RPMI (Gibco) + 10% FBS 
(Sigma Aldrich) + 1% penicillin/streptomycin + 1% L-glutamine + 20 ng/ml GM-CSF 
(Peprotech)). BMDCs were isolated using the CD11c Microbeads Ultrapure (Miltenyi Biotec) kit. 
4x105 BMDCs were cultured with 4x106 heat-killed bacteria for four hours, washed once in PBS, 
and then resuspended in fresh BMDC-media and collected after 20 hours.  
4.2.11 ELISA 
IL-12p70 was measured in 24 hour supernatants of heat-killed bacteria-stimulated BMDCs 
using the IL-12p70 ELISA kit (R&D Systems).  
Stool of naïve WT1 and WT2 mice were homogenized in PBS to 100mg stool/1mL PBS. 
Supernatants were diluted 1:10 in PBS + 3% FBS + 0.05% Tween-20. IgA was captured using an 
anti-mouse IgA antibody (Bethyl A90-103A) and measured by detecting the reaction signal of goat 
anti-mouse IgA HRP conjugate antibody (Bethyl A90-103P) with TMB one-component HRP 
substrate. Plate signals were read at 450 nm using a microplate reader (Model 3550; Bio-Rad 
Labs).  
4.2.12 CD8 depletion 
300µg of anti-CD8 (Bio X Cell, clone YTS 169.4) or isotype control (Bio X Cell, clone 
LTF-2) antibodies diluted in PBS were intraperitoneally injected into 9 or 12-13 week-old WT1 
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mice or 7-10 or 12-13 week-old WT2 mice. Specific timings of injections are described in the 
Figure Legends. 
4.2.13 CD8 T cell adoptive transfer 
 8 week-old GF Rag1-/- mice were colonized with SPF WT1 or WT2 intestinal 
homogenates. WT2 splenic CD8 T cells were bead-isolated using the mouse CD8a+ T Cell 
Isolation Kit (Miltenyi-Biotec). 3x106 CD8 T cells were intravenously injected into colonized GF 
Rag1-/- mice. Adoptive transfers were done by Hideaki Fujiwara. Four weeks after CD8 T cell 
colonization, mice were treated with AOM and one round of 1.5% DSS followed by two rounds 
of 1% DSS to ensure survival. Weights were measured throughout AOM/DSS. Mice were 
sacrificed on day 60 of AOM/DSS for tumor counting.  
4.2.14 MC38 subcutaneous tumor model  
 1x106 MC38 cells were injected into the flank of 8-10 week-old SPF WT1 or WT2 mice. 
All mice were sacrificed on day 23. Endpoint subcutaneous tumors were cut out from the flank 
and weighed before immune cell isolation processing. 
4.2.15 Isolation of bacterial DNA and 16S rRNA sequence analyses 
16S rRNA analysis was performed with fecal samples that had been collected from mice 
on the day of AOM injection and were frozen at -20 or -80° C. Bacterial DNA was isolated using 
the PowerSoil-htp 96 Well Soil DNA isolation kit (Qiagen) with the epMotion 5075 manually with 
the DNeasy PowerSoil Kit (Qiagen). The V4 region of the 16S rRNA gene was amplified using 
custom barcoded primers, sequenced with the Illumina MiSeq Personal Sequencing platform, and 
processed using the mothur software package to reduce sequencing errors and remove chimeras as 
previously described (Kozich et al., 2013; Schloss et al., 2009). Sequences were aligned to the 
SILVA 16S rRNA sequence database (Pruesse et al., 2007). Sequences were grouped based on 
their taxonomic classification or clustered into operational taxonomic units (OTUs) using a 97% 
similarity cutoff. Parallel sequencing and processing of a mock community allowed us to 
determine a sequencing error rate of 1.38%. Dissimilarity in community structure between samples 
was calculated using the θYC (thetaYC) distance metric. ThetaYC distances between the samples 
were used for two-dimensional ordination analysis by non-metric dimensional scaling (NMDS). 
Microbial alpha diversity was calculated using the inverse Simpson index and the observed number 
of OTUs (richness) (37). Analysis of MOlecular VAriance (AMOVA) was used to determine 
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significance between community structure differences of different groups of samples. LEfSe and 
Metatstats in mothur were used to determine statistically differential OTUs between group (166, 
167). All FASTQ sequences can be obtained from the Sequence Read Archive at NCBI (BioProject 
number PRJNA557261). 
4.2.16 Statistical analyses 
Continuous data are shown as mean ± SEM. Sample sizes can be found in the Figure 
Legends. Statistical analyses were performed using GraphPad Prism7, R and mothur software. 
Statistically significant differences were determined by Mann-Whitney when only two groups are 
compared (e.g., cell number, etc.). Differences in bacterial community structure were analyzed 
using AMOVA in mothur (168). P-values below 0.05 were considered statistically significant and 
are represented as follows: *p<0.05.  
 
4.3 Results 
4.3.1 Host immune differences are measured between WT1 and WT2 mouse colons 
 To initially determine if differential gene expression occurred between SPF WT1 and WT2 
mice, we performed a microarray using RNA isolated from untreated and early inflammation (day 
10 of AOM/DSS) SPF WT1 and WT2 colon tissue. We measured the relative expression of 
significantly differentially expressed genes and grouped the genes based on function. A large 
number of immunoglobulin (Ig) and Ig receptor genes were more highly expressed in naïve WT1 
colons but were more highly expressed WT2 colons after inflammation (Figure 4.1). Additionally, 
several interferon induced genes including Oas2, Ifit1, Ifi44, and more, were also more highly 
expressed in WT2 colons after inflammation (Figure 4.1), which may be consistent with higher 
inflammation and increased histologic scores (which includes epithelial loss) in WT2 mice at day 
12 of AOM/DSS (Figures 2.1E and 2.1F). Additional inflammatory and immune cell-related 
genes that are increasingly upregulated in inflamed WT2 colons include but are not limited to 
Saa3, Tarm1, Slfn4, Duox2, and Cd274. Interestingly, major urinary proteins show a striking 
difference; they are increased in naïve WT2 colons but after inflammation, increased in WT1 
colons (Figure 4.1). However, the significance of these proteins in inflammation or host immunity 
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is unknown. Altogether, this microarray data suggests there may be differential host immune and 
inflammatory gene expression between WT1 and WT2 mice before and during inflammation. 
 
Figure 4.1 Microarray of relative RNA expression from distal colon tissue of WT1 and WT2 mice on day 0 and 
10 of AOM/DSS treatment 
Red represents genes that are more highly expressed in WT2 mice and green represents genes that are more highly 
expressed in WT1 mice. WT1: d0 n=4, d10 n=5; WT2: d0 n=3, d10 n=6. 
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4.3.2 Dysbiotic microbiome of WT2 mice promotes inflammation-associated 
tumorigenesis via adaptive immune cells 
To determine whether the difference in tumor susceptibilities between WT1 and WT2 mice 
were associated with altered baseline immune responses, immune cell compositions were analyzed 
from spleen, bone marrow, and entire colon of untreated WT1 and WT2 mice by flow cytometry. 
No differences in colon LP monocytes, neutrophils, dendritic cells (DCs) or NK cells were 
observed, but WT2 mice had increased B and T cell populations compared to WT1 mice (Figure 
4.2A). No differences in immune cell composition were measured in the spleen and mesenteric 
lymph nodes (MLNs) (Figures 4.2B and 4.2C). This suggests that the WT2 microbiome may 
exert its tumor-promoting effect via colon LP adaptive immune cells. 
 
Figure 4.2 WT2 mice have increased colon LP B and T cells 
Immune cell subsets were measured by flow cytometry in the colon LP (A), spleen (B), and MLNs (C). Immune 
subsets measured include: DCs (CD11c+ CD11bint), NK cells (NK1.1+), monocytes (CD11b+ Ly6Chi Ly6Gint), 
neutrophils (CD11b+ Ly6Cint Ly6G+), T cells (CD3+ B220-), and B cells (B220+ CD3-). Data are mean ± SEM and are 
representative of or pooled from at least two independent experiments. LP: n=5-7/group; SP: n=3-6/group; MLN: 
n=5-6/group. *p<0.05 by Mann-Whitney 
 
To examine this possibility, GF Rag1-/- mice were gavaged with anaerobically prepared 
SPF WT1 or WT2 stool and cecal homogenates (Figure 4.3A). After four weeks, successful 
colonization of WT1 and WT2 microbiomes were detected as shown by relative family 
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abundances, as measured by thetaYC distances, and as visualized by NMDS plots (Figures 4.3B-
D). Following four weeks of colonization, mice were then treated with AOM/DSS to induce 
tumors.  
GF Rag1-/- mice with WT2 microbiota developed fewer and smaller tumors compared to 
SPF WT2 controls (Figures 4.3E and 4.3F), suggesting that the dysbiotic WT2 microbiome 
promotes tumor susceptibility by acting on adaptive immune cells. GF Rag1-/- mice with WT1 
microbiota developed slightly increased tumor numbers compared to SPF WT1 control mice 
(Figure 4.3E), which may indicate a protective role for adaptive immune cells in the context of 
the WT1 microbiome. Of note, GF Rag1-/- mice had significantly more tumor numbers compared 
to SPF Rag1-/- mice suggesting that the absence of any microbiota can be lead to increased 
tumorigenesis susceptibility, which is consistent with previous reports which suggest that GF mice 
are more susceptible to both DSS-induced injury and AOM/DSS-induced tumorigenesis (123, 
160). 
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Figure 4.3 The WT2 microbiome promotes increased AOM/DSS-induced colon tumor burdens via adaptive 
immune cells 
A) GF Rag1-/- mice were gavaged with SPF WT1 or WT2 stool and cecal contents followed by AOM injection and 
three rounds of 1.5% DSS after four weeks of colonization. Mice were sacrificed on day 61 for tumor counting. 
B) Relative bacterial family abundances of colonized GF Rag1-/- mice four weeks after gavage of SPF WT1 or WT2 
intestinal contents. 
C and D) Microbiome similarity between donors and colonized mice are measured by thetaYC distances (C) and 
shown by an NMDS plot (D). *p<0.05 by AMOVA 
E and F) Tumor numbers (E) and sizes (F) are shown. Data are mean ± SEM. *p<0.05 by Mann-Whitney 
n=4-6/group. 
 
4.3.3 WT2 mice have increased colon LP CD8+ IFNg+ T cells 
We and others have previously shown a role of T cells in affecting tumor susceptibility in 
the AOM/DSS model (169, 208). Here, we further examined potential T cell subset differences in 
the colon LP. By flow cytometry, WT2 mice have increased colon LP CD8 T cells compared to 
WT1 mice (Figure 4.4A). To determine if T cell activity was altered between WT1 and WT2 mice, 
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we examined LP T cell cytokine production after four hours of ex vivo-stimulation by phorbol 
myristate acetate (PMA) and ionomycin. Specifically, colon LP CD8+, but not CD4+, IFNg+ T cells 
are increased in naïve WT2 mice (Figure 4.4B). In contrast, there were no differences in colon LP 
CD4+ IL-17+ or CD4+ Foxp3+ cells (Figure 4.4B), suggesting that Th17 and Treg cells do not 
contribute to the increased inflammation and tumor susceptibility of WT2 mice. To further define 
the nature of the CD8 T cell differences between WT1 and WT2 mice in the colon LP, we 
examined levels of activated CD8+ CD69+ cells, resident memory CD8+ CD69+ CD103+ cells, and 
effector memory CD8+ CD44+ CD62L- cells and observed increased levels in the WT2 colon LP 
whereas there were no differences in activated, resident memory, or effector memory CD4 T cells 
in the colon LP between WT1 and WT mice (Figures 4.4C-E). Furthermore, no differences in 
CD3, CD4 or CD8 T cells were measured in mesenteric lymph nodes (MLNs) of naïve mice 
(Figures 4.5A and 4.5B), and no differences in IFNg-producing CD8 or CD4 T cells were 
measured (Figure 4.5C). Altogether, this shows that CD3+, and specifically CD8+ IFNg+, T cell 
differences are specific to the colon LP. 
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Figure 4.4 Naive WT2 mice have increased IFNg-producing, activated, resident memory, and effector memory 
colon LP CD8 T cells 
A) Number of CD4 and CD8 T cells in colon LP T cells of WT1 and WT2 mice as determined by flow cytometry. 
n=8/group. 
B) Intracellular cytokine production (IFNg and IL-17) was measured after four hours of PMA + ionomycin + monensin 
stimulation. Intracellular Foxp3 staining was performed after four hours of monensin incubation. Representative flow 
plots are shown. n=8-9/group. 
C-E) Naïve colon LP CD4 and CD8 cells were further characterized for activation (CD69+) (C), resident memory 
(CD69+ CD103+) (D), or effector memory (CD8+ CD44+ CD62L-) (E). Cells are gated on CD45.2+ CD3+ or CD3+, 
n=5-6/group. 
Data are mean ± SEM and are pooled from at least two independent experiments. *p<0.05 by Mann-Whitney 
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Figure 4.5 No T cell differences are present in mesenteric lymph nodes 
A-B) MLN CD3 T cells (A) were measured and further characterized into CD4 and CD8 T cells (B) by flow cytometry. 
C-D) Intracellular IFNg production by CD8 (C) and CD4 (D) T cells was measured after four hours of PMA + 
ionomycin + monensin stimulation.  
Data are mean ± SEM and are pooled from at least two independent experiments. n=5-9/group, *p<0.05 by Mann-
Whitney 
 
We next analyzed the colon LP immune cell composition during the acute inflammatory 
response to DSS, specifically on day 12 of AOM/DSS which is when colon inflammatory immune 
cell infiltration peaked as measured in WT2 mice (Figure 4.6). As in naïve mice, there were 
significantly increased CD3 and CD8, but not CD4, T cells, in WT2 mice compared to WT1 mice 
(Figures 4.7A and 4.7B). Additionally, colon LP CD8+ IFNg+ T cells were increased in WT2 
mice, but no differences in CD4+ IFNg+, CD4+ IL-17+ or CD4+ Foxp3+ subsets were measured 
(Figure 4.7C). Colon LP monocytes and neutrophils in WT2 mice were also elevated to a greater 
extent than WT1 mice (Figure 4.7A), likely reflecting greater levels of inflammation that occur in 
WT2 mice due to DSS treatment (Figure 2.3E).  
 
Figure 4.6 WT2 mice have increased colon inflammatory cell infiltration on day 12 of AOM/DSS 
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Figure 4.7 WT2 mice have increased colon LP CD8+ IFNg+ T cells on day 12 of AOM/DSS 
Mice were injected with AOM and five days later, treated with 2% DSS for five days. Two days after DSS treatment 
completion, mice were sacrificed for colon LP flow cytometry analysis.  
A and B) Colon LP immune cells (A) and T cell subsets (B) were analyzed by flow cytometry. Immune subsets 
measured include: DCs (CD11c+ CD11bint), NK cells (NK1.1+), monocytes (CD11b+ Ly6Chi Ly6Gint), neutrophils 
(CD11b+ Ly6Cint Ly6G+), T cells (CD3+ B220-), and B cells (B220+ CD3-). 
C) Intracellular cytokine production (IFNg and IL-17) by colon LP immune cells was measured after four hours of 
PMA + ionomycin + monensin ex vivo-stimulation. Intracellular Foxp3 staining was performed after four hours of 
monensin incubation. Representative flow plots are shown.  
Data are mean ± SEM and are pooled from at least two independent experiments. n=5-9/group, *p<0.05 by Mann-
Whitney 
 
4.3.4 Colon LP CD8 T cells partly mediate increased tumor susceptibility in WT2 
mice 
To determine whether CD8 T cells specifically contributed to increased tumorigenesis in 
WT2 mice, SPF Cd8-/- mice were treated with an antibiotic cocktail and antifungal water before 
gavage of SPF WT1 or WT2 stool and cecal contents for three consecutive days. This method of 
microbiome transfer has been successful in stably implanting donor microbiomes (209). Four 
weeks after the last gavage, mice were treated with AOM/DSS to induce tumors (Figure 4.8A). 
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When we analyzed the microbiome collected on the day of AOM injection after four weeks of 
colonization, the microbiomes of recolonized Cd8-/- mice resembled that of the SPF WT1 or WT2 
microbiome donors (Figure 4.8B). Namely, Cd8-/- mice colonized with WT2 microbiota 
(WT2>CD8 KO) have increased Prevotellaceae and compared to Cd8-/- mice colonized with WT1 
microbiota (WT1>CD8 KO) (Figure 4.8B). Furthermore, WT1>CD8 KO mice were measured to 
have significantly distinct microbiome compositions as WT2>CD8 KO mice similar to the 
difference measured between control SPF WT1 and WT2 mice as measured by thetaYC distances 
and AMOVA (Figure 4.8C). While the microbiomes of WT1>CD8 KO mice were similar to WT1 
control mice by thetaYC distances, the compositions were still significantly different, possibly due 
to significant differences in a few specific bacteria (Figure 4.8C). Furthermore, by NMDS 
ordination, WT1>CD8 KO mice clustered closely with WT1 control mice, and WT2>CD8 KO 
clustered with WT2 control mice suggesting near-complete microbiome transfer (Figure 4.8D). 
Importantly, WT1>CD8 KO mice developed similar tumor numbers as SPF WT1 control mice 
whereas WT2>CD8 KO mice developed significantly fewer and smaller tumors compared to SPF 
WT2 control mice (Figures 4.8E and 4.8F), strongly suggesting that the dysbiotic microbiome in 
WT2 mice mediates its tumor-promoting effects in part via pro-inflammatory CD8 T cells. 
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Figure 4.8 Colon LP CD8 T cells partly mediate increased tumor susceptibility in WT2 mice 
A) SPF Cd8-/- mice were treated with antibiotic and antifungal water for one week prior to three consecutive gavages 
of SPF WT1 or WT2 microbiota. Four weeks of bacteria colonization, mice were injected with AOM and treated with 
three rounds of 2% DSS. Mice were sacrifice on day 62 of AOM/DSS for tumor counting.  
B) Relative family abundances of Cd8-/- mice after four weeks of recolonization. Stool was collected on the day of 
AOM injection for 16S rRNA sequencing and analysis. 
C and D) 16S rRNA sequencing was performed on fecal microbiota from SPF Cd8-/- mice recolonized with SPF WT1 
or WT2 stool homogenates after antibiotic and antifungal treatment. Microbiome composition dissimilarity was 
analyzed by ThetaYC distance (C) and shown as an NMDS plot (D). *p<0.05 by AMOVA 
E and F) Tumor numbers (E) and sizes (F) were measured on day 62 of AOM/DSS. Data are mean ± SEM. *p<0.05 
by Mann-Whitney 
n=4-6/group. 
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4.3.5 WT2 microbiota directly promote increased colon LP CD8+ IFNg+ T cells 
To determine if WT2 microbiota directly contribute to increased colon LP CD8+ IFNg+ T 
cells in naïve WT2 mice, we gavaged WT2 mice stool and cecal homogenates into SPF WT1 mice 
after antibiotic and antifungal water treatment. After nine weeks of recolonization, WT1 mice 
reconstituted with WT2 microbiota (WT1+WT2bac) had microbiomes closely resembling WT2 
donor inputs as well as antibiotic-treated WT2 mice reconstituted with WT2 microbiota 
(WT2+WT2bac) by NMDS ordination although there were still significant differences between 
groups based on thetaYC distances (Figures 4.9A and 4.9B). Importantly, WT1+WT2bac mice 
had increased colon LP CD3 and CD8, but not CD4, T cells, as well as increased CD8+ IFNg+ T 
cells compared to the control WT1 mice that were recolonized with WT1 bacteria (WT1+WT1bac) 
(Figures 4.9C and 4.9D). WT1+WT2bac mice also had increased CD4+ IFNg+ T cells compared 
to WT1+WT1bac mice, but no differences in CD4+ IL-17+ or CD4+ Foxp3+ subsets (Figure 4.9D). 
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Figure 4.9 SPF WT1 mice colonized with WT2 microbiota have increased colon LP CD8+ IFNg+ T cells 
SPF WT1 and WT2 mice were treated with antibiotics and antifungal water for one week prior to three consecutive 
gavages of SPF WT1 or WT2 microbiota. Nine weeks after colonization, the colon LP was analyzed by flow 
cytometry. 
A and B) Microbiome composition dissimilarity was analyzed by ThetaYC distance (A) and shown as an NMDS plot 
(B). *p<0.05 by AMOVA 
C) CD3 T cell and T cell subsets were analyzed by flow cytometry.  
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D) Colon lamina propria immune cells were ex vivo-stimulated with PMA and ionomycin and monensin for four hours 
before flow cytometry analysis. Non-stimulated cells were incubated with monensin for four hours before and flow 
cytometry analysis.  
Data are mean ± SEM and are representative of two independent experiments. n=5/group, *p<0.05 by Mann-Whitney 
unless otherwise noted. 
 
 We also gavaged GF WT mice with WT1 or WT2 microbiota prepared from stool and cecal 
contents. After eight weeks of colonization to allow microbial and immune cell reconstitution, the 
colon LP immune cell populations were analyzed by flow cytometry. While no differences in CD3, 
CD8, or CD4 T cells were observed (Figure 4.10A), GF WT mice colonized with WT2 microbiota 
had increased colon LP CD8+ IFNg+ T cells, but no differences in CD4+ IFNg+, CD4+ IL-17+, or 
CD4+ Foxp3+ subsets, similar to what is observed in naïve SPF WT2 mice (Figure 4.10B).  
 
Figure 4.10 GF WT mice colonized with WT2 microbiota have increased colon LP CD8+ IFNg+ T cells 
GF WT mice were gavaged with SPF WT1 or WT2 microbiota. Eight weeks after colonization, the colon LP was 
analyzed by flow cytometry. 
A) CD3 T cell and T cell subsets were analyzed by flow cytometry.  
B) Colon lamina propria immune cells were ex vivo-stimulated with PMA and ionomycin and monensin for four hours 
before flow cytometry analysis. Non-stimulated cells were incubated with monensin for four hours before and flow 
cytometry analysis.  
Data are mean ± SEM and representative of two independent experiments. n=5/group, *p<0.05 by Mann-Whitney 
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4.3.6 WT2 microbiota may promote increased colon LP CD8+ IFNg+ T cells through 
IL-12 production by DCs 
We explored potential mechanisms of how the WT2 microbiome may alter CD8 T cell 
responses in the colons of WT2 mice. First, we examined the expression of the T cell 
chemoattractants CXCL9 and CXCL10 in the colon epithelium of naïve WT1 and WT2 mice by 
qPCR, and observed no differences, suggesting that the increase in CD8 T cells in the colon LP 
WT2 is not necessarily due to increased recruitment via epithelial chemokine production (Figure 
4.11A). To determine if WT2 mice were predisposed to inflammation, we measured expression of 
IL-6 and the antimicrobial peptides, Reg3g or b-defensin2, but no differences were detected 
(Figure 4.11A). Interestingly, there was increased expression of IL-1b in WT2 epithelium, which 
has been shown to promote effector T cell responses including the production of IFNg (210) as 
well as occludin, although the significance of this is unclear (Figure 4.11A).  
Production of IL-12 by dendritic cells (DCs) can promote CD8 T cell activation and IFNg 
production (211-213). To determine if WT2 bacteria promotes increased IL-12 production by DCs, 
we cultured WT1 and WT2 bone marrow-derived dendritic cells (BMDCs) with heat-killed (HK) 
stool from either SPF WT1 or WT2 mice and measured IL-12 in the supernatant. HK WT2 bacteria 
promoted increased IL-12 production by both WT1 and WT2 BMDCs compared to HK WT1 
bacteria (Figure 4.11B). Altogether, these data strongly support a role for the WT2 microbiota in 
upregulating colon LP IFNg+ CD8+ T cell responses.  
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Figure 4.11 WT2 microbiota promotes increased IL-12 production by BMDCs 
A) mRNA expression of several epithelial cell-related genes relative to actin by untreated WT1 and WT2 epithelial 
cells. IL-6: n=4/group; rest: WT1 n=10, WT2 n=6 (βdef2), 7 (CXCL9, Reg3g, and IL-1β), or 8 (CXCL10 and 
occludin).  
B) IL-12p70 levels were measured by ELISA in 24-hour supernatants of bone marrow-derived dendritic cells exposed 
to heat-killed SPF WT1 or WT2 bacteria cultures. n=3 mice/colony. WT1 data are representative of three independent 
experiments. WT2 data are representative of two independent experiments.  
*p<0.05 by Mann-Whitney 
 
4.3.7 CD8 T cell depletion does not promote increased tumorigenesis in WT1 mice 
To complement our study of the impact of WT1 and WT2 microbiota in Cd8-/- mice, we 
carried out CD8 depletion experiments. We determined that five days after an injection of 300ug 
anti-CD8 antibody/mouse, mice were specifically depleted in CD8, but not CD4, T cells in the 
colon LP and spleen (Figures 4.12A and 4.12B). Thus, we depleted CD8 T cells in WT1 mice 
beginning one day prior to the start of AOM/DSS treatment and then every five days until day 12 
of the model. However, we observed that WT1 mice became visibly sick with increased weight 
loss compared to isotype-treated WT1 mice during and immediately after the first cycle of DSS 
(Figure 4.13A), suggesting that the presence of CD8 T cells early on may be important for limiting 
colitis-susceptibility, which, in turn, can affect tumor susceptibility via a mechanism not related to 
anti-tumor immunity.  
We subsequently conducted a second experiment in which CD8 T cells were depleted 
starting at day 10 of AOM/DSS, which is at the end of the first round of DSS during acute 
inflammation, and every five days afterward until the tumor endpoint. With this timing, no 
difference in weights were measured between CD8-depleted and isotype control-treated WT1 mice 
(Figure 4.13B). However, this resulted in a trend towards increased tumors in CD8 T cell-depleted 
WT1 mice compared to that of isotype control-treated mice that did not reach significance (Figure 
4.13C). We believe these CD8 antibody depletion experiments may be difficult to interpret as the 
timing and length of depletion may separately alter both colitis and tumor susceptibility. 
Regardless, as shown in Figure 4.8, microbiome-depleted CD8 KO mice that were recolonized 
with WT2 microbiota were partly protected from increased tumorigenesis, which was not observed 
with CD8 KO mice reconstituted with WT1 microbiota, suggesting CD8 T cells do play a role in 
mediating increased tumorigenesis, at least in the context of the WT2 microbiome. 
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Figure 4.12 Mice remain CD8-depleted five days after antibody-mediated depletion 
Mice were treated with anti-CD8 or isotype control antibodies and sacrificed after five days for depletion efficacy by 
flow cytometry. CD8 (A) and CD4 (B) T cells in the colon LP and spleen were analyzed. 
Data are mean ± SEM. n=2/group, *p<0.05 by Mann-Whitney 
 
 
Figure 4.13 Antibody-mediated CD8 depletion in WT1 mice can exacerbate DSS-induced colitis and may 
promote tumorigenesis 
A) 12-13 week-old SPF WT1 mice were treated with anti-CD8 or isotype control antibody on days -1, 4, and 9 of 
AOM/DSS. Mice were sacrificed on day 12. Percent weight loss is shown. 
B and C) 9 week-old SPF WT1 mice were treated with anti-CD8 or isotype control antibody every five days starting 
on day 10 of AOM/DSS until the tumor endpoint. Weight change (B) and tumor numbers (C) are shown. 
Data are mean ± SEM. n=5-6/group, *p<0.05 by Mann-Whitney 
 
4.3.8 CD8 T cells may promote increased tumorigenesis in the context of the WT2 
microbiome 
To determine if CD8 T cells promote increased tumorigenesis in the context of the WT2 
microbiome, we performed CD8 depletion and T cell adoptive transfer experiments. Similar to 
WT1 mice (Figure 4.13A), WT2 mice treated with anti-CD8 depleting antibody developed more 
severe weight loss than WT2 mice that received the isotype control (Figure 4.14A) suggesting 
CD8 T cells play a protecting role in early colitis and tumorigenesis. Furthermore, we depleted 
CD8 T cells during early AOM/DSS and examined that effect on tumorigenesis. While no 
differences in weight loss was measured (Figure 4.14B), there was a trend of decreased tumors in 
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WT2 mice that were depleted of CD8 T cells in early AOM/DSS compared to WT2 mice that 
received the isotype control (Figure 4.14C).  
 
Figure 4.14 Antibody-mediated CD8 depletion in WT2 mice can exacerbate DSS-induced colitis but may reduce 
tumorigenesis 
A) 12-13 week-old SPF WT2 mice were treated with anti-CD8 or isotype control antibody on days -1, 4, and 9 of 
AOM/DSS. Mice were sacrificed on day 12. Percent weight loss is shown. 
B and C) 7-10 week-old SPF WT2 mice were treated with anti-CD8 or isotype control on days 7, 12, and 17 of 
AOM/DSS treatment. Weights (B) and tumor numbers (C) are shown.  
 
  
As we have found CD8 depletion experiments to be dependent on the length of antibody 
depletion and the timing of treatment, we adoptively transferred T cells into GF Rag1-/- mice 
colonized with WT1 or WT2 microbiomes as this would allow us to directly assess the effect of T 
cells on tumorigenesis in the context of two different microbiomes. GF Rag1-/- mice were gavaged 
with SPF WT1 or WT2 intestinal contents and after four weeks, were intravenously injected with 
donor splenic CD8 T cells. Four weeks after immune cell colonization, mice were treated with 
AOM/DSS to induce tumorigenesis. Unfortunately, we did not transfer Treg cells and this 
experiment resembled the T cell colitis model where mice in both microbiome groups had 
increased weight loss. However, GF Rag1-/- mice that received WT2 microbiota (WT2>GF Rag) 
had more weight loss than GF Rag1-/- mice that received WT1 microbiota (WT1>GF Rag) (Figure 
4.15A). Additionally, significantly more WT2>GF Rag mice died during AOM/DSS treatment 
(Figure 4.15B). On day 60 of AOM/DSS, tumor counts revealed WT1>GF Rag mice developed 
few to no tumors where the single WT2>GF Rag mouse that survived developed 30 tumors 
(Figure 4.15C). Altogether, this preliminary experiment suggests CD8 T cells may directly 
promote increased tumorigenesis in WT2 mice but must be repeated. 
B
DSS
0 10 20 30 40 50 60
-25
-15
-5
5
15
SPF WT2: αCD8/isotype
weights
Day after AOM
%
 w
ei
gh
t c
ha
ng
e
isotype
αCD8
Ab inj
WT2 ⍺CD8 depletion C
isotype αCD8
0
5
10
15
20
25
SPF WT2: αCD8/isotype
tumors
antibody treatment
# 
tu
m
or
s
WT2 ⍺CD8 depletion
-1 1 3 5 7 9 11 13
-10
0
10
Day after AOM
%
 w
ei
gh
t c
ha
ng
e
SPF WT2: CD8 depletion
DSS
*
Ab inj
αCD8
isotype
*
WT2 ⍺CD8 depletionA
80 
 
 
Figure 4.15 CD8 T cells promote increased tumorigenesis in the context of a WT2 microbiome 
GF Rag1-/- mice were colonized with WT1 or WT2 microbiota for four weeks before receiving 3x106 splenic CD8 T 
cells. Four weeks after CD8 T cell adoptive transfer, mice were treated with AOM and one round of 1.5% DSS 
followed by two rounds of 1% DSS. Mice were sacrificed for tumor counting on day 60 of AOM/DSS. Weight loss 
(A), survival (B), and tumor numbers (C) are shown.  
Intravenous adoptive transfer injections were done by Hideaki Fujiwara. 
Data are mean ± SEM. n=5/group, *p<0.05 by Mann-Whitney 
 
4.3.9 Intratumoral T cells in WT2 mice exhibit an exhausted phenotype  
CD8 T cells and IFNg production are important for anti-tumor immunity (102, 103, 214, 
215); consistently, increased CD8 T cells and a Th1 gene signature within the tumor 
microenvironment correlates with improved CRC patient outcomes (102). Yet, our data suggests 
that increased homeostatic levels of CD8+ IFNg+ T cells, associated with dysbiosis, can promote 
inflammation and tumorigenesis. To determine the activity of CD8 T cells within tumors of WT1 
and WT2 mice, we analyzed the immune composition of tumor tissue (“tum”) and non-tumor 
tissue adjacent to tumors (“adj”) by flow cytometry. No differences in total T cells or CD4 T cells 
were measured between WT1 and WT2 mice in both tumor and adjacent tissues (Figures 4.16A 
and 4.16B). However, contrary to naïve and acute inflammatory conditions, WT2 CD8 T cells are 
decreased in both tumor and adjacent tissue compared to WT1 tissues (Figure 4.16B). 
Furthermore, both intratumoral WT2 CD8 and CD4 T cells have reduced IFNg responses 
compared to WT1 CD8 and CD4 T cells upon ex vivo-stimulation (Figures 4.16C and 4.16D) 
while no differences in intratumoral CD4+ IL-17+ or CD4+ Foxp3+ cells were observed (Figures 
4.16E and 4.16F).  
Based on the pattern of increased CD8+ IFNg+ T cells at baseline and during chronic 
inflammation followed by reduced CD8+ IFNg+ T cells within the tumor microenvironment and 
adjacent normal tissue in WT2 mice, we hypothesized that the dysbiotic microbiome of WT2 mice 
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promotes T cell exhaustion. T cell exhaustion can occur as a result of prolonged antigen exposure 
and chronic inflammation (216, 217) and is also observed with tumor infiltrating lymphocytes, 
which can promote tumor progression (218-223). To determine if intratumoral WT2 T cells exhibit 
an exhausted phenotype, we measured inhibitory receptors typically expressed by exhausted T 
cells by flow cytometry. Indeed, there were greater numbers of PD-1+ Lag-3+ and PD-1+ Tim-3+ 
CD8 T cells within WT2 tumors compared to WT1 tumors (Figures 4.16G). Additionally, tumor-
infiltrating WT2 CD4 cells also exhibited increased PD-1 and Lag-3 expression compared to WT1 
CD4 T cells (Figures 4.16H). Altogether, these data suggest that dysbiosis can lead to T cell 
exhaustion by chronically inducing IFNg production in CD8 T cells, which may result in impaired 
immune surveillance and increased susceptibility to tumorigenesis.  
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Figure 4.16 Intratumoral WT2 CD8 T cells display decreased IFNg activity and increased exhaustion 
A-D) Immune cell subset differences between SPF WT1 and WT2 mice in tumor (A and B) and normal adjacent 
tissue (C and D) in tumor-bearing mice. Immune subsets measured include: DCs (CD11c+ CD11bint), NK cells 
(NK1.1+), monocytes (CD11b+ Ly6Chi Ly6Gint), neutrophils (CD11b+ Ly6Cint Ly6G+), T cells (CD3+ B220-), and B 
cells (B220+ CD3-). n=5-7/group. 
E and F) Number of T cells (E), CD4 and CD8 T cells (F) in tumor (”tum”) and adjacent (“adj”) tissue from 
AOM/DSS-treated WT1 and WT2 mice as analyzed by flow cytometry on day 60. n=6-10/group. 
K
adj tumor
0
20
40
60
CD8+ PD-1+ Lag-3+
%
 C
D
8+
 
*
adj tumor
0
20
40
60
80
CD8+ PD-1+ Tim-3+
%
 C
D
8+
 
*
adj tumor
0
20
40
60
80
CD4+ PD-1+ Tim-3+
%
 C
D
4+
 
WT1 WT2
L
adj tumor
0
20
40
60
CD4+ PD-1+ Lag-3+
%
 C
D
4+
 
*
adj tumor
0
20
40
60
80
CD4+ PD-1+ Tim-3+
%
 C
D
4+
 
adj tumor
0
20
40
60
80
CD4+ PD-1+ Tim-3+
%
 C
D
4+
 
WT1 WT2
WT1
WT2
E
adj tumor
0
2000
4000
6000
8000
10000
CD45.2+ CD3+
# 
ce
lls
 / 
m
g 
tis
su
e
WT1 WT2WT1
F
WT1
WT2
*
adj tumor
0
500
1000
1500
2000
CD3+ CD8+
# 
ce
lls
 / 
m
g 
tis
su
e
*
WT1 WT2
adj tumor
0
2000
4000
6000
8000
CD3+ CD4+
# 
ce
lls
 / 
m
g 
tis
su
e
WT1 WT2
adj tumor
0
2000
4000
6000
8000
CD3+ CD4+
# 
ce
lls
 / 
m
g 
tis
su
e
WT1 WT2
WT1
WT2
G
adj tumor
0
100
200
300
400
CD3+ CD8+ IFNγ+
# 
ce
lls
 / 
m
g 
tis
su
e
* *
no
 st
im
PM
A/I
no
 st
im
PM
A/I
*
*
WT1
WT1
WT2
WT2
adj tumor
0
500
1000
1500
2000
CD3+ CD4+ IFNγ+
# 
ce
lls
 / 
m
g 
tis
su
e
*
*
*
no
 st
im
PM
A/
I
no
 st
im
PM
A/
I
WT1 WT2
**
H
WT1
WT2
WT1
WT1
WT2
WT2
adj tumor
0
500
1000
1500
2000
CD3+ CD4+ IFNγ+
# 
ce
lls
 / 
m
g 
tis
su
e
*
*
*
no
 st
im
PM
A/I
no
 st
im
PM
A/I
WT1 WT2
**
WT1
WT1
WT2
WT2
adj tumor
0
500
1000
1500
2000
CD3+ CD4+ IFNγ+
# 
ce
lls
 / 
m
g 
tis
su
e
*
*
*
no
 st
im
PM
A/
I
no
 st
im
PM
A/
I
WT1 WT2
**
I
WT1
WT2
adj tumor
0
200
400
600
CD3+ CD4+ IL-17+
# 
ce
lls
 / 
m
g 
tis
su
e *
no
 st
im
PM
A/I
no
 st
im
PM
A/I
* *
J
WT1
WT2
adj tumor
0
500
1000
1500
2000
CD3+ CD4+ Foxp3+
# 
ce
lls
 / 
m
g 
tis
su
e
WT1 WT2
*
DC Mono Neut NK T B
0.0
5.0×103
1.0×104
1.5×104
2.0×104
Tumor immune cell composition
ce
lls
 / 
m
g 
tis
su
e
WT1
WT2
TumorA
DC Mono Neut NK T B
0.0
5.0×103
1.0×104
1.5×104
2.0×104
Tumor-adjacent tissue 
immune cell composition
# 
ce
lls
 / 
m
g 
tis
su
e
WT1
WT2
Adja entC
DC Mono Neut NK T B
0
5
10
15
Tumor immune cell composition
%
 fr
eq
ue
nc
y 
WT1
WT2
*
*
*
*
TumorB
DC Mono Neut NK T B
0
5
10
15
20
Tumor-adjacent tissue 
immune cell composition
%
 fr
eq
ue
nc
y 
WT1
WT2
Adja entD
83 
 
G-J) Representative flow plots after ex vivo-stimulation of cells for four hours and analysis of IFNg (n=8-10/group), 
FoxP3 and IL-17 (n=4-6/group).  
K and L) Representative flow plots and quantification of PD-1, Tim-3, and Lag-3 on CD8 (K) or CD4 T (L) cells. 
n=5-7/group. 
Data are mean ± SEM and are pooled from at least two independent experiments. *p<0.05 by Mann-Whitney 
 
4.3.10 Increased intratumoral WT2 exhausted T cells are specific to AOM/DSS 
tumors 
 To determine if the increase in WT2 intratumoral exhausted T cells in AOM/DSS-induced 
tumors is driven by inflammation, we analyzed intratumoral T cells in the CDX2-Cre Apcfl/fl and 
MC38 subcutaneous models of CRC. In CDX2-Cre Apcfl/fl mice gavaged with WT1 or WT2 
microbiota, no differences in intratumoral CD3, CD4 or CD8 T cells were measured (Figures 
4.17A and 4.17B). No differences in intratumoral exhausted CD8 T cells were measured while a 
small increased in exhausted CD4 PD-1+ Tim-3+ T cells were measured in CDX2-Cre Apcfl/fl mice 
gavaged with WT microbiotas (Figure 4.17C). Additionally, in MC38 subcutaneous tumors, no 
differences in CD3, CD4, CD8 or exhausted T cells were measured between WT1 and WT2 mice 
(Figures 4.17D-F). As exhausted intratumoral T cells are present in these two models which are 
not expressly driven by inflammation, the intratumoral T cell exhaustion difference between 
AOM/DSS-treated WT1 and WT2 mice is likely driven by inflammation differences promoted by 
the microbiome differences.  
 
Figure 4.17 No differences in CD8 T cell exhaustion are measured in CDX2-Cre Apcfl/fl and MC38 tumors 
A-C) Microbiome-depleted CDX2-Cre Apcfl/fl mice were gavaged with WT1 or WT2 microbiomes for three 
consecutive days. Eleven weeks after the last gavage, intratumoral T cell exhaustion was analyzed by flow cytometry. 
n=4-6/group, *p<0.05 by Mann-Whitney 
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D-F) MC38 cells were injected into the flank of WT1 or WT2 mice. Intratumoral T cell exhaustion was analyzed on 
day 23 by flow cytometry. D and E: n=8-9/group, F: n=3-4/group. 
 
4.3.11 Intratumoral tumor antigen-specific CD8 T cells are not associated with 
MC38 subcutaneous tumors 
We also wanted to assess the effect of the WT2 microbiota on the induction of tumor-
specific antigen responses. Since no tumor-specific antigen has been identified in AOM/DSS-
induced colon tumors, we used the syngeneic MC38 colorectal cancer cell line. MC38 cells contain 
the tumor-specific MHC-I presented mutant peptide (ASMTN[R/M]ELM) derived from the gene 
Adpgk, which can serve as a neo-antigen where adgpk-specific immune cells can be detected by 
fluorescent tetramers and flow cytometry (Kuai et al., 2017). After subcutaneous injection of 1x106 
MC38 cells into the flanks of WT1 and WT2 mice, we isolated tumors on day 23 after injection 
when tumors reached an average size of 800mm3 and adgpk+ CD8+ or CD4+ T cells were measured. 
There was increased frequency of intratumoral adgpk+ CD8+, but not CD4+, T cells in WT2 mice, 
suggesting that the presence of WT2 microbiota may result in increased tumor-specific antigen 
responses (Figures 4.18A and 4.18B). However, we did not observe a difference in overall tumor 
weights (Figure 4.18C).  
In general, the MC38 subcutaneous tumor model is very different from the AOM/DSS 
model and therefore, we believe it is difficult to extrapolate definite conclusions drawn from this 
model to the in vivo model of inflammation-associated colon tumorigenesis.  
 
Figure 4.18 Increased intratumoral tumor antigen-specific CD8 T cells in subcutaneous MC38 tumors are not 
associated with increased tumor size 
SPF WT1 and WT2 mice were subcutaneously injected with 1x106 MC38 cells and sacrificed on day 23. 
A and B) CD8 (A) and CD4 (B) T cells were isolated from MC38 tumors and analyzed by flow cytometry for adgpk 
specificity. 
C) Endpoint M38 tumor weights on day 23.  
Data are mean ± SEM and are pooled from two independent experiments. n=8/group, *p<0.05 by Mann-Whitney 
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4.4 Discussion and Future Directions 
As microbiota can modulate host immunity, in this chapter, we wanted to determine if the 
microbiome differences between WT1 and WT2 mice altered immune responses and how that may 
influence tumorigenesis. Specific to the colon LP, naïve WT2 mice have increased B and T cells; 
in particular, colon LP CD8+ IFNg+ T cells are increased in naïve WT2 mice where the WT2 
microbiome directly promotes increased colon LP CD8+ IFNg+ T cells. We determined that WT2 
bacteria can promote increased IL-12 production by DCs where IL-12 can promote T cell IFNg 
responses. Interestingly, after AOM/DSS, WT2 mice had decreased intratumoral CD8 T cells and 
reduced IFNg responses. This reduction in IFNg activity after prolonged inflammation is 
reminiscent of T cell exhaustion. Indeed, intratumoral WT2 CD8 T cells had upregulated 
exhaustion markers compared to intratumoral WT1 CD8 T cells, specific to AOM/DSS-induced 
tumors and not in MC38 subcutaneous or CDX2-Cre Apcfl/fl WT2 tumors, suggesting rolonged 
inflammation is necessary for the increased exhaustion phenotype.  
In previous chapters, we tested and compared microbiome transfer methods of cohousing 
and cross-fostering with the gold standard, gavage into GF mice. In this chapter, we used a fourth 
method: gavage of microbiota into microbiome-depleted SPF mice (Figures 4.8 and 4.9). Based 
on thetaYC dissimilarity, we observed effective microbiome transfer in mice that were gavaged 
with cecal and fecal contents from donor mice after antibiotic depletion, although not necessarily 
as complete as in GF mice. Other groups also observed similar transfer results by this method (209, 
224, 225). Further studies are needed to determine the antibiotic combination, length of treatment, 
and number of gavages for optimal transfer of microbiota and phenotype. Nonetheless, this 
approach may still be a reasonable alternative to GF mice in determining the effects of specific 
microbial communities on phenotype. 
We provide evidence of increased colon LP CD8+ IFNg+ T cells in naïve and acutely 
inflamed (day 12 of AOM/DSS) WT2 mice but not WT1 mice. How dysbiosis promotes the 
accumulation of activated CD8+ IFNg+ T cells in naïve WT2 mice is unclear and may be 
multifactorial in nature. It has been previously shown that Bifidobacterium is capable of priming 
DCs to enhance CD8 T cell proliferation and IFNg production (226). Similarly, we observed 
increased IL-12 production by BMDCs stimulated with HK WT2 microbiota (Figure 4.11B). 
Therefore, it is possible that the presence of certain bacterial populations in the gut of WT2 mice 
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selectively expands and primes the activation of colon LP CD8 T cells via DC activation. 
Gnotobiotic mouse studies also suggest that the accumulation of CD8+ IFNg+ T cells is a result of 
chemokine induction by specific bacteria proximal to the intestinal epithelium, (84); however, we 
did not observe any differences in epithelial production of CXCL9 or CXCL10 in WT1 and WT2 
mice. As bacteria-produced metabolites can have immunomodulatory effects (227-229), it is also 
possible that WT2 microbiota-specific metabolites may contribute to increased colon LP CD8+ 
IFNg+ T cells. For example, the gut microbiota can modulate levels of all-trans-retinoic acid levels 
that can promote CD8 T cell responses in CRC (230). 
Inconsistencies in antibody-mediated CD8 depletion experiments due to un-optimized 
dosing and timing suggested to us that CD8 adoptive transfer into immune-deficient mice may be 
an improved method to examine if CD8 T cells directly mediate tumor differences between WT1 
and WT2 mice. We show preliminary results where CD8 T cells may directly promote increased 
tumorigenesis in GF Rag1-/- mice colonized with WT2 microbiota compared to GF Rag1-/- mice 
colonized with WT1 microbiota (Figure 4.16). However, the results of this experiment are 
confounded as these colonized mice experienced CD8 T cell-induced colitis before AOM/DSS-
induced inflammation due to the absence of CD4 Treg cells. To clarify the findings of this 
experiment, we should repeat the experiment but adoptively transfer both CD8 T and Treg cells to 
ameliorate extraneous colitis, as seen in the T cell transfer colitis model (231), which may affect 
AOM/DSS tumorigenesis. 
By gavaging WT2 microbiota into microbiome-depleted WT1 mice or GF mice, we show 
in Figures 4.9 and 4.10 that the WT2 microbiota directly promotes increased colon LP CD8+ 
IFNg+ T cells. However, it remains unclear if the WT2 microbiome can not only alter host immune 
responses but lead to increased intratumoral CD8 T cell exhaustion. We can use these two 
microbiome transfer methods, as we know they promote appropriate immune changes, with the 
addition of AOM/DSS treatment, to determine if the WT2 microbiota can directly promote 
increased intratumoral exhausted CD8 T cells.  
 In this chapter, we focus on examining the role of CD8 T cells in promoting increased 
tumorigenesis. However, our data also suggest a role of B cells in mediating tumorigenesis. 
Although there are conflicting results about the role of B cells in cancer due to B cell subset 
differences, similar to CD8 T cells, increased mature, tumor-infiltrating B cells are associated with 
better CRC patient prognosis and lower cancer stages (232-234). Furthermore, in one study, tumor-
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infiltrating B20+ B cells were significantly with associated with intratumoral CD8 T cells (232). 
Consistently, in this chapter, we show that increased frequency of intratumoral B cells are found 
in WT1 mice where WT1 mice develop fewer AOM/DSS-induced tumors and rarely have tumor-
associated mortality compared to WT2 mice (Figure 4.16B). In Figure 4.1, microarray data shows 
significant upregulation of immunoglobulin (Ig) and Ig receptor expression in early inflamed (day 
10 of AOM/DSS) WT2 mouse colons compared to WT1 mouse colons. Preliminary Ig 
measurements also reveal decreased IgA levels in the stool of naïve WT2 mice compared to that 
of WT1 mice (Figure 4.19A). Additionally, in breast cancer, as production of tumor-associated 
autoantibodies may promote anti-tumor responses (235, 236), it would be worthwhile to determine 
the expression of Igs and Ig receptors at the tumor endpoint. As IgA has been shown to target 
colitogenic bacteria (237), it would also be valuable to determine if these Igs are specific for gut 
microbiota. Interestingly, we show that the absence of adaptive immune cells significantly reduces 
tumorigenesis in WT2 mice (Figure 4.3), where the absence of CD8 T cells only partially reduces 
tumorigenesis (Figure 4.8), further suggesting B cells may play a tumor-promoting role in WT2 
microbiota mice. However, no colon LP B cell differences were measured in either WT2-colonized 
GF WT or microbiome-depleted WT1 mice (Figures 4.19B and 4.19C), suggesting the WT2 
microbiota might not directly promote increased colon LP B cells as measured in untreated WT2 
mice (Figure 4.2A). Overall, additional studies are needed to determine the role of B cells in the 
context of WT1 and WT2 microbiomes.  
 
Figure 4.19 Naïve WT2 mice have decreased stool IgA levels and SPF WT2 microbiota do not directly promote 
colon LP B cell differences 
A)Stool of WT1 and WT2 mice were homogenized in PBS, and IgA was measured in the supernatant by ELISA. WT1 
n=9, WT2 n=7, *p<0.05 by Mann-Whitney 
B) GF WT mice were colonized with SPF WT1 or WT2 microbiota and colon LP immune cell subsets were analyzed 
after eight weeks of bacteria colonization. B cells were determined as B220+ CD3- cells. n=5/group. 
C) SPF WT1 mice were microbiome depleted and colonized with SPF WT2 microbiota. Colon LP immune cell subsets 
were analyzed after nine weeks of bacteria colonization. n=3-5/group. 
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It is also unclear why WT2 mice have decreased intratumoral CD8 T cells. While no 
differences in intratumoral Tregs were measured, WT2 mice have increased Tregs in the normal 
adjacent tissue at the tumor endpoint (Figure 4.16J), where Tregs have the ability to kill CD8 T 
cells and antigen-presenting DCs to dampen inflammation and anti-tumor responses (238, 239). 
Additionally, intratumoral DCs, which can promote anti-tumor responses by CD8 T cells, are 
reduced in frequency in WT2 mice, where WT2 intratumoral CD8 T cells may have decreased DC 
help. Whether adjacent-tissue Tregs in WT2 tumor-bearing mice promote an immunosuppressive 
environment or kill DCs and CD8 T cells remains unknown. 
Lastly, while we’ve shown that WT2 mice have increased exhausted intratumoral CD8 T 
cells, it remains to be determined if prevention of CD8 T cell exhaustion and/or reduced tumor 
numbers or size is possible with checkpoint blockade immunotherapy. To this end, we can treat 
WT2 mice with anti-PD-1 antibody starting at various timepoints of AOM/DSS and measure tumor 
outcomes where antibody clone, optimal dose, start day, and length of treatment are factors that 
have to optimized. These factors are important as anti-PD-1 can promote increased colon 
inflammation, which is a common side effect, which can be attributed to CD8 T cells and gut 
microbiota (240, 241), and therefore could alter our inflammation-dependent tumor results. As 
most patients receive anti-PD-1 blockade after tumors have formed, starting injections around DSS 
round 3, as WT2 mice develop tumors by the end of DSS round 2 (37), may be a starting point.  
Here, we have shown that the WT2 microbiome promotes increased colon LP CD8+ IFNg+ 
T cells in naïve mice where WT2 intratumoral CD8 T cells become more exhausted at the tumor 
endpoint, consistent with increased tumor burdens. Future studies are needed to further elucidate 
the mechanism(s) by which the microbiota activates CD8 T cells and promotes their exhaustion.
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CHAPTER 5: Conclusion 
5.1 Summary 
 The overall objective of this dissertation was to explore microbiome-host interactions that 
underlie susceptibility to inflammation-associated tumorigenesis in two C57BL/6 WT colonies.  
 In Chapter 2, we present two colonies of WT mice that develop different colitis-associated 
tumor burdens. WT1 mice develop five tumors on average, and WT2 mice develop 15 tumors on 
average. Since WT2 mice derive from the WT littermates of Nod1-/- mice, where the microbiomes 
of Nod1-/- mice promote increased susceptibility to colitis-associated colon tumorigenesis, we 
determined that the WT2 microbiome composition is significantly different from that of WT1 
mice. Naïve WT2 mice already have microbiome compositions that resemble that of IBD and CRC 
patients compared to naïve WT1 mice. Additionally, the tumor burden differences between the 
two colonies can be directly attributed to the microbiome differences. Lastly, some of the bacteria 
that promote tumor burden differences are cultivable. 
 In Chapter 3, we delve deeper into examining microbiome differences between the two 
colonies. We first try several cohousing and cross-fostering microbiome transfer methods to 
determine if tumor burden phenotype can be transmissible through microbiome transfer. While 
cross-fostering yielded overall better microbiome transfer than cohousing, cross-fostered mice had 
an intermediate tumor burden phenotype where significant bacteria differences between cross-
fostered and control mice remained. Despite incomplete microbiome transfer, we were able to use 
the microbiome data from these mice to determine specific bacteria that are statistically associated 
with low or high tumor burdens. We consolidated a list of nine candidate bacteria: two low tumor-
associated bacteria and seven high tumor-associated bacteria. Their low relative abundances in 
stool proved to be difficult to overcome in preliminary efforts to culture these bacteria. 
 In Chapter 4, we explored possible host immune differences between WT1 and WT2 mice 
as specific microbiota can promote host immune cell differences. We found that specific to the 
colon LP, naïve WT2 mice have increased CD8+ IFNg+ T cells, where this increase can be directly 
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attributed to the WT2 microbiome. Similarly, WT2 mice also had increased colon LP CD8+ IFNg+ 
T cells on day 12 of AOM/DSS or during the acute inflammation response. However, at the tumor 
endpoint, WT2 tumors have decreased CD8 and IFNg-producing T cells in addition to increased 
exhausted CD8 T cells compared to WT1 tumors, which is consistent with increased WT2 
tumorigenesis. No differences in intratumoral CD8 T cells were measured in non-inflammation-
associated colon cancer models. We also show preliminary data that CD8 T cells adoptively 
transferred into Rag1-/- mice promote increased tumorigenesis in the presence of WT2, but not 
WT1, microbiota.  
 These findings are broadly summarized in Figure 5.1.  
 
Figure 5.1 Visualization of the microbiota and CD8 T cell activity in WT1 and WT2 mice during AOM/DSS 
tumorigenesis 
WT1 and WT2 mice have significant microbiome differences, where WT2 microbiota promote increased colon LP 
CD8+ IFNg+ T cells. During AOM/DSS treatment, WT2 mice develop more colon inflammation and have more colon 
LP CD8+ IFNg+ T cells than WT1 mice. At the tumor endpoint, WT2 mice have more colon tumors and increased 
intratumoral T cell exhaustion than WT1 mice. The figure image was made with BioRender.com. 
91 
 
 In summary, the main contributions of this dissertation to the field are as follows: 
1. Dysbiosis promotes increased colon LP CD8+ IFNg+ T cells and CRC susceptibility 
2. Increased CD8+ IFNg+ T cells are associated with more colon inflammation and tumorigenesis 
3. Dysbiosis-associated inflammation and tumorigenesis are associated with greater intratumoral 
CD8 T cell exhaustion 
5.2 Discussion and Future Directions  
Notably, our results suggest a novel role of dysbiosis in promoting T cell exhaustion, 
which, within the tumor microenvironment, can reduce anti-tumor immunity. Specifically, in 
contrast to increased colon LP CD8+ IFNg+ T cells in naïve and acutely-inflamed WT2 mice, there 
were significantly decreased tumor-infiltrating CD8+ IFNg+ cells as well as in normal adjacent 
tissue. A potential explanation for the observed reduction in CD8+ IFNg+ cells is that chronic 
stimulation and activation of intestinal LP CD8 T cells by WT2 gut microbiota leads to their 
exhaustion and results in reduced immune surveillance and ultimately increased tumor burden. 
Conversely, it is also possible that WT1 microbiota limit T cell exhaustion during the development 
of inflammation and tumors in the colon. Thus, it may be important to identify bacterial 
populations that not only induce protective CD8+ IFNg+ responses within the tumor 
microenvironment, but also attenuate T cell exhaustion to maximize anti-tumor immunity.  
 In Chapter 3, we reveal nine tumor-associated candidate bacteria which have not been 
previously classified to the species level. We plan to isolate as many of these bacteria as possible, 
and we hope to show by proof of principle that after AOM/DSS treatment, GF WT mice colonized 
with low tumor-associated candidates will develop few tumors, and that GF WT mice colonized 
with high tumor-associated candidates will develop higher tumor burdens. Additionally, while 
we’ve shown that WT2 microbiota can directly promote increased colon LP CD8+ IFNg+ T cells 
in untreated mice, we can also determine if the high tumor-associated candidate bacteria also 
directly promotes increased colon LP CD8+ IFNg+ T cells. 
It is important to note that in this dissertation, we focused on the bacteria component of the 
microbiome, but enteric viruses (virome), which includes bacteriophages, and fungi (mycobiome) 
may also contribute to CRC susceptibility in these two mouse colonies, as dysbiotic bacteriophage 
and fungal compositions have been reported in CRC patients (242-244). It has also been proposed 
that enteric bacteriophages can directly promote dysbiotic bacterial microbiomes during IBD and 
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CRC (243, 245, 246). One group further determined that bacteriophages exacerbated colon tumor 
growth and stimulated host immunity as phage-primed dendritic cells promoted IFNγ responses 
by CD4 T cells via TLR9 (247). In addition to the virome, the mycobiome has also been implicated 
in colitis and CRC. One study observed altered mycobiomes after DSS-induced colitis in mice and 
increased colitis after anti-fungal treatment compared to normal control mice (248). Additionally, 
another group found that while the mycobiome member Schizosaccharomyces pombe was detected 
in both CRC patients and healthy controls, four S. pombe-secreted proteins were specifically 
associated with late stage CRC, suggesting a possible role of the mycobiome secretome (249). 
Altogether, further studies are needed to determine how the virome and mycobiome are involved 
in CRC development. It would be worthwhile to investigate the viral and fungal microbiome 
components in our unique two-colony system in the context of CRC. 
 One mechanism to be explored relates to our preliminary PICRUSt data in Chapter 1, is 
determining differences in microbial metabolites that are produced by low tumor-associated 
bacteria and high tumor-associated bacteria, where the differential metabolites can influence anti- 
or pro-tumorigenic activity. It is also possible that these bacteria are not sufficient to induce tumor 
burden differences. In that case, we would analyze metabolite differences between naïve WT1 and 
WT2 mice as we know the differing microbiomes promote tumor burden differences, possibly via 
promoting CD8 T cell differences.  
 We’ve shown that the WT2 microbiome promotes increased CD8 T cell differences and 
plan to determine how WT2 bacteria, and possibly high tumor-associated candidate bacteria, 
promotes increased CD8 T cells before tumorigenesis. As direct adhesion of segmented 
filamentous bacteria to intestinal epithelial cells is necessary for its ability to induce Th17 cell 
differentiation (202), one mechanism we could explore is localization and direct interaction of 
microbiota with the host. We and others have used fluorescence in situ hybridization (FISH) to 
visualize spatial localization of gut bacteria with respect to the host (194, 250-252). With FISH, 
we can also determine not only where certain bacteria are in relation to the mucus layer and 
epithelium, but also in relation to immune cells, including CD8 T cells at both naïve and tumor 
endpoint timepoints.  
 WT2 mice, which develop significantly more tumors after AOM/DSS treatment than WT1 
mice, have an altered microbiome that is associated with increased LP CD8+ IFNg+ T cells at 
baseline and during acute inflammatory responses in the colon. Although CD8 T cells are known 
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for their cytotoxic, anti-tumor activity, our results suggest that in the presence of dysbiosis, they 
can also have a pathogenic role by promoting damaging, chronic inflammation, and consequently, 
tumor development. Consistently, Rag1-/- and Cd8-/- mice transplanted with microbiomes from 
WT2 donor mice developed significantly fewer tumors. Furthermore, intratumoral WT2 CD8 T 
cells display decreased IFNg activity and increased markers of exhaustion, further suggesting the 
inflammatory environment promoted by the WT2 microbiome leads to CD8 T cells exhaustion 
which in turn results in increased tumorigenesis. We have also shown that DCs stimulated with 
heat-killed WT2 microbiota promotes IL-12 production which can induce IFNg responses by CD8 
T cells. We have begun CD8 T cell and bacteria-primed BMDC cocultures to determine if the IL-
12 production by DCs is sufficient to induce CD8 T cell IFNg responses. However, it remains 
unclear how the microbiota promotes increased IL-12 production by DCs. Additionally, it is 
unknown how naïve WT2 mice have increased colon LP CD8 T cells as we’ve determined that 
there are no differences in chemokine production between naïve WT1 and WT2 mice. Since 
recruitment is unlikely, it is possible the increase in WT2 colon LP CD8 T cells is due to cellular 
expansion, which can be measured by Ki67 staining and flow cytometry. However, the exact 
mechanisms of how the WT2 microbiota promotes increased inflammation and CD8 T cell 
activation in naïve mice are unknown.  
 Although there is significant evidence supporting a role of commensal-specific CD4 T cells 
in mediating inflammatory Th1 and Th17 responses (253, 254), less is known about the 
contribution of CD8 T cells in driving colon inflammation. CD8 T cells have been implicated in 
IBD where increased colon LP activated cytotoxic CD8 T cells are associated with active disease 
(255). In certain mouse models, host antigen-reactive CD8 T cells have been shown to be major 
drivers of colitis (256-258). However, whether WT2 microbiota promotes the generation of 
commensal-specific CD8 T cells to potentiate colitis-associated tumorigenesis remains to be 
determined. Additionally, the absence of CD8 T cells in the presence of a WT2 microbiome does 
not completely suppress tumorigenesis suggesting the possibility that WT2 microbiota can also 
promote tumorigenesis via CD8-independent mechanisms and/or CD8 T cells can also contribute 
to tumor suppression. 
In this study, we focus on the role of CD8 T cells, but our data in Chapter 3 suggest a 
possible role for B cells. Compared to Rag1-/- mice colonized with WT2 mice, Cd8-/- mice 
colonized with WT2 mice didn’t develop as few tumors as WT1 mice, suggesting that B cells or 
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CD4 T cells may play a role in promoting tumorigenesis in WT2 mice. No differences in CD4 
subsets were measured between WT1 and WT2 mice, but naive WT2 mice have increased colon 
LP B cells and decreased intratumoral B cells, strongly suggesting that B cells may play a role in 
WT2 microbiota-mediated tumorigenesis. While GF WT and microbiome-depleted WT1 mice 
colonized with WT2 microbiota displayed increased colon LP CD8+ IFNg+ T cells similar to SPF 
WT2 controls, no differences in B cells were measured (Figures 4.19B and 4.19C), demonstrating 
that the WT2 microbiota aren’t sufficient to promote increased colon LP B cells as measured in 
control untreated SPF WT2 mice (Figure 4.2A).  
It is possible that B cells are playing a secondary role in promoting WT2 tumorigenesis. 
(232) show that CRC patients with both increased tumor-infiltrating CD20+ B cells, which includes 
naive, germinal center B cells, and memory B cells, as well as CD8 T cells, had better outcomes 
compared to patients with high CD8 T cell tumor infiltration but poor B cell tumor infiltration. 
Moreover, in patients with low tumor-infiltrating CD8 T cells, the level of B cell infiltration was 
no longer a strong predictor of patient outcomes, further linking CD8 T cells and B cells (232). 
Tumor-infiltrating B cells are not as well characterized and may have different roles in different 
cancers, but some studies suggest anti-tumor activities of intratumoral B cells include producing 
tumor antigen-specific antibodies, promoting intratumoral CD8 T cell anti-tumor responses, as 
well as FasL and/or TRAIL-mediated tumor cell killing (236, 259, 260). While B cells can have 
anti-tumorigenic activity, they can also contribute to autoimmune diseases where they produce 
autoantibodies that target self-antigens and commensal bacteria and can interact with the 
complement system, act as antigen-presenting cells to T cells, and influence DC migration (233, 
261, 262). Altogether, our data suggests B cells play a role in mediating tumorigenesis, possibly 
via CD8 T cell interactions. B cell differences, including B cell subsets, Ig production, Ig 
specificity, localization and interaction with CD8 T cells, and more, between WT1 and WT2 mice 
at naïve and tumor timepoints remain to be determined.  
 In addition to CD8 T cells, DCs, and B cells, colon epithelial cells may also contribute to 
inflammatory and tumorigenic responses as the AOM/DSS model causes epithelial barrier injury 
and tumors develop due to abnormal epithelial barrier repair and cell division. Furthermore, as 
discussed in Chapter 1, specific microbiota have been shown to promote increased Wnt cell cycle 
signaling and epithelial cell proliferation. Our microarray and qPCR data (Figures 4.1 and 4.11) 
propose possible epithelial gene expression and therefore functional differences between WT1 and 
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WT2 mice, but more experiments are needed to determine if and when they play a role in immune 
and tumor differences.  
One area of study we’ve only begun to explore in this project is the role of the gut 
microbiome in checkpoint blockade immunotherapy efficacy which has been shown in multiple 
other studies (226, 263-265). Both CD8 T cells and gut microbiota can affect immune checkpoint 
inhibitor success, and certain microbiota are associated with increased CD8 T cell anti-tumor 
activity via augmented DC responses (84, 226). It would be interesting to determine if the 
microbiome differences promote immune checkpoint inhibitor therapy response differences and if 
the microbiome could be manipulated to improve immunotherapy responses. As certain bacteria 
are being explored as predictors of immunotherapy efficacy (266), it is possible our two colonies 
could reveal new bacteria that are linked to immunotherapy effectiveness. In the future, patients’ 
microbiota could be screened to determine their responsiveness to certain therapies over others. 
Additionally, while there are differences in PD-1+ T cells between WT1 and WT2 tumors, it is 
unclear if there are differences in PD-L1 expression in the different tumors, where PD-L1 is the 
ligand for PD-1 and is upregulated by tumors as a means of immune evasion. It would be 
worthwhile to explore the effects of the different WT1 and WT2 microbiota and metabolites on 
PD-L1 expression by tumors, as the binding of PD-L1 on tumor cells to PD-1 on T cells results in 
inhibitory signaling in T cells which leads to exhaustion. 
 In conclusion, our data demonstrate a role of the gut microbiome in altering CD8 T cell 
activity in the colon LP to impact tumorigenesis through early CD8 T cell activation, which can 
have long-term negative consequences by increasing susceptibility to inflammation and 
exhaustion, which can result in colon tumorigenesis. While more studies are needed to determine 
mechanisms of action, our findings further our knowledge of host-commensal interactions in CRC 
and reinforce the idea of the gut microbiome’s potential in advancing personalized medicine.
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APPENDIX 
Chapter 1 
Modified from a review chapter titled, “The Gut Microbiome and Colorectal Cancer,” 
which was co-authored with Grace Y. Chen that was accepted for publication in the Springer 
Physiology in Health and Disease series titled: Inflammation, Infection, and Microbiome in 
Cancers: Evidence, Mechanisms, and Implications. 
Contributions: Amy I. Yu and Grace Y. Chen wrote the final manuscript.  
 
Chapter 2, 3, and 4 
Modified from the manuscript published at Cell Reports titled, “Gut microbiota modulate 
CD8 T cell responses to influence colitis-associated tumorigenesis,” which was co-authored with 
Lili Zhao, Kathryn A. Eaton, Sharon Ho, Jiachen Chen, Sara Poe, James Becker, Allison Gonzalez, 
Delaney McKinstry, Muneer Hasso, Jonny Mendoza-Castrejon, Joel Whitfield, Charles 
Koumpouras, Patrick D. Schloss, Eric C. Martens, and Grace Y. Chen (267). 
Manuscript and supplemental information can be found online at: 
https://doi.org/10.1016/j.celrep.2020.03.035 
Contributions: Amy I. Yu and Grace Y. Chen were responsible for conceptualization and 
methodology. Formal and statistical analyses were done by Amy I. Yu, Lili Zhao, and Grace Y. 
Chen. Experimental investigation was carried out by Amy I. Yu, Lili Zhao, Kathryn A. Eaton, 
Sharon Ho, Jiachen Chen, Sara Poe, James Becker, Allison Gonzalez, Delaney McKinstry, Muneer 
Hasso, Jonny Mendoza-Castrejon, Joel Whitfield, Charles Koumpouras, Eric C. Martens, and 
Grace Y. Chen. Histologic interpretation and scoring was completed by board-certified veterinary 
pathologist Kathryn A. Eaton. Patrick D. Schloss and Eric C. Martens provided resources for the 
completion of this manuscript. Amy I. Yu and Grace Y. Chen wrote the final manuscript. This 
work was supported by funding acquired by Amy I. Yu: 1) University of Michigan Rackham 
Research Grant, 2) NIH grant T32 AI007413, and Grace Y. Chen: 1) NIH grant R01 CA166879, 
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